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Abstract   
The synthesis of new chemical entities as potential drug candidates is a promising 
and challenging aspect in drug discovery. Investigations on success rates showed 
higher values for three-dimensional molecules than for planar ones and recom-
mended an “escape from flatland” strategy for the chemical synthesis of compound 
collections. Following these suggestions, a synthetic route was devised for the gen-
eration of bridged bicyclic compounds as an example for molecules possessing a 
permanent three-dimensional structure. This route involved [4+2] cycloaddition reac-
tions between a collection of cyclic dienes and a collection of dienophiles, thereby 
combining privileged core structures provided by the reaction partners. A consider-
able fraction of the novel molecules showed biological activity in a general assay 
based on interference with the proliferation of mammalian cells. Two profiling meth-
ods, cellular impedance measurement and high-content cellular image analysis, 
were used to obtain suggestions for the types of bioactivities exerted by the positive 
compounds. Although the results of these experiments showed considerable varia-
tion, it was in two instances possible to identify cellular processes with which the ac-
tive compounds interfere. In one case, the inhibition of tubulin polymerization was 
observed, in the other case, interference with proteasome function could be con-
firmed. The bridged bicyclic compounds synthesized and examined in the course of 
this thesis are just one example for structures that possess a permanent three-
dimensionality. The results obtained encourage further exploration of this region of 
the chemical space by generation of larger and more structurally diverse collections 
of bridged bicyclic compounds and related molecules. Furthermore, other synthetic 
pathways, leading to different types of three-dimensional compounds, may be devel-
oped and explored. 
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Zusammenfassung 
Die Synthese „neuer chemischer Einheiten“ zur Gewinnung von Wirkstoff-Kandidaten 
ist ein vielversprechender und herausfordernder Aspekt der Wirkstoffforschung. 
Untersuchungen über Erfolgsraten ergaben höhere Werte für dreidimensionale 
Moleküle als für planare und legten eine “Ausstieg-aus-dem-Flachland“-Strategie für 
die Synthese von Molekülbibliotheken nahe. In Verfolgung dieses Vorschlags wurde 
eine Syntheseroute für die Erzeugung verbrückt bizyklischer Verbindungen als ein 
Beispiel für Moleküle mit permanent dreidimensionaler Struktur entwickelt. Diese 
Route beinhaltete [4+2]-Zykloadditionsreaktionen zwischen Kollektionen von 
zyklischen Dienen und von Dienophilen, wobei durch die Reaktionspartner 
privilegierte Kernstrukturen miteinander kombiniert wurden. Ein signifikanter Teil der 
neuen Moleküle zeigte in einem globalen Test, der die Beeinträchtigung der 
Proliferation von Säugerzellen maß, biologische Aktivität. Zwei Profilierungs-
Methoden, Verfolgung der zellulären Impedanz und extensive zelluläre Bildanalyse, 
wurden eingesetzt, um Hinweise auf die Arten der Bioaktivitäten der positiven 
Verbindungen zu erhalten. Obwohl die Ergebnisse dieser Experimente beträchtliche 
Streuungen zeigten, war es in zwei Fällen möglich, die zellulären Prozesse zu 
identifizieren, mit denen die aktiven Verbindungen interferierten. In einem Fall wurde 
die Inhibition der Tubulin-Polymerisation beobachtet, im anderen Fall konnte eine 
Störung der Proteasom-Funktion bestätigt werden. Die synthetisierten Verbindungen 
sind nur ein Beispiel für Moleküle, die eine permanente Dreidimensionalität besitzen. 
Die erzielten Ergebnisse sprechen für eine weitere Untersuchung dieser Region des 
„chemischen Raums“ durch Erzeugung größerer und strukturell vielfältigerer 
Sammlungen derartiger Verbindungen und verwandter Moleküle. Ferner könnten 
andere Synthesewege, die zu alternativen Typen dreidimensionaler Verbindungen 
führen, entworfen und auf bioaktive Moleküle untersucht werden. 
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1. Introduction 
Drug discovery is an important research area to obtain new chemical entities which 
can be lead structures for successful drug candidates. The aspect of drug discovery 
is gaining importance year by year, for example, by the evolution of resistance to ex-
isting anticancer1-4 and antimicrobial agents.5-8 In addition, for emerging infectious 
diseases such as Influenza A, Dengue fever and West Nile disease etc. there is an 
essential requirement to find new drugs.9 However, the drug discovery rate is almost 
the same as in the last 50 years, which is below the required level.10 This can be 
seen, for example, by the numbers of drugs approved by the FDA since 1993,11 as 
shown in Fig. 1. Therefore, there is a dire need to synthesize or isolate new drug 
candidates. 
 
Fig. 1: New molecular entities (NMEs) and biologics license applications (BLAs) approved 
by the center for drug evaluation and research since 1993. (Adapted from Ref. 11) 
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1.1. Source and strategies in drug discovery 
The general ways of contribution to the development of new drug candidates are iso-
lation and/or synthesis.  
Isolation of molecules from the extracts of natural resources like plants, mi-
croorganisms etc. provides natural compounds, which have typically evolved in na-
ture for a particular biological function. They served remarkably as source of drugs 
including antibacterials and cytotoxic agents for cancer.12 Despite of these positive 
results, natural products have some limitations in drug discovery which are worth 
mentioning. Even though nature created these complex molecules in order to inter-
act with biological targets, the complications involved in the isolation, purification and 
the frequently required subsequent chemical derivatization of these compounds of-
ten severely limits their availability. Consequently, large collections of discrete natu-
ral products are not available for use in high-throughput screening and the lead op-
timization process.13,14 
On the other hand, chemical synthesis is also a principal source for the dis-
covery of new entities. This includes, on one end, the total synthesis of natural prod-
ucts that are otherwise difficult to obtain or to derivatize, and on the other end, the 
generation of drug-like organic molecules. Natural products have diverse and often 
complex molecular architectures. These challenges revealed gaps in the methods of 
organic synthesis, providing inspiration to fill them with novel methodologies and 
routes.15 The possibility to optimize pharmacokinetic and pharmacodynamic proper-
ties by chemical synthesis is also an advantage in providing leads for drug discovery.  
The evolution of modern methods in stereoselective organic synthesis and 
methodologies developed from solution chemistry15 to solid phase chemistry16-20 has 
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provided the means to generate not only compounds for a specific target, but also 
collections of structurally diverse compounds. Therefore it is possible to follow differ-
ent synthetic strategies in drug discovery.  
On one extreme there is target-oriented synthesis (ToS).21 ToS means the 
synthesis of compounds destined to interact with a known target. This furthermore 
requires the knowledge of the interaction site through which the target exerts its bio-
logical effect and which should be addressed by the drug molecule. Very helpful is 
the knowledge of its three-dimensional structure in order to be able to carry out mo-
lecular docking studies with candidate compounds. Apparently, identification of a 
specific interaction site on a macromolecule and the elucidation of its three-
dimensional structure are often complex and time-consuming. Even if this knowledge 
is available, the design of a molecular shape able to efficiently and specifically dis-
turb this interaction is anything but a straightforward endeavor. The reasons include 
the flexibility of protein structure, the shortcomings of available programs for molecu-
lar docking and the limitations of the chemical tool box itself. Thus, for example, only 
1 or 2 CH2 units can be added where 1.5 would be required to obtain a positioning of 
the ligand that would yield a strong interaction.  
The other end of the synthetic strategies is generation of diverse small mole-
cule libraries, which are then screened against a variety of potential cellular target 
molecules. The libraries may be synthesized with different types of approaches such 
as diversity-oriented synthesis (DoS),21 biology-oriented synthesis (BioS),22 and 
fragment-based drug discovery (FBDD).23  
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1.2. Compound collections and hit-rate problem 
Technological advances facilitated the proficient synthesis of libraries containing 
thousands of compounds efficiently and allowed to screen large collections to iden-
tify lead candidates.24-26 However, these phenotypic screenings and biochemical as-
says often resulted in unsatisfactory outcome in terms of specificity and efficiency of 
the obtained hits. In other words, such synthetic compound collections suffer from 
low hit rates.27 Mainly, their synthetic strategies are chemistry-driven. Compounds 
that are easy to synthesize are the major contributors for most compound collec-
tions. Thus, compounds are produced in view of quantity rather than quality by com-
bining more reactive, but biologically undesirable functional groups. Clearly, strate-
gies for the chemical synthesis of compound libraries should be more structure-
driven, i.e., they should address structural features that distinguish drugs and bioac-
tive compounds from compounds in general.  
1.3. Criteria for the synthesis of structure-driven compound libraries 
There have been attempts28a,b to predict the druglikeness of molecules considering 
molecular descriptors proposed by Lipinski29 and combining them with computational 
methods, but no generally applicable means of differentiating drug-like compounds 
from non-drug-like compounds exists. Eventually, a simple method employing five 
physico-chemical parameters, molecular weight, topological surface area, rotatable 
bonds and hydrogen bond donors and acceptors was introduced by Lipinski as the 
“Rule-of-Five” (RO5) concept and got widespread popularity in the drug discovery 
and development field. The medicinal chemist’s community became increasingly 
aware of the value of considering calculated physical properties. These properties 
are examined thoroughly and compound collections are filtered by the ‘RO5’ as they 
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progress from hits through leads to drugs. However, it proved insufficient to deter-
mine the pharmacologically relevant properties for druglikeness with the descriptors 
mentioned. Therefore parameters related to structure, like shape and rigidity are also 
to be considered and additional methods to identify distinguishing features between 
drugs and other organic molecules are required. 
 
Fig. 2:. Comparison of three different classes of molecules was analyzed on the basis of a 
variety of molecular properties. Databases contained compounds from combinatorial chem-
istry (a), natural products (b) and drugs (c). A statistical approach known as principal com-
ponent analysis was applied to the data to yield a two-dimensional representation of the dis-
tribution of these compounds in the chemical space. Plots of the first two principal compo-
nents, which explain about 54% of the variance in the properties analyzed, are shown. Com-
binatorial compounds cover a limited region in the space specified by these principal com-
ponents. (Adapted from Ref. 30) 
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Comparisons of synthetic molecules with those of drugs and natural products 
can reveal features lacking in the first group. This would give hints about how to in-
crease the quality in the small molecule libraries and thereby address the hit-rate 
problem. Feher and Schmidt30 performed a comparison between three classes of 
compounds, marketed drugs, compounds originating from combinatorial synthesis 
and natural products, based on variety of simple descriptors to identify how these 
classes populate the n-dimensional chemical space, where ‘n’ designates the num-
ber of descriptors or parameters or properties used in the comparison. A result of 
this analysis is shown in Fig. 2. It indicates that the structural diversity of combinato-
rial compounds is substantially lower than that of either drugs or natural products. 
The former are restricted to only a confined region of the chemical space. 
In the following years, several proposals and approaches were reported con-
cerning the definition of chemical space and the chemical space occupied by existing 
chemical entities.31-34 These studies also suggest an unexplored medicinally relevant 
space which awaits the synthesis of respective molecules. This unexplored chemical 
space was recently defined by Reymond and co-workers with an enumeration of 
166.4 billion virtual molecules, considering molecular shape as one of the descrip-
tors.35 Their study revealed that the majority of the synthesized molecules possess-
ing reported biological activities and being clinically approved compounds were dis-
tributed in space regions characteristic for flat molecules (rod or disc shapes). Very 
few compounds were found in the space harbouring three-dimensional structures 
(spheres), as shown in Fig. 3. These results were consistent with other publications. 
Thus, Sauer et al. reported that the majority of the molecules synthesized in medici-
nal chemistry are either linear or planar structures and only a minority possesses 
three-dimensional structures.36  
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Fig 3:. Frequency of molecules with different shape in different databases. Molecular shape 
analyzed by the “principal moments of inertia”. P1 and P2 are the normalized ratios of the 
principal moment of inertia. Occupancy of the P1, P2 plane is coloured from blue 
(1cpd/pixel) to purple (maximal value). Public compound archives PubChem, ChEMBL and 
DrugBank, the latter containing only approved drugs were considered for the analysis. The 
inserts show a magnified view of the lower left edge of each triangle. In all collections the 
lower left edge representing either rod or disc like structures is predominantly occupied 
whereas at the other end of the space, compound population is very low. In case of stereoi-
somers of compounds, only one isomer was considered for the analysis. (Adapted from Ref. 
35) 
Furthermore, a detailed study of the comprehensive medicinal chemistry da-
tabase of 5120 molecules revealed that only very few synthesized compounds have 
a three-dimensional scaffold.37 However, it was reported that molecules with a sig-
nificant three-dimensional portion are known to have higher success rates in drug 
development.38a,b This may be rationalized by the following considerations. A perma-
nent three-dimensional structure gives a molecule a rigid skeleton. The rigid nature 
of a small molecule can play vital role in binding to macromolecules. They can form 
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hydrogen bonds and hydrophobic interactions with proteins or other partners with 
low entropic losses in comparison to a flexible ligand with the same interaction pat-
tern.39 The presence of a rigid scaffold and very few rotatable bonds is frequently 
observed in bio-active molecules.30 Therefore, compounds with a permanent three-
dimensional structure may exploit the thermodynamic advantages attained by the 
rigidity in increased binding enthalpy and selectivity. Moreover, rigidity of a ligand 
may induce plasticity in the cellular target to attain maximum binding affinity.40 For 
these reasons, an “escape from flatland” has been suggested as a valuable strategy 
to search for bioactive compounds.38a 
1.4. The synthetic pathway devised for the generation of three-dimensional 
molecules  
The above mentioned features of three-dimensional structures encouraged us to 
throw focus on the synthesis of three-dimensional compounds in order to explore a 
novel region of the chemical space for drug-like molecules. 
Out of the many strategies to obtain three-dimensional molecules, we decided 
on a chemo-enzymatic route that starts from “privileged” core structures to yield 
bridged bicyclic compounds as end products. Privileged scaffolds are core structures 
frequently found in bioactive compounds.41 The devised synthetic pathway is shown 
in Fig. 4. It comprises the following steps. 
i) Conversion of aromatic or hetero-aromatic compounds into cyclic cis-dienediols via 
enzyme-catalyzed microbial oxidation.   
ii) Protection of hydroxy groups, if required. 
iii) [4+2] cycloaddition between the cyclic dienediols and dienophiles. 
iv) Deprotection of hydroxy groups. 
INTRODUCTION 
 
11 
 
 
Fig. 4: Devised chemo-enzymatic route to synthesize three-dimensional compounds. 
ARHDO: Arylhydroxylating dioxygenase. Only one of the possible stereoisomers is shown.  
1.4.1. Enzymatic formation of cyclic cis-dienediols   
Cyclic dienediols may conveniently be obtained from aromatic compounds by enzy-
matic dioxygenation. The respective biocatalysts, aryl-hydroxylating dioxygenases 
(ARHDO), are bacterial enzymes that use molecular oxygen to activate the aromatic 
nucleus. This oxidation can be carried out with whole cells, either of mutant strains, 
deficient in a further metabolism of the generated dienediols, or of appropriate re-
combinant strains. This biocatalytic transformation involves the highly endothermic 
disruption of aromaticity and the introduction of two hydroxy groups, cis to each other 
on vicinal carbons, and of a diene ring structure42 with defined stereochemistry. In 
1973, Kobal et al. used such dienediols for the first time as a precursor in an organic 
reaction.43 These molecules contain a remarkable combination of mutually con-
nected functionalities that make them interesting as synthons for further diversifica-
tion (Fig. 5).44  
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Fig. 5: Different reaction possibilities of cis-dienediols. (Adapted from Ref. 44). 
 
1.4.2. The [4+2] Cycloaddition or Diels-Alder Reaction   
For our purpose to synthesize three-dimensional molecules, the [4+2] cycloaddition 
or Diels-Alder reaction with the conjugated diene unit in the cis-dienediols, was of 
particular interest. 
Since the invention in 1928, the Diels-Alder reaction is one of the well-
investigated and widely used reactions in synthetic organic chemistry. It involves two 
reaction partners, a diene and dienophile, and is used for the construction of cyclic, 
polycyclic and hetero-cyclic compounds. New C-C, C-N or C-O bonds are formed, 
mostly under mild and simple reactions conditions in a single-step conversion. A 
bridged bicyclic skeleton may be obtained with either one or two cyclic reaction part-
ners. The formation of two regio-isomers, the endo and exo forms of the resultant 
cycloadduct are therefore possible. However, in most instances the reaction is highly 
stereospecific and leads to the endo product. The diene skeleton present in the cis-
diendiols is known to be reactive in cycloadditions. A first Diels-Alder reaction with 
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such a molecule was reported in 1973 by Kobal et al. in an attempt to confirm the 
stereochemistry of a dihydrodiol.43 
In this work, two types of reaction partners for the dienediols were considered 
for the generation of the bridged bicycles. Either dienophiles containing privileged 
structures, for example, chalcone or flavanoid structures, or molecules possessing 
physico-chemical parameters favourable for druglikeness. 
1.5. Outline of the thesis work 
In the course of this thesis work, the following tasks were planned to be carried out. 
I. Synthesis of a collection of dienophiles as precursors for the cycloaddition re-
action. 
II. Generation of a collection of bridged bicyclic compounds by Diels-Alder reac-
tions between the dienophiles and dienediols supplied by a commercial 
source or by the lab of Bernd Hofer.  
III. Assessments of how many of the bridged bicycles if any possess general bio-
activity. 
IV. For compounds positive in step III, characterization of the type of bioactivity 
with the aid of two different profiling methods, namely cellular impedance 
measurement and high content analysis with automatic microscopic imaging. 
V. For compounds positive in step IV, verification of the profiling results by spe-
cific biological assays. 
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Questions to be answered in the course of this work include 
I. Is it possible to obtain bioactive compounds by the devised synthetic route? 
II. Do the bioactive compounds obtained show preferences for certain cellular 
processes? 
III. Can the results of the profiling methods be confirmed by the specific bioactiv-
ity assays? 
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2. Results and Discussion 
 
2.1. Chemistry 
The generation of a mini library of bridged bicyclic compounds was pursued by a 
chemo-enzymatic pathway, shown in Fig. 4. One of the dienediols was from a com-
mercial source; the others were supplied by the laboratory of Dr. Bernd Hofer. There-
fore, the first part of this thesis starts with the second step of the above-mentioned 
pathway, a [4+2] cycloaddition or Diels-Alder reaction. This required the synthesis of 
most of the dienophile reaction partners (see below). Subsequently bridged bicyclic 
compounds were synthesized. Compound purification was done by flash column 
chromatography unless stated otherwise. The analytical techniques routinely used 
(unless stated otherwise) for the assessment of compound purity and structure were 
NMR and mass spectrometry.  
2.1.1. Synthesis of dienophiles 
From the chemical point of view, the dienophiles considered as reaction partners fall 
into two groups, maleimide-based and quinone-based dienophiles. Some of the die-
nophiles were from commercial sources, but the majority was synthesized as part of 
this thesis. An overview showing all of these dienophiles is given in Fig. 6. The reac-
tions carried out for the synthesis of dienophiles, are described in the following chap-
ters. 
2.1.1.1. Synthesis of N-aryl or -alkyl maleimides 
For the synthesis of N-aryl or -alkyl maleimides dienophile reaction partners, different 
substituted aromatic or aliphatic amines were reacted with maleic anhydride to pro-
duce N-aryl maleimides. The latter contain two electron-withdrawing groups on the 
RESULTS AND DISCUSSION 
 
16 
 
dienophile which enhances their reactivity in cycloaddition reactions. Seven maleim-
ide derivatives were prepared as shown in Scheme 1. Maleic anhydride (1) was re-
acted with the aromatic or aliphatic amines (2) in diethylether or in ethyl acetate at 
RT to afford the corresponding aryl-oxoaminobutenoic acid intermediate (3) in excel-
lent yield. Subsequent cyclization with sodium acetate and acetic anhydride at 80 
ºC45 afforded N-aryl or –alkyl maleimides in moderate to good (40-65%) yields. Two 
more N-aryl- and N-alkyl-substituted maleimides were bought from a commercial 
source (shown in Fig. 6). 
 
Scheme 1: Reaction scheme for the synthesis of N-aryl or -alkyl maleimides 
2.1.1.2. Synthesis of 4ʹ-aminochalcone-based maleimides 
Chalcones or 1,2-diphenyl-2-propen-1-ones are Michael acceptors and comprise an 
important natural product group belonging to the flavonoid family.46 They have been 
reported to have wide variety of biological activities.47 Therefore, the dienophile col-
lection was further enlarged by the synthesis of 4-aminochalcone-based maleimides 
as described by Jha et al..48 This is depicted in Scheme 2. The reaction between 4’-
aminoacetophenone (5) and maleic anhydride (1, Scheme 1) produced 4’-acetyl-N-
maleanilinic acid as intermediate (7). Claisen-Schmidt condensation between this 
compound and various substituted aryl aldehydes (8) afforded the 4ʹ-aminochalcone-
maleimic acids (9). Dehydration of the latter with sodium acetate and acetic anhy-
dride yielded the desired chalcone-maleimide derivatives (10). Due to activation by 
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its electron-withdrawing neighbouring groups, it is the C-C double bond of the 
maleimide unit, not of the chalcone, that later will participate in the [4+2] cycloaddi-
tions. 
 
Scheme 2: Synthetic pathway for the preparation of 4ʹ-aminochalcone-based maleimides. 
 
2.1.1.3. Synthesis of 4ʹ-aminocinnamate-based maleimides 
As the substituted and unsubstitued trans-cinnamic acids and their derivatives pos-
sess a variety of biological activities,49a,b three 4ʹ-aminocinnamate-based maleimides 
were included in the dienophile collection. 
2.1.1.3.1. Synthesis from methyl-p-aminocinnamate 
Trans-p-aminocinnamic acid was first esterified with methanol under acidic condi-
tions to obtain methyl-p-aminocinnamate (11). As shown in 
Scheme 3, this was then reacted with maleic anhydride to obtain the oxoaminobuten-
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ioc acid intermediate (12). Cyclization with sodium acetate and acetic anhydride re-
sulted in methyl-4ʹ-aminocinnamate-maleimide (13).  
Scheme 3: Synthetic route for the preparation of 4ʹ-amino methylcinnamate-based maleim-
ide. 
2.1.1.3.2. Synthesis from 4-aminomethylcinnamic acid 
An alternate route using the free acid (Scheme 4) was taken into consideration be-
cause of the possibility to diversify the maleimide in the last step by different esterifi-
cations. As shown in 
Scheme 4, trans-p-aminocinnamic acid was first reacted with maleic anhydride in 
ethyl acetate at RT to form the oxoaminobutenoic acid intermediate (15). Dehydra-
tion of the intermediate with sodium acetate and acetic anhydride yielded 4’-
aminocinnamic acid-based maleimide 16. Reactions to form the intermediate (15) 
and the latter cyclization to get compound (16) proceeded equally well as with the 
ester (11, Scheme 3). Esterification of the acid 16 with methanol or ethanol under 
acidic conditions yielded the respective alkyl-4ʹ-aminocinnamte-maleimides. The 
products possessed the expected E- configured double bond. This was shown by the 
trans-specific coupling constants in 1H NMR spectroscopy. 
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Scheme 4: Alternate route for the synthesis of -4ʹ-amino alkylcinnamatebased-maleimides 
 
2.1.1.4. Synthesis of a chromone-based maleimide 
Chromones are one of the major classes of naturally occurring compounds. Chro-
mone is the core structure of flavonoids. Thus, it is not surprising that chromones 
have been reported to posses multiple biological activities.50 Therefore, a chromone-
based maleimide was synthesized as shown in scheme 5. First, commercially avail-
able 7-amino-2-methylchromone (18) was reacted with maleic anhydride (Scheme 1) 
followed by cyclization to afford a chromone-maleimide compound (20) with good 
yield (70%). 
Scheme 5: Reaction scheme for the preparation of 7-maleimido-methyl chromone 
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2.1.1.5. Synthesis of amino-N-alkanoic acid-based maleimides 
Further diversification of maleimide dienophiles was attempted by reacting maleic 
anhydride with aminoalkanoic acids,51 as depicted in Scheme 6. These products were 
later not reacted at preparative scale with the dienediols, because their reactivity in 
cycloaddition reactions was found to be sluggish. 
 
Scheme 6: Synthesis for amino-N-alkanoic acid-based maleimides 
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2.1.1.6. Overview of the dienophiles 
All dienophiles used in subsequent cycloadditions are shown in Fig. 6. Five were 
from commercial sources (see legend); the others were synthesized as described in 
the preceding chapters. In these reactions, reactivities and yields were similar to 
data reported in the literature.52,53,54 The chromone-based maleimide D22 and the 
chalcone-based maleimide D20 were not previously described in the literature. 
 
Figure continued on next page… 
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Fig. 6: Overview of structures of dienophiles synthesized in the course of this thesis or ob-
tained commercially (D01, D03, D23, D25 and D26).  
 
2.1.2. Synthesis of bridged bicyclic compounds 
Bridged bicyclic compounds are a class of molecules that possess a permanent 
three-dimensional structure. A collection of bridged bicyclic compounds was synthe-
sized by means of the Diels-Alder reaction as outlined in the introduction (Fig. 4). In 
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order to optimize the reaction conditions for the cycloaddition reactions, experiments 
were started with a simple diene, 1,3-cyclohexadiene, and commercially available 
dienophiles like benzoquinone, naphthoquinone, substituted maleic anhydrides, N-
aryl and -alkyl maleimides. The reactions with N-aryl and alkylsubstitued maleimides 
afforded products in considerably good yields. These reactions proceeded well in 
chloroform as solvent at reflux conditions. Therefore the identical conditions were 
considered for the reactions with dienediols 22 and 23.  
2.1.2.1. Synthesis of bridged bicyclic compounds from (1S-cis)-3-bromo-3,5-
cyclohexadiene-1,2-diol (22) 
In order to establish the reaction conditions for the Diels-Alder reaction with a pro-
tected dienediol, the first round of  experiments was carried out with a commercial 
dienediol, (1S-cis)-3-Bromo-3,5-cyclohexadiene-1,2-diol (Scheme 7, 22), which was 
available in gram quantities. 
2.1.2.1.1. Protection of (1S-cis)-3-bromo-3,5-cyclohexadiene-1,2-diol (22) 
It was reported that synthetic applications involving cis-diol metabolites often require 
protection of the hydroxy groups.55 Therefore the two hydroxy groups of the dienediol 
were reacted at low temperatures with 2,2-dimethoxypropane to form an acetonide 
(23), as shown in Scheme 7.56 This was obtained in excellent yield (90%) after rapid 
purification by flash column chromatography. A dimerization of acetonides (protected 
diol) was reported upon storage at -30 ºC in pure form.57 Therefore the compound 
was prepared in 100 milligram quantity, diluted in dichloromethane to approximately 
10M and stored at -70 ºC until it was used in further reactions. Dimerization (ap-
proximately 25 %) was observed even at -70 ºC after several weeks.  
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Scheme 7: Protection of hydroxy groups with 2,2-dimethoxy propane 
2.1.2.1.2. [4+2] cycloaddition reactions with the protected diol, (1S-cis)-3-
bromo-3,5-cyclohexadiene-1,2-diol (23) 
The acetonide (23) was reacted with all maleimido-dienophiles shown in Fig. 6 ex-
cept for D08, D12, D14, D16, D25, and D26, to afford bridged bicyclic structures in a 
simple one-step reaction. Reaction progress was monitored by thin layer chromatog-
raphy (TLC). The rates of these reactions, when performed at RT, were sluggish, 
thus affording long reaction times (4-7 days). Refluxing the solution of the protected 
dienediol (23) and a dienophile in chloroform resulted in good yields of a mixture of 
two products in an approximate ratio of 3:2 with some exceptions, which are de-
scribed later (see 2.1.2.3). The NMR characterization showed that they were isomers 
of the expected product. Their ratio was similar to data given in previous reports.57 
Both isomers were separated well, with an Rf difference of 0.3. They were purified by 
flash silica gel column chromatography and characterized by proton and carbon 
NMR spectroscopy. As expected, the dienophile was added to the dienediol (23) in a 
stereoselective manner to give only endo isomers. The major adduct was the result 
of an endo-addition of the dienophile syn to the isopropylidenedioxy ring face of the 
diene, and the minor adduct was formed by an endo-addition to the anti-face of the 
diene, as depicted in scheme 8.57,58 These structures were identified by two dimen-
sional NMR spectroscopy with NOE data. In case of the endo-syn isomer, a through-
space interaction was found between one of the methyl groups of the isopropylidine 
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ring and the methine protons of the maleimide moiety. For the endo-anti isomer, a 
similar proximity was observed between the methine protons of the maleimide ring 
and the protons on the carbons bonded to the two oxygens of isopropylidine ring. 
 
Scheme 8: Isomers formed in cycloadditions between dienediol 23 and various dienophiles. 
Syn and anti are assigned with respect to isopropylidine ring. 
 
 2.1.2.1.3. Deprotection of the acetonide group 
 In the specific interactions between small molecules and their cellular targets, hy-
drogen bond donors and acceptors play a major role to provide binding strength and 
specificity.59 The removal of the acetonide group provides two additional free hy-
droxy groups that possess both hydrogen bond donor and acceptor capability. To 
deprotect the cycloadducts, compounds were refluxed under acidic conditions like 
aqueous trifluoroacetic acid and amberlyst acidic resin, as previously reported.60a,b 
However, all reactions resulted in poor yields (less than 30%).   
2.1.2.1.4. [4+2] cycloaddition reactions with unprotected (1S-cis)-3-bromo-3,5-
cyclohexadiene-1,2-diol (22) 
Because of the poor yields in deprotection, Diels-Alder reactions were attempted 
without prior protection of the hydroxy groups. Cycloadditions were performed with 
the dienediol 22 and the entire collection of dienophiles (Fig. 6). Progress of the re-
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actions was monitored by TLC. The first reactions were done under the same condi-
tions stated above, but the reactions proceeded at very slow rates and required 2-4 
days. Therefore conditions were changed to toluene reflux with a temperature in-
crease of 40 ºC. This alleviated the product formation and significantly reduced the 
reaction time (24 h). These conditions were applied for all of the dienophiles. 
Cycloaddition products from all dienophiles were obtained successfully in moderate 
to good yields in the range of 40-70%, except with quinone-based dienophiles (D25, 
D26). The reaction profiles, as analyzed by TLC were clean, showing the two iso-
mers and a low percentage of undesired products. The isomers ratio with all dieno-
philes was discussed later (see 2.1.2.3). The TLC separation of the two unprotected 
isomers was good with a Rf value of 0.6 for the endo-syn and of 0.3 for the endo-anti 
isomer. The quinone-based dienophiles D25 and D26 were reacted under conditions 
reported for a similar cycloaddition reaction with identical dienophiles61a,b,c i.e., reflux-
ing in tetrahydrofuran and water (9:1) to obtain the cycloadducts. No compound was 
isolated from the reaction with D15 because of the product instability. 
 Cycloaddition reactions with prtotected and unprotected cis-dienediols were 
first reported by Gillard and Burnell.58 They reacted cis-cyclohexa-3,5-diene-1,2-diol 
with two dienophiles. The yield with both protected and unprotected dienediols was 
similar to what was obtained with dienediols 22 and 23 in the current work. Accord-
ing to Gillard and Burnell, the protected dienediol showed higher reactivity than the 
unprotected one under identical conditions. However, with dienediols 22 and 23 the 
reactivity observed towards several dienophiles was the same under identical reac-
tion conditions.   
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An overview of the structures of all cycloaddition products obtained from di-
enediols 22 and 23 is shown in Fig. 7. It also includes cycloadducts that had been 
subjected to additional modification reactions which are described later (2.1.3). All 
bridged bicyclic compounds shown were not previously reported. 
Fig continued on next page… 
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Figure continued on next page… 
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Figure continued on next page… 
 
 
RESULTS AND DISCUSSION 
 
30 
 
 
 
Fig. 7: Structures of bridged bicyclic compounds obtained from cycloaddition reaction be-
tween dienediols 22, and/or 23 (Scheme 7) and our collection of dienophiles (Fig. 6). This 
overview also shows same additionally modified molecules (see 2.1.3). Structures are or-
dered by the number given to the dienophile. The compound codes shown contain the fol-
lowing information. The first three letters are the dienediol abbreviations used, BrD for di-
enediol 22 and BzD for the debrominated dienediol 22. ‘P’ or ‘U’ stands for protected or un-
protected, respectively. This is followed by the dienophile number. The next letter represents 
the stereochemistry of the structure, either –syn (S) or –anti (A). Occasionally this is followed 
by R for reduction of the C-C double bond in one of the bridges or Ac for acetyl protection of 
the hydroxy groups. 
 
2.1.2.2. Synthesis of bridged bicyclic compounds from hetero-aryl benzenes 
Many privileged structures are hetero-aromatic scaffolds. Therefore, such hetero-aryl 
structures were selected as starting material for the synthesis of a second series of 
bridged bicyclic compounds. 
2.1.2.2.1. Synthesis of cis-dienediols from hetero-aryl benzenes 
Five hetero-aryl-substituted benzenes were converted to corresponding cis-
dienediols with recombinant bacterial cells that efficiently synthesize an aryl-
hydroxylating dioxygenase enzyme. The respective dienediol structures are shown in 
Fig. 8. As can be seen, dienediol formation was always directed towards the ortho 
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and para positions of the homo-aromatic ring, whereas the hetero-aryl substituent 
remained unchanged.  
 
Fig. 8: Structures of hetero-aryl dienediols dienediols 
After purification these compounds were obtained in quantities around 100 
mg. They were supplied by the laboratory of Bernd Hofer.62 Because of the limited 
amounts, cycloaddition reactions with these dienediols could only be carried out with 
a small number of the available dienophile partners.  
2.1.2.2.2. Selection of dienophiles for the cycloadditions with hetero-aryl di-
enediols 
Nine dienophiles were selected for the synthesis of cycloadducts with hetero-aryl di-
enediols. This was based on reactivity and yields with dienediols 22 and 23 and on 
the results of the biological activity screening of the first collection of bridged bicycles 
(see 2.2.1). With respect to biological activity as measured in the cytotoxicity assay, 
a threshold IC50 value around 15 µg/mL was set for the selection. But this was not 
strictly obeyed for the sake of structural diversity. Six of the selected dienophiles 
(D13, D17, D18, D19, D20 and D21, see Fig. 6), were chalcone-based maleimides 
and the rest were N-(3,4,5-trimethoxy phenyl)maleimide (D06) and 4-phenyl-1,2,4-
triazoline-3,5-dione (D01).  
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2.1.2.2.3. Cycloadditions with hetero-aryl dienediols 
Because of the problems with deprotection of the bridged bicyclic products derived 
from the protected dienediol 23, all cycloadditions were carried out with unprotected 
hetero-aryl dienediols. The first cycloaddition reactions with the selected dienophiles 
were performed with dienediol 28 (Fig. 8), which was available in relatively high 
amount amongst the in-house generated dienediols. Reactions were carried out with 
three of the selected dienophiles (D06, D10 and D17) under the same conditions 
used for dienediols 22 and 23. However, the progress of the reactions was very 
slow. Even after 4-6 days of refluxing, only about 10% of the desired product, but 
many by-products were observed by LC-MS. Therefore reaction trials were carried 
out. They were limited to only one dienophile (D10) because of its high reactivity. Dif-
ferent solvents like tetrahydrofuran and dioxane were used, but there was no im-
provement in the conversion. Thereafter, the reaction was carried out in a sealed 
tube with chloroform as solvent at 100-120 ºC for 3 days, but no substantial im-
provement was observed in the product formation. However the product with the di-
enophile D10 (Fig. 9, ImDUD10S), was synthesized on preparative scale, following 
the sealed tube reaction conditions. The yield was rather low (22%), but sufficient for 
isolation by preparative HPLC. Only one compound was obtained after purification, 
and NMR spectroscopy showed that the isolated product was in the endo-syn con-
figuration, as expected from the previous reaction products of the unprotected di-
enediol 22.  
Because of these disappointing results, several attempts were undertaken 
with dienediol 28 by employing microwave irradiation. In the past few years cycload-
dition reactions in many cases have greatly benefited from the focused microwave 
irradiation, if they normally require elevated reaction temperatures for lengthy times 
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and high pressure. The short reaction time associated with microwave activation 
avoids decomposition of reagents and products. It also prevents polymerization of 
dienes and dienophiles.63a,b Microwave conditions with different reaction times in a 
sealed vessel were tried with dienediol 28, but there was no significant change in 
yield. 
In order to check the reactivity of the other dienediols in the cycloaddition, re-
actions were performed with dienediol 27. The same conditions were used as men-
tioned above with chloroform as solvent at elevated temperature in a sealed vessel. 
This time the products were obtained in relatively high yield (40-60%) with all of the 
selected dienophiles and were isolated. 
Dienediol 25 was reacted with the nine dienophiles under similar conditions. 
The reactivity of this dienediol was slightly lower than that of the dienediol 27. Ac-
cordingly, the yields of the cycloaddition products were only in the range of 30-45%. 
Eight compounds were purified. The only exception was the product from the reac-
tion with D18 (Fig. 6) which was not isolated because of multiple product formation. 
Finally dienediol 26 was reacted with two dienophiles D01, D17 (Fig. 6) and 
24 was reacted only with D01, because of their limited availability. The reactivity of 
both of these dienediols was similar to that of dienediol 25. 
Altogether, 21 bridged bicyclic compounds were synthesized with the five het-
ero-aryl dienediols (Fig. 9). The predominant products formed were always the endo-
syn isomers with approximate ratios of 9:1, except for dienophile D01. For D01 iso-
lated isomers were in the endo-anti configuration. Only the major isomers were iso-
lated for further use. They were purified by flash chromatography and characterized 
by NMR and high resolution mass spectrometry. 
RESULTS AND DISCUSSION 
 
34 
 
 
Figure continued from previous page… 
RESULTS AND DISCUSSION 
 
35 
 
 
Fig. 9: Structures of the cycloaddition products obtained from the reaction between hetero-
aryl dienediols and nine selected dienophiles. All isolated isomers were endo-syn, except for 
dienophile D01, where all isolated isomers were in the endo-anti configuration. The struc-
tures are ordered according to the dienediol number. Details of compound codes are given 
in the legend of Fig. 7. Dienediol abbreviations are Py2D, Py3D, Py4D, PmD and ImD for 
dienediols 25 to 28 (Fig. 8). 
2.1.2.2.4. Reactivity of the hetero-aryl dienediols 
The lower reactivity of the hetero-arylsubstituted dienediols in the cycloaddition reac-
tions, in comparison to the dienediol 22, may be explained by the electron distribu-
tion between the diene and the hetero-aromatic ring attached to the dienediols. In 
terms of molecular orbital theory, in a normal electron-demand Diels-Alder reaction, 
electron-donating groups on the diene skeleton increase the energy of its highest 
occupied molecular orbital (HOMO), thereby leading to a smaller energy gap with the 
lowest unoccupied molecular orbital (LUMO) of the electrophilic dienophile. Electron-
withdrawing groups show the opposite effect and decrease the reactivity of the di-
ene. Therefore, the extended conjugation system present in the hetero-aryl rings at-
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tached to the dienediol strongly withdraws electrons from the diene even when the 
heterocyclic nitrogens are not directly attached to the diene, thus making it more sta-
ble towards the reaction. In dienediols 22 and 23, the bromine is less electron-
withdrawing than the aromatic heterocycles. Thus, compounds 22 and 23 are more 
reactive than their hetero-aryl counterparts.   
2.1.2.3. Preferences in isomer formation in the cycloaddition reactions 
The protected dienediol 23, when reacted with the dienophiles of the collection, in 
most cases yielded endo-syn and endo-anti isomers in a 3:2 ratio. However, there 
were some significant exceptions. In the reactions with dienophiles D10 and D11 
(Fig. 6), the two isomers were produced in a 1:2 ratio and the cycloaddition with die-
nophile D23 yielded a 2:3 ratio. The typically observed preference for the syn isomer 
agrees with literature data on Diels-Alder reactions with the acetonides of dienediols, 
which reported similar preferences for this isomer.58,64,65 However, no explanations 
were given for this selectivity. Typically, acetonides of dienediols show a strong pref-
erence for formation of the anti adduct.64,65 The syn priority seems to be a special 
case that is observed with maleimides as dienophiles.65 A strong syn selection is 
generally noticed when the diol groups of the dienes are not protected (my results 
discussed below).64,65 This is ascribed to the formation of H-bonds between the diol 
and the dienophile which direct the latter to the syn face.64 We propose a similar ef-
fect also for protected diols. The two oxygens are still available as H-bond acceptors. 
Hydrogens at double- or triple-bonded carbons possess certain acidity. In the case of 
maleimide, this is expected to be enhanced by the vicinal oxygens. Therefore, the 
formations of weak bonds of these lowly acidic hydrogens to the acetonide oxygens 
may exert a weak directing effect towards the syn face. When comparing the struc-
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tures of the dienophiles that yielded a lower preference for the syn isomer (D10, 
D11, D23) to the structures of related dienophiles, that showed a higher syn prefer-
ence (e.g. D09, D24), a straightforward explanation for these differences was not 
apparent.  
 The strongest deviation from the syn preference was noticed with D01, which 
exclusively yielded the anti isomer. This is in agreement with literature data43,64 and 
is probably explained by a strong electrostatic repulsion between the lone electron 
pairs of the acetonide oxygens and of the triazolidinone nitrogens upon approach of 
the dienophile at the syn face. 58,64 
 Isomer ratios showed much less variations in the reactions with unprotected 
dienediols, the one derived from bromobenzene as well as those derived from the 
heteroaromatics. Here, all dienophiles, with the single exception of D01, yielded syn 
and anti isomers in a ratio of approximately 9:1. Therefore, the stereochemical out-
come of these cycloadditions can be interpreted, as just mentioned, by electrostatic 
repulsions in the case of D01 and by H-bonding in all other cases. 
2.1.3. Structural modifications of bicyclic compounds 
Because of their available quantity, four compounds were considered for further 
modification by introduction of small structural changes. Small changes would allow 
to correlate potential differences in biological activity with single structural features. 
The modifications were introduced with single-step reactions.  
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2.1.3.1. Debromination 
A radical debromination reaction was performed with the acetonides of two com-
pounds, BrDPD10A and BrDPD01S, as shown in Scheme 9, using tributyltin hydride 
and AIBN.66 The desired compounds were obtained in 60-70% yields after purifica-
tion. 
 
Scheme 9: Free-radical-mediated debromination 
2.1.3.2. C-C double bond reduction 
.In two unprotected compounds (BrDUD02S and BrDUD01A),  the double bond pre-
sent in the unsubstituted bridge was reduced by hydrogenation with activated palla-
dium, as shown in Scheme 10, to afford the desired compound with 85% yield.67 
Subsequently, the free hydroxy groups were protected with acetyl functionality to ob-
tain compounds with different substitutions on the free hydroxy groups. Acetylation 
protects hydroxy groups without introducing an extra five-membered ring on the bi-
cyclic core structure.  
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Scheme 10: Reduction of the etheno-bridge double bond. 
 
2.2. Biology 
2.2.1. Screening for the microbial growth inhibition 
Because of the increasing antibiotic resistance of microbial strains, resulting in in-
creased numbers of difficult-to-treat microbial infections, a highly desired, but hard to 
obtain biological activity is the ability to inhibit microbial growth. The agar diffusion 
assay is a classical method to determine such activity. The bacteria or fungi to be 
assayed are suspended in liquefied soft agar which is then poured uniformly onto an 
agar plate. A paper disc, to which a solution of the compound of interest is applied, is 
placed on the surface of the agar. The compound diffuses through the disk into the 
agar. After incubation, halos are observed where the compound concentration is 
greater than or equal to the one required to inhibit growth. This halo is termed zone 
of inhibition and its diameter is used to estimate the microorganism’s sensitivity to 
that particular compound.68 
All of the synthesized cycloadducts were used in the assay. A sensitive Gram-
positive bacterial strain Micrococcus luteus, and a yeast strain, Hansenula anomala, 
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were used as microorganisms. None of the compounds showed any zone of inhibi-
tion with both of the microbial strains.  
2.2.2. Screening for growth inhibition of mammalian cells 
A cell proliferation test was used for the general screening of the synthesized bicyclic 
compounds for biological activity. To this end, a colorimetric cell viability assay (MTT 
assay) was performed with a mouse connective tissue cell line, L929 (fibroblast). In 
this screening, biological activity is determined as a compound-cell interaction that 
reduces the number of viable cells.69 It must be kept in mind that neither this nor any 
other assay is able to detect all types of bioactivity. Moreover, the obtained viability 
values vary from one cell type to another. Thus, these are solely specific for the cells 
used in the test. 
In this assay cells were incubated with the test compounds for 5 days. After 
the incubation period, the number of viable cells was determined by adding a solu-
tion of a tetrazole dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT). The celluar oxidoreductase enzymes present in viable cells reduce the MTT 
to the insoluble purple-colored-formazan. Thus, the intensity of the purple color re-
flects the number of viable cells. In this way half maximal inhibitory concentration 
values (IC50) of the screened compounds were determined and used as a rough 
quantification of their bioactivity. The results obtained with bridged bicycles derived 
from bromobenzene and hetero-aryl benzenes are shown in Tables 1 and 2, respec-
tively. 
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Table 1: Bioactivity values of bridged bicyclic compounds derived from bromoben-
zene as determined in a cell viability assay. Standard deviations are indicated. Com-
pound structures are found in Fig. 7. 
Compound 
 
IC50 
(µg/mL) 
Compound IC50 
(µg/mL) 
Compounds from N-phenyl  Compounds from chalcone-  
tetrazolidinone  based maleimides  
BrDUD01A 15±2.8 BrDUD12S 19±1.4 
BrDUD01AR 25±0.7 BrDUD13S 24±2.8 
BrDUD01ARAc >40 BrDPD13S 12±1.06 
BrDPD01A 24±2.8 BrDPD13A 5±0.35 
BzDPD01A 10±4.9 BrDUD14S 18±0.7 
Compounds from N-aryl  BrDPD15S 12±0.7 
and –alkyl maleimides  BrDPD15A 12±1.4 
BrDUD02S >40 BrDUD16S 3.5±0.14 
BrDUD02SR >40 BrDUD17S 7±0.35 
BrDUD02SRAc >40 BrDPD17S 20±2.1 
BrDPD02A >40 BrDPD17A 5±0.21 
BrDPD02S >40 BrDUD18S 10±2.8 
BrDUD03S >40 BrDPD18A 10±1.06 
BrDPD03S >40 BrDUD19S 2.5±0.14 
BrDPD03A >40 BrDUD20S 12±2.1 
BrDUD04S >40 BrDPD20S 17±1.06 
BrDPD04S >40 BrDPD20A 14±1.06 
BrDPD04A >40 BrDUD21S 17±0.7 
BrDUD05S >40 BrDPD21A 19±1.4 
BrDUD05A >40 BrDUD22S >40 
BrDPD05S >40 BrDUD23S >40 
BrDPD05A >40 BrDPD23S >40 
BrDUD06S 20±1.4 BrDPD23A >40 
BrDUD06A >40 BrDUD24S >40 
BrDPD06S >40 BrDPD24S >40 
BrDPD06A >40 BrDPD24A >40 
BrDUD07S >40 Compounds from  quinone-  
BrDUD07A >40 based maleimides  
BrDPD07S >40 BrDUD25A 7±1.4 
BrDPD07A >40 BrDUD26S 14±0.7 
BrDUD08S 16±1.06   
BrDUD08A >40   
Compounds from  
cinnamate- 
   
based maleimides    
BrDPD09S 12±2.1   
BrDUD10S >40   
BrDUD10A >40   
BrDPD10S 18±0.7   
BrDPD10A 6±1.06   
BzDPD10A 7±2.5   
BrDPD11A >40   
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The first set of compounds (Table 1) is significantly larger than the second 
and enables correlations between small differences in molecular structures and bio-
activity values. 
As can directly be seen in Table 1, compounds synthesized with cinnamate-
based maleimides and chalcone-based maleimides generally showed higher bio-
activities than the N-aryl and –alkyl maleimide based compounds. More specifically, 
such differences were also observed in the comparisons of the IC50 values of pairs of 
compounds that are identical except for the absence or presence, respectively, of 
the α,β-unsaturated keto moiety. For example, compound BrDUD06S (Table 2), 
showed an IC50 value of 20 µg/mL, but its analogue with a chalcone backbone, com-
pound BrDUD19S exerted the same effect at an almost 10-fold lower concentration 
(2.5 µg/mL). Protection of the diol hydroxy groups resulted in no clear tendency. 
Both, increases and decreases in activity were observed. When hydroxy groups 
were protected, the anti-isomer always showed higher bioactivity than the syn-
isomer. This may be seen, for example, in the case of compounds BrDPD17A and 
BrDPD17S. Amongst the cycloadducts with chalcone backbone, different substitu-
tions of the terminal phenyl ring result in different IC50 values. The 3,4,5-trimethoxy 
and 4-methyl substitutions (BrDUD19S and BrDUD16S) yielded particularly low IC50 
values of 2.5 or 3.5 µg/mL, respectively. Modifications like debromination 
(BzDPD01A, BzDPD10A), reduction of C-C double bond (BrDUD01AR, 
BrDUD02SR) and acetyl protection of hydroxy groups (BrDUD01ARAc, 
BrDUD02SRAc) of the bicyclic compounds showed no significant influence on their 
bioactivity.  
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 In the collection of molecules synthesized from hetero-aryl dienediols, all 
compounds possed unprotected hydroxy groups and all, with the exception of the 
one derived from D01, were endo-syn isomers.  
Table 2: Bioactivity values of bridged bicyclic compounds derived from hetero-aryl 
benzenes as determined in a cell viability assay. Standard deviations are indicated. 
Compound structures are found in Fig. 9. Values of the respective molecules derived from 
bromobenzene (unprotected dienediol 22) are included for comparison. 
Dienophiles 
used for syn-
thesis 
IC 50 vlaues (µg/mL) 
Dienediols used for synthesis 
22 24 25 26 27 28 
D01 15±2.8 30±3.5 25±4.2 30±1.4 35±4.9 NP* 
D06 20±1.4 NP >40 NP 29±2.83 NP 
D10 >40 NP 22±3.53 NP 36±1.43 28±5.6 
D13 24±2.8 NP 20±0.7 NP 15±2.1 NP 
D17 7±0.35 NP 20±1.4 NP 35±4.9 NP 
D18 10±2.8 NP NP NP NP >40 
D19 2.5±0.14 NP 7±0.7 NP 18±0.35 NP 
D20 12±2.1 NP 20±2.8 NP 20±0.35 NP 
D21 17±0.7 NP 18±5.3 NP 22±1.4 NP 
         *NP-compound not prepared 
Among these relatively small numbers of compounds, it is impossible to draw 
general conclusions with respect to the influence of specific structural features. 
However, when comparing the cycloaddition products derived from hetero-aryl di-
enediols with their counterparts derived from the bromo-substituted dienediols (Table 
2), the former in most cases showed higher IC50 values than the latter. It is also 
noteworthy that, among the former compounds, again a compound which possesses 
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the 3,4,5-trimethoxy substitution at the aromatic ring (Py3DUD19S) exhibited the 
lowest IC50 value (7 µg/mL). 
 The total fraction of bridged bicyclic compounds that displayed biological ac-
tivity in this assay was about 26%, taking an IC50 of 15 µg/mL as threshold value.  
2.2.3. Bio-activity profiling 
After having verified biological activity in a mammalian cell line for an appreciable 
fraction of the synthesized bridged bicyclic compounds, it was of interest to obtain 
suggestions about with which cellular processes the molecules interfere. To this end, 
two general bioactivity profiling methods were applied. 
I) Measurement of cellular impedance 
II) High content image analysis 
Altogether, 30 compounds were selected for these profilings; the 16 most ac-
tive of the bromobenzene-derived molecules (Table 1) and the 14 most active of the 
hetero-arylbenzene derived molecules (Table 2).  
 
2.2.3.1. Cellular impedance measurement 
Biological profiling via impedance measurement of cell cultures is a label-free real-
time monitoring technique of cell perturbation. Cellular impedance is the opposition 
of cells to alternating current when voltage is applied. Typically the time course of 
impedance is measured over several days, yielding so-called time-dependent cellu-
lar response profiles (TCRP). The change of cellular impedance over time is sensi-
tive to cellular phenomena like adhesion, proliferation, morphological changes, apop-
tosis and many intracellular interactions. For interpretation of the results, the TCRPs 
of test compounds with unknown mode of action are compared to those obtained 
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from reference compounds for which the phenomena with which they interfere are 
known. Mathematical analysis of these TCRPs by a spline-fitting method and con-
struction of a distance matrix using the basis spline coefficients as descriptors, yields 
distance metrics with numerical values (Euclidean distance) between the reference 
compounds and the compounds under investigation. Hierarchical clustering using 
the distance matrix derived from the spline fitting of TCRPs was used to visualize 
similiarities of the curves represented as a dendrogram. A heatmap representation of 
the Z-transformed basis spline coefficient was used to represent the deviation of the 
basis spline coeficient for each TCRP from the mean.  Compounds which cluster to-
gether might have a similar mode of action. 
To carry out such impedance measurements, cells are incubated and treated 
with the test compounds in a micro-titre plate (E-plate) with embedded gold elec-
trodes at the bottom of each well. The incubation period can be up to 5 days.70 L929 
cells were used for this assay, because they are known to grow in micro-titre plates 
with good adhesion, which is an important criterion for the impedance measurement. 
According to the experience in our laboratory, compounds are added to the cells at 
IC90 concentrations as obtained from the cell viability assay (2.2.2). 
As any clustering algorithm works with certain rules, the dendrograms ob-
tained give not always correct representations of TCRP similarities. Therefore, we 
used the exact numerical values (Euclidean distance) of the curve distances for the 
evaluation. The smaller this value is, the higher is the similarity between the com-
pared curves. The respective distance matrices of the experiments are given in the 
Appendix. 
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2.2.3.1.1. Cellular Impedance profiling with compounds derived from (1S-cis)-3-
bromo-3,5-cyclohexadiene-1,2-diol (22) and protected (1S-cis)-3-bromo-3,5-
cyclohexadiene-1,2-diol (23) 
As the compounds derived from hetero-aryl dienediols were synthesized later, the 
first impedance experiments were carried out with the 16 compounds selected from 
the cycloadditions with unprotected and protected, respectively, dienediols 22 and 
23. The heat map obtained in the first experiment is shown in Fig. 10a.  
 
Fig. 10a: A heat map deduced from the cellular impedance measurement of 16 cycloadducts 
derived from dienediols 22 and 23, co-clustered with a heat map of 24 reference com-
pounds. On the y-axis, TCRP similarity is indicated by a dendrogram representation. On the 
x-axis, time-segmented curve descriptors defined by cubic smoothing of spline-fitted TCRPs 
are shown for the measurement time of 120 h. The ‘z’ score indicates the standard deviation 
from the mean value of the descriptors. For the structures of the bridged bicycles see Fig. 7. 
From the distance matrices (see Appendix), compounds with relatively close 
proximity to reference compounds were identified. Two compounds, BrDP20A (dis-
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tance of 1.15), BrDU22S (distance of 1.7) were relatively close to the reference 
compounds for respiratory-system inhibition and two compounds, BrDUD17S (dis-
tance of 2.04), BrDUD19S (distance of 2.01) were moderately close to translation 
inhibitors. Three compounds (BrDUD01A, BrDPD10A and BrDPD10S) were in prox-
imity to both assayed histone deacetylase (HDAC) inhibitors, scriptamid and oxam-
flatin (distance of 0.56-0.9) and to the tubulin polymerization inhibitors griseofulvin 
and tubulysin (distance of 0.7-1.2). The other compounds showed no close similarity 
to the reference compounds. 
The experiment was repeated with the same compounds under identical con-
ditions to verify the reproducibility of the results. 
 
Fig. 10b.  Heat map cluster from a repetition of the experiment of Fig. 10a. 
The results of the repetition experiment were not in good correlation with the 
first experiment. Only three compounds, which were close to the HDAC inhibiting 
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reference compounds, showed similar results as in the first assay. Among the other 
compounds, one compound (BrDPD17A) was similar (distance of 0.98) to mevas-
tatin and simvastatin, which are known cholesterol biosynthesis inhibiting com-
pounds, and two compounds (BrDUD12S and BrDUD14S) were close (distance of 
1.1, 1.4) to respiratory-chain inhibiting reference compounds. 
2.2.3.1.2. Cellular impedance measurements with compounds derived from 
unprotected hetero-aryl dienediols 
The 14 selected bridged bicyclic compounds synthesized from hetero-aryl dienediols 
were profiled under the same assay conditions used in the above two experiments.  
 
Fig. 11a. A heat map deduced from the cellular impedance measurement of 14 cycloadducts 
derived from unprotected hetero-aryl dienediols, co-clustered with 24 reference compounds. 
For further explanations see legend of Fig 10a. 
The numerical values in distance matrices resulting from the first assay (see 
Appendix) indicated that 12 out of 14 compounds showed the highest TCRP similari-
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ties (distance of 0.5-1.0) with the known proteasome inhibitors MG132 and Velcade. 
Of these molecules, some (Py3DUD01A, PmDUD06S, PmDUD20S and ImDUD10S) 
also displayed TCRP similarities with the curves for inhibitors of translation (distance 
of 0.8-1.0), tubulin polymerization (distance of 0.6-0.7) and p-38 MAP kinase (dis-
tance of 0.87). Among the remaining two compounds one (PmDUD19S) was close to 
translation inhibitors (distance of 1.2) and the other one (Py3DUD19S) clustered with 
a transcription inhibitor (distance of 0.8). The compounds were reexamined under 
identical conditions (Fig. 11b). 
 
Fig. 11b. Heat map cluster from a repetition of the experiment of Fig.11a. 
The outcome of the repetition experiment was fairly consistent with the first 
experiment according to the distance values (see Appendix). Thus, 12 out of 14 
compounds were close (distance of 0.6-0.9) to the proteasome inhibitors, Velcade 
and MG-132. Three compounds (Py3DUD01A, Py3DUD10S and ImDUD10S) from 
these 12 were also close (distance of 0.8-1.0) to p-38 MAP kinase inhibitors. Of the 
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two remaining two compounds, one (Py3DUD19S) was in the proximity of translation 
inhibiting compounds (distance of 0.84) and the other one (Py3DUD13S) was close 
to (distance of 0.9) respiratory-chain inhibiting compounds. Both experiments sug-
gested for the majority of the compounds to be able to inhibit the proteasome. 
2.2.3.2. High content image analysis 
High content image analysis (HCIA) is a bioactivity profiling method that uses the 
visualization of physiological alterations of cells with fluorescent markers. Analysis is 
done by high-throughput automated imaging of multi-labeled cells and statistical 
analysis of sub-cellular image localization and pattern.71a,b This multi-dimensional 
analysis method yields high information content. This method was established in our 
laboratory and assay conditions were optimized as described by Diestel et al..72 
Similar procedures and conditions were adopted to perform the assay in this work 
(for details see Materials and Methods). The cells used are KB 3‒1 (human cervical 
cancer cell line) or A‒498 (human kidney cancer cell line). Incubations are done with 
test compounds and with reference compounds for which the cellular targets are 
known. This is done in a micro-titre plate for overnight. Subsequently, cells are fixed 
and stained with primary antibodies for the protein of interest and complementary 
secondary antibodies that carry a fluorescent reporter. Images of labeled cells are 
recorded at four different sites in each well with the help of automated microscope. 
An example of captured images from one of the experiments is shown in Fig. 12. 
 These images are analyzed with segmentation by specifying parameters like 
stained area, intensity etc. Image analysis information is quantified with defined de-
scriptors (see Table 5, 8 and 9 in Materials & Methods) to produce numerical data. 
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Mining of the numerical data results in correlation coefficient values and different 
visual representation like heat map with dendrogram. 
          
      (A)        (B) 
                                    
                                           (C)  
Fig. 12. Example images of KB 3‒1 cells labeled with (A) DAPI staining of the nucleus 
(blue); (B) an antibody against the endoplasmic reticulum and a fluorescent rabbit anti-rat 
IgG (red); (C) an antibody against cytokeratin and a fluorescent anti-mouse IgG (green); the 
images were captured by the automated microscope.  
All of the 30 compounds selected from both sets of syntheses (see 2.2.3), to-
gether with 63 reference molecules were simultaneously subjected to this profiling 
technique. After image acquisition and analysis, the data were compiled in different 
output forms. One type of the output is in the form of a heat map, associated with a 
dendrogram to show the proximities between test and reference compounds. The 
result of the first experiment, as shown in this form, is depicted in Fig. 13a. As men-
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tioned earlier (refer 2.2.3.1) these dendrograms do not accurately display all dis-
tances. Therefore the numerical correlation values for the exact similarity between 
two compounds, calculated by the Euclidean squared method, were considered for 
the evaluation. The values for the 30 most similar reference compounds are given in 
the Appendix. The closer these values to one, the higher the similarity between two 
compounds. 
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Fig. 13a. A heat map and dendrogram obtained from the high content image analysis with 
30 bridged bicyclic compounds and 64 reference compounds.  
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 The numerical data obtained from the above experiment (see Appendix), 
showed that some test compounds gave good correlation values with more than one 
reference. Eighteen (BrDUD01A, BzDPD01A, BzDPD10A , BrDUD16S, BrDUD17S, 
BrDPD17A, BrDUD18S, BrDUD19S, BrDPD20A, BrDUD26S, Py3DUD01A, 
Py3DUD10S, Py3DUD20S, Py3DUD21S, PmDUD06S, PmDUD19S, and 
ImDUD10S) showed similarity (correlation values of 0.8-0.93) with inhibitors of 
different kinases, 14 (BrDUD01A, BrDPD10S, BrDPD13A, BrDUD12S, BrDUD14S, 
BrDPD17A, BrDUD19S, BrDPD20A, BrDUD26S, Py3DUD13S, Py3DUD17S, 
Py3DUD20S, Py3DUD21S and PmDUD20S) were close (correlation values of 0.8-
0.9) to translation inhibitors, 12 compounds (BrDUD01A, BzDPD01A, BzDPD10A, 
BrDPD10S, BrDPD13A, BrDPD17A, BrDUD17S, BrDPD20A, BrDUD21S, 
Py3DUD21S PmDUD20S and PmDUD13S) showed similarity (correlation values of 
0.77-0.85) to tubulin polymerization inhibiting compounds and 12 compounds 
(BzDPD01A, BrDPD10A, BrDPD13A, BrDUD18S, BrDUD19S, Py3DUD13S, 
Py3DUD17S, Py3DUD19S, Py3DUD20S Py4DUD01A, PmDUD20S and 
PmDUD21S), were close to Golgi appratus-destroying compounds (correlation 
values of 0.8-0.9) Thus, for several of the test molecules, there were indications for 
more than one bioactivity. For example, out of 18 compounds similar to kinase 
inhibitors, some were also close to tubulin polymerization inhibitors.   
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Fig. 13b. Heat map cluster from a repetition of the experiment of Fig. 13a. 
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 The results of the first experiment were not well reproduced, as may be seen 
by comparing Figs. 13a and 13b. The majority of the compounds (BrDUD01A, 
BrDPD10A, BzDPD10A, BrDUD12S, BrDUD14S, Py3DUD01A, Py3DUD19S, 
Py3DUD21S, Py4DUD01A, PmDUD06S, PmDUD21S and ImDUD10S) showed 
close proximity with different kinase-inhibiting compounds (correlation values of 0.75-
0.88) and 9 compounds (BrDUD01A, BzDPD01A BzDPD10A, BrDPD10S, 
BrDUD17S, BrDPD20A, Py3DUD10S, Py3DUD21S and PmDUD13S) showed simi-
larity to actin polymerization-related compounds (correlation values of 0.74-0.87).  
2.2.3.3. Comparison of cellular Impedance measurement and high content im-
age analysis results 
The results acquired from both profiling techniques were compared to select com-
pounds with the highest probability for interference with a particular cellular process. 
These compounds subsequently should be subjected to specific biological assays in 
order to verify the suggested activity. According to the evaluation of the high content 
analysis, the predominant prediction was transcription inhibition and actin polymeri-
zation inhibition, in contrast to the impedance measurement results. The impedance 
profiling suggested proteasome inhibitory activity for many compounds. All of them 
came from the compound collection obtained from hetero-aryl dienediols. Surpris-
ingly, high content image analysis never pointed to this target. For only one com-
pound, both profiling techniques suggested the same phenotype, namely MAP-
kinase pathway inhibition.  
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2.2.3.4. Selection of compounds for specific biological assays from impedance 
measurement and high content image analysis  
Because of the differing results between the two profiling methods, compounds were 
selected separately, based on the following threshold values: ≤1 for impedance 
measurement and ≥ 0.8 for high content image analysis. For impedance measure-
ment 2.26% of all distance values were under the set limit, for high content screening 
0.87% of all correlation values were above the indicated threshold. There was a par-
tial overlap in the assigned compounds. However, assignments typically were for dif-
ferent cellular processes. There was only one case (compound ImDUD10S) to which 
both methods assigned the same activity, inhibition of the MAP kinase pathway.  
 Additional criteria for the assays to be carried out were availability of reagents, 
complexity and laboratory experience with the assay. Thus, eventually four different 
assays were carried out involving 28 compounds, which corresponded to 17 different 
compounds (see Table 3).  
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Table 3. List of selected compounds and specific biological assays from the cellular imped-
ance measurement and high content analysis 
Actin polymerization 
inhibition Assay 
Tubulin polym-
erization inhibi-
tion Assay 
HDAC inhibition 
Assay 
Proteasome inhi-
bition Assay 
BrDUD01A BrDUD01A BrDUD01A PmDUD06S 
BrDUD10S BrDPD10A BrDPD10A PmDUD13S 
BrDUD17S BrDUD18S BzDPD10A PmDUD21S 
BrDUD18S BrDUD19S  Py3DUD01A 
PmDUD13S PmDUD06S  Py3DUD10S 
PmDUD20S Py3DUD01A  Py3DUD17S 
Py3DUD10S Py3DUD21S  Py3DUD20S 
Py3DUD21S ImDUD10S  Py3DUD21S 
   ImDUD10S 
 
2.2.4. Specific biological assays 
A number of specific biological assays were carried out in order to verify the potential 
bioactivities suggested by the two profiling techniques, impedance measurement and 
high content image analysis. The selection of the respective compounds was de-
scribed under 2.2.3.4.  
2.2.4.1. Assay for inhibition of actin-polymerization 
The globular protein actin dynamically forms helical microfilaments, which are in-
volved in important cellular processes like motility, cell division, cytokinesis, vesicle 
and organelle movement etc. It maintains cell adhesion and cell shape.73 Actin po-
lymerization inhibitors interrupt the filamenting process, thereby causing cell death.74 
As shown in Table 3, eight compounds were selected to assay inhibition of actin po-
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lymerization. Ptk2 cells (potooro kidney, epithelium-like) were used for this assay be-
cause of their robust adherence towards several washing steps and their flat mor-
phology for clear visualization of labeled protein structures. The cells were incubated 
overnight with the test compounds at two different concentrations, which were the 
IC50 and IC70 determined in the MTT test (see 2.2.2.). Cells were fixed and subse-
quently stained with Alexa Fluor 488 phalloidin to visualize the actin protein struc-
ture. The cells were examined under the fluorescence microscope. Rhizopodin, 
which is a known actin polymerization inhibitor, was used as positive control. One of 
the compounds, Py3DUD21S, showed a detectable effect on the cytoskeleton of the 
cells by disturbing its tight structure (Fig. 14). However, some stress fibers were still 
observed (shown by red arrows in Fig. 14), which are characteristic actin structures. 
Therefore, a clear effect on actin polymerization could not be confirmed in this assay.  
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(A)                                                                                                (B)                   
 
                                                                                           
                   (C)             (D) 
 Fig. 14. Assay for inhibition of actin polymerization. PtK2 cells were treated with (A) the sol-
vent DMSO as a negative control, (B) Rhizopodin as positive control, (C) and (D) compound 
Py3DUD21S in concentrations of 18 µg/mL, and 23 µg/mL, respectively. Cells were labeled 
with DAPI (blue), Alexa Fluor 488 phalloidin (green). Red arrows indicate stress fibers, which 
are typical actin structures.  
 
2.2.4.2. Assay for inhibition of tubulin polymerization  
Tubulin is a globular polypeptide of 50 KDa. In a reversible reaction it polymerizes to 
form microtubules, which play a vital role in growth, division, and cytoskeletal organi-
zation of normal and tumor cells. Tubulin-polymerization-affecting compounds attack 
microtubules by interfering with the dynamics of tubulin polymerization and depoly-
merization, resulting in apoptotic cell death.75a,b Eight compounds (listed in Table 3) 
were selected for the tubulin inhibition assay. Ptk2 cells were incubated overnight 
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with the test compounds at concentrations of 18 and 23 µg/mL, which were the IC50 
and IC70 determined in the MTT test (see 2.2.2). Nocodazole, a known inhibitor of 
tubulin polymerization, was used as positive control. The cells were fixed and subse-
quently stained with a primary antibody against α-tubulin, followed by a complemen-
tary labeled antibody, anti-mouse IgG, to visualize the tubulin structure. Additionally, 
the cell nucleus was labeled with DAPI. The cells were examined under the fluores-
cence microscope. One of the eight compounds, Py3DUD21S, showed an effect on 
the tubulin structure of the cells at 23 µg/mL (IC70). To determine the concentration-
dependence of this effect, the assay was repeated with concentrations below the 
IC70. As shown in Fig. 15, the compound caused a slight disruption of the tubulin 
structure at 19 µg/mL and a strong disruption 21 µg/mL (indicated by red arrows in 
Fig. 15). As these two concentrations are rather similar, the assay was repeated to 
verify this steep concentration-dependence. The result was well reproduced. The 
enhancement in activity, with a small concentration difference of 2 µg/mL, may be 
due to a cytotoxic effect of the compound on the cells used.  
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(A)                                                                                  (B) 
                       
                                                (C )                                                                                (D)       
Fig. 15. Assay for the inhibition of tubulin polymerization. Microscopic images of compound-
treated PtK2 cells are shown. Cells were labeled with an antibody against α-tubulin and anti-
mouse IgG (green) and with DAPI (blue). (A) cells with solvent control (DMSO), (B) cells with 
nocodazole (0.16 µM) as positive control, (C) and (D) cells treated with 19 µg/mL or 21 
µg/mL, respectively, of compound Py3DUD21S. Red arrows point to the disruption of tubulin 
structures.   
2.2.4.3. Histone deacetylase (HDAC) inhibition Assay 
The reversible acetylation of histones is a vital process, which is critical for the regu-
lation of gene expression via transcription in eukaryotic cells. Histone deacetylase 
(HDAC) removes acetyl groups from lysine residues of histone proteins. The result-
ing positive charges increase the histone affinity towards DNA and thereby block the 
access of positive transcription factors. This down-regulates gene expression. 
HDACs are involved in a number of human disease states, namely several cancers, 
neurological disorders, and aging.76 
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Fig. 16. Fluorometric HDAC inhibition assay. The measured fluorescence is directly propor-
tional to the deacetylation activity of the sample. Assay 1 shows the blank with only cell lys-
ate with HDAC and assay 2 shows the positive control, Trichostatin. Assays 3-6 show the 
results with the compounds, BrDUD01A, BrDPD10A and BzDPD10A. Standard deviations 
are indicated. 
Three compounds (shown in Table 3) were assayed for potential HDAC inhibi-
tory activity. HDAC activity is assayed by a two-step process. In the first step deace-
tylation of the acetylated lysine side-chain of a peptide, coupled with a fluorescent 
reporter, 7-amino-4-methylcoumarin (AMC) is catalyzed by a HDAC-containing HeLa 
cell lysate. In the next step, to quantify this reaction, trypsine is added to catalyse the 
cleavage of the deacetylated substrate to release fluorescent AMC. The decrease in 
emitted fluorescence is directly proportional to the activity of the test compound.77 
The HeLa cell lysate with peptide substrate was incubated with the test compounds 
for 30 min in a tissue culture plate. The trypsin reagent was added to generate the 
fluorescence emitter. A known HDAC inhibitor, trichostatin A, was used as positive 
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control. A plot of the fluorescence signals at different concentrations of the com-
pounds is shown in Fig. 16. The results did not show an HDAC inhibition and did not 
confirm the suggestions of both profiling techniques, impedance measurement and 
high content image analysis. 
2.2.4.4. Proteasome inhibition assay 
The proteasome, a multicatalytic complex, is responsible for most of the intracellular 
protein degradation, including proteins that regulate cell cycle and apoptosis. Inhibi-
tion of the proteasome results in accumulation of unwanted proteins and leads to cell 
death.78a,b Nine of the profiled compounds, shown in Table 3, were selected to verify 
proteasome inhibition. The assay performed measures the proteolytic activity asso-
ciated with the proteasome via bioluminescence. KB 3‒1 cells were used in this as-
say because of their good adherence and growth. A proteasome substrate peptide 
that was conjugated with a luminogenic reporter group, aminoluciferin, was added to 
the KB 3‒1 cells. The cellular proteasome cleaves the peptide to release the amino-
luciferin. The luminescence signal is proportional to proteasome activity. The cells 
were incubated with the test compounds for 2 h. Thereafter, the proteasome sub-
strate was added and the generated luminescence was measured. A known protea-
some inhibitor, MG-132, was used as positive control. All compounds were used at 
two concentrations, 25 and 50 µg/mL. One out of the nine compounds, PmDUD21S, 
showed significant inhibition. The assay was repeated with different amounts of this 
compound to determine the concentration-dependency of the effect (Fig. 17). This 
clearly confirmed the inhibitory effect at concentrations of 25 µg/mL or above. 
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Fig. 17. Bioluminescent proteasome inhibition assay. Proteolysis is proportional to the rela-
tive luminescence units (RLU) determined. Column 1 shows the solvent control, DMSO and 
MeOH in a 1:1 ratio (v/v). Column 2 shows MG-132 as positive control (4 µM). Columns 3-7 
show the effects of compound PmDUD21S at 20, 25, 30, 35, 40 µg/mL concentrations. 
Standard deviations are indicated. 
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3. Conclusions 
 
3.1. Chemistry 
In order to carry out Diels-Alder reactions with dienediols, a protection of the hydroxy 
groups is not generally required. However, protection exerts a considerable influence 
on the stereoselectivity in the cycloaddition reactions. The presence of free hydroxy 
groups typically strongly favours formation of the syn isomer. Thus, no protection of 
the diol moiety is recommended, if this is the desired isomer. The opposite recom-
mendation holds, if the anti isomer is to be obtained in higher yields. 
 The reactivity of heteroaryl-substituted dienediols in [4+2] cycloaddition was 
significantly lower than that of the bromo-substituted dienediol. Conditions for the 
cycloadditions with heteroaryl dienediols have not yet been described. From the ex-
perience of this work, suitable reaction conditions are working at elevated tempera-
tures (100-120 ºC) in a sealed vessel.  
The distribution between syn and anti isomers in the cycloadducts was largely 
in accordance with literature data. Thus, also after protection of the syn-directing diol 
moiety, the predominant isomer obtained with maleimide-derived dienophiles was in 
most cases the syn product. A maleimide-specific directing effect, involving H-bond 
formation, is proposed to explain this finding.  
3.2. Biology 
It was possible to obtain a significant fraction of bioactive compounds through the 
described synthetic route, leading to bridged bicyclic compounds.  
With the bioactivity profiling methods and conditions used, it was difficult to 
identify specific activities for active compounds. Possible reasons include the, in my 
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hands, limited reproducibility of the results as well as limitations in the number and 
kind of available reference compounds.  
In spite of these problems and with a limited number of assays, that could be 
carried out, two types of bioactivity predictions of the profilings were confirmed: i) in-
terference with the polymerization of tubulin and ii) inhibition of the proteasome.   
 The bridged bicyclic compounds synthesized in this work are just one exam-
ple for molecules possessing a permanent three-dimensional structure. Following the 
devised synthetic route and principles, larger and structurally more diverse collec-
tions of bridged bicycles and related molecules may be generated with the aid of 
solid-phase chemistry. Moreover, other synthetic pathways, leading to different types 
of three-dimensional compounds, may be developed and explored. 
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4. Materials and Methods 
4.1. Materials 
4.1.1. Instruments/Equipment 
Automatic Microsope ImageXpress Micro (Molecular Devices) 
Bacterial cell incubator Memmert 
Cell counter Cedex XS (Innovatis) 
Centrifuges 5810R (Eppendorf) 
Eucoryatic cell incubator CO2-Auto-Zero (Heraeus) 
Fluorescence microscope Axioplan (Zeiss) with  camera Axiocam (Zeiss) ca 
Incubator (Impedance 
measurement) 
MIDI 40, CO2 incubator (Thermo Fischer Scientific) 
Impedance recorder RTCA single plate (Roche/Acea Biosciences) 
Laminar airflow Maxisafe 2020 (Thermo Fisher Scientific) 
Light microscope Axiovert 35 (Zeiss) 
Microlitre plate reader Infinite M200 pro (Tecan) 
Microlitre plate washer BioTek, 405-select TS 
Microlitre pipettes Research und Reference (Eppendorf) 
Pipetting robot with 
pintool 
Biomek FXP Laboratory Automation Workstation 
(Beckman Coulter) 
Shaker Titramax 1000 (Heidolph) 
Vacum pump Vacusafe comfort (Integra Biosciences) 
4.1.2. Softwares 
ChemBio Draw, ACD Labs (for NMR analysis), AxioVision 3.1, SigmaPlot 12.3, Mi-
crosoft Office 2010. 
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4.1.3. Antibodies/Dyes 
Primary Antibodies  
Alexa Fluor 488 Phalloidin Invitrogen 
Anillin Antibody (Rabbit) Bethyl Laboratories 
Anti-Calmodulin (Mouse) Invitrogen 
Anti-c-Fos (Rabbit) Sigma 
Anti-phospho-CREB (Rabbit) Sigma  
DAPI dihydrochloride  Sigma 
GRP94 (Rat) Dianova  
Monoclonal anti-p53, Clone BP53-12 (Mouse) Sigma  
Monoclonal anti-Pan Cytokeratin, Clone C-11 (Mouse) Sigma  
Monoclonal anti-Splicing Factor SC-35, Clone SC-35 
(Mouse) 
Sigma 
Monoclonal anti-α-Tubulin, Clone B-5-1-2 (HCA), Clone 
DM1A (Mouse) 
Sigma  
Phospho-p38 MAPK (Thr180/Tyr182) Antibody (Rabbit) New England Biolabs 
Phospho-p44/42 MAPK (Thr202/Tyr204) Antibody 
(Mouse) 
New England Biolabs 
Secondary Antibodies  
Atto 488 anti-rabbit (Goat) Sigma  
Alexa Fluor 488 anti-rat (Rabbit) Invitrogen  
Atto 594 anti-mouse (Goat) Sigma  
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4.1.4. Culture media 
 For bacterial cultures EBSS,79 and for hyphal fungi M9080 medium was used. All 
media components were purchased from Becton Dickinson, Fluka, Merck, Roth or 
Sigma and Gibco. Media was prepared by mixing the following components at RT.   
EBSS (pH 7.0):    Peptone (5 g/l) 
         Proteosepeptone (5 g/l) 
Meat extract (1 g/l) 
Yeast extract (1 g/l) 
HEPES (10 g/l) 
M90 (pH 5.6):    Malt extract (30 g/l)  
    Peptone (3 g/l) 
For the agar media (agar diffusion tests), 15 g/L agar was added. The media were 
prepared in distilled H2O and autoclaved immediately. The autoclaved media were 
then stored at 4 °C. 
5.1.5. Media for cell cultures 
Eukaryotic cells used for the assays with their respective media are given in the Ta-
ble 4. 
Table 4. Media used for different cell lines 
Cell line Medium Manufacturer Supplements 
PtK2 MEM Gibco 
- 1x Non-essential amino ac-
ids (Gibco) 
- 1x GlutaMAX (Gibco) 
- 10 % FBS (Lonza) 
L-929, KB-3-1 DMEM Lonza 10 % FBS (Lonza) 
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4.1.6. Assay kits 
Histone Deacetylase Assay, Fluorometric Sigma 
Proteasome-GloTM Assay Promega 
 
4.1.7. Microorganisms and cell lines 
The microorganisms and eukaryotic cells used for the bioactivity assays are listed 
below in the Tables 5 and 6.  
Table 5. Microorganisms and their sources 
Microorganisms Abbreviation Source Type 
Micrococcus luteus Mcl HZI collection Gram-positive 
bacterium 
Hansenula anomala Hna DSMZ 70263 Yeast 
 
Table 6. Mammalian cell lines with their source, origin and morphology 
Cell line Source Species Origin Morphology 
L-929 
DSMZ 
ACC2 
Mouse Connective tissue Fibroblast 
KB 3‒1 
DSMZ 
ACC158 
Human Cervical cancer 
Epithelium-
like 
PtK2 
ATCC CCL-
56 
Potoroo Kidney 
Epithelium-
like 
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4.2. Methods 
4.2.1. Chemistry 
4.2.1.1. Chromatography 
A. TLC 
TLC was performed on pre-coated aluminum sheets, silica gel 60 F254 with concen-
trating zone 20 x 2.5 cm (Merck). Zones were detected by fluorescence quenching 
with irradiation at 254 nm and/or staining using a solution of Vaughn’s reagent 9.6 
g (NH4)6 MO7O24 4 H2O and 0.4 g Ce(SO4)2 4 H2O in 200 mL 7 M H2SO4) followed by 
heating with a heat gun until the solution was dried. 
 B. Column chromatography/flash chromatography 
This was done with flash silica gel (J. T. Baker) having pore size of 60 Å. Column 
size and silica gel quantity was selected according to a previous report.81 
C. Preparative HPLC  
A Merck-Hitachi (L-6200A) pump with UV detector (L-7400) was used with 1% 
trifluoroacetic acid in acetonitrile and water as eluent for purification. A Phenomenex 
Luna C18 RP column (250 mm length) with 20 mm diameter was used.  
4.2.1.2. Microwave reactions 
The reactions were performed in a sealed reaction vessel of an MLS START 1500 
microwave synthesizer with an output power of 500 W. Reactions were carried out 
with time intervals of 10-15 minutes with TLC monitoring. 
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4.2.1.3. NMR spectrometry  
Spectral data was recorded with instruments Bruker DPX-Bruker AV II-300 (300.1 
MHz for 1H NMR, 13C NMR with 75.5 MHz, T = 296 K), AV III-400 (400.1 MHz for 
1H NMR, 13C NMR with 100.6 MHz, T = 296 K), Bruker DRX-400 (400.1 MHz for 1H 
NMR, 13C NMR with 100.6 MHz, T = 300 K), and Bruker AV II-600 (600.1 MHz for 
1H NMR; 13C NMR with 150.3 MHz). The chemical shifts  are given in ppm and 
referenced to the internal solvent standard. Multiplicities of NMR signals are indi-
cated as follows: s (singlet), d (doublet), t (triplet), m (multiplet), dd (doublet of dou-
blets), dt (doublet of triplets) and br. s (broad singlet). 
4.2.1.4. Synthetic procedures 
All non-aqueous reactions were conducted in dried glassware under drying tube. All 
yields refer to isolated compounds after the final purification process, unless other-
wise stated. For all purified compounds, the purity was estimated by 1H NMR spec-
trometry. The purity of the compounds was always above 85%.  
4.2.1.4.1. General procedure for the preparation of N-aryl or -alkyl maleimides 
(D2, D4-D8, D23 and D24)  
Appropriate aryl or alkyl amine (2, 5.8 mmol) was added to the solution of maleic an-
hydride (1, 5.1 mmol) in ethyl acetate (15 mL) and stirred at RT for 1 h. The resultant 
solid precipitate was filtered and dried under vacuum to get the intermediate, N-
substituted aminobutenoic acid (3). A mixture of NaOAc (2.55 mmol) and acetic an-
hydride (25.5 mmol) was heated to 80 ºC in an oil bath until all NaOAc had dis-
solved. The intermediate (3) was added to this solution and stirred at 80 ºC. After 1 
h, the reaction was cooled to RT and diluted with ice cold-water (15 mL). The aque-
ous layer was extracted with ethyl acetate (2 x 15 mL). The organic layers were 
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combined and dried over Na2SO4. The organic layer was evaporated at 30 ºC under 
reduced pressure. The obtained crude compounds were purified by column chroma-
tography using petroleum ether and ethyl acetate as eluents to obtain compounds in 
40-65% yield. Compounds were characterized by 1H NMR and 13C NMR spectrome-
try. 
1-(4-fluorophenyl)-1H-pyrrole-2,5-dione (D02) 
1H NMR (500 MHz, CDCl3): δ 6.85 (s, 2H), 7.15 (dd, J = 9.00, 8.24 Hz, 2H), 7.28–
7.33 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 116.1, 116.3, 127.2, 127.9, 134.3, 
160.9, 162.8, 169.4. 
1-(4-acetylphenyl)-1H-pyrrole-2,5-dione (D04) 
1H NMR (500 MHz, CDCl3): δ 2.61 (s, 3H), 6.88 (s, 2H), 7.48–7.59 (m, 2H), 8.00–
8.09 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 26.7, 125.4, 129.2, 134.5, 135.6, 136.0, 
169.0, 197.0. 
1-(4-methoxyphenyl)-1H-pyrrole-2,5-dione (D05) 
1H NMR (500 MHz, CDCl3): δ 3.85 (s, 3H), 6.85 (s, 2H), 6.97–7.02 (m, 2H), 7.22–
7.27 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 55.5, 114.5, 123.8, 127.6, 134.2, 159.0, 
169.9. 
1-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (D06) 
1H NMR (500 MHz, CDCl3): δ 3.84 (s, 9H), 6.52 (s, 2H), 6.84 (s, 2H); 
13C NMR (126 
MHz, CDCl3): δ 56.3, 60.9, 104.1, 126.7, 134.2, 137.9, 153.5, 169.7. 
 
 
MATERIALS AND METHODS 
 
75 
 
3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl acetate (D07) 
1H NMR (700 MHz, CDCl3): δ 2.29 (s, 3H), 6.83 (s, 2H), 7.10 (ddd, J = 8.23, 2.21, 
0.97 Hz, 1H), 7.19 (t, J = 2.15 Hz, 1H), 7.26–7.29 (m, 1H), 7.42–7.47 (m, 1H); 13C 
NMR (176 MHz, CDCl3): δ 21.1, 119.0, 120.9, 122.8, 129.7, 132.2, 134.3, 150.8, 
169.1. 
1-(4-nitrophenyl)-1H-pyrrole-2,5-dione (D08) 
1H NMR (500 MHz, CDCl3): δ 6.92 (s, 2H), 7.64–7.71 (m, 2H), 8.29–8.36 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 124.5, 125.5, 134.6, 137.1, 146.3, 168.5. 
1-(2-morpholinoethyl)-1H-pyrrole-2,5-dione (D24) 
1H NMR (300 MHz, CDCl3): δ 2.42‒2.49 (m, 4H), 2.52 (t, J = 6.40 Hz, 2H), 3.59‒3.68 
(m, 6H), 6.68 (s, 2H); 13C NMR (126 MHz, CDCl3): δ 36.0, 53.1, 56.3, 67.2, 134.1, 
168.2. 
4.2.1.4.2. General procedure for the preparation of 4'-amino chalcone-based 
maleimides (D12-D20) 
A solution of the appropriate aromatic aldehyde (8, 1.5 mmol) in ethanol (1 mL) was 
cooled in an ice bath to 0 ºC, after which a precooled solution of sodium hydroxide in 
water (2.3 mmol in 2 mL) was added dropwise with stirring. A precooled mixture of 
oxoaminobutenoic acid (7, 1.3 mmol), and sodium hydroxide (2.6 mmol) in water (2 
mL) was added dropwise to the stirring solution of the aryl aldehyde over a period of 
15 min with stirring. The reaction mixture was stirred at RT for 14 h, acidified with 2N 
hydrochloric acid and stirred for another 1h. The resultant precipitate was filtered, 
washed with water and vacuum dried. The completely dried solid intermediate (9) 
was added to the mixture of NaOAc (0.7 mmol) and acetic anhydride (7.7 mmol), 
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which was preheated to 90 ºC for 20 min. The resultant reaction mixture was stirred 
at 90 ºC.  After 1 h, the reaction was allowed to cool to RT and quenched with ice-
cold water (5 mL). The aqueous layer was extracted with ethyl acetate (2 x 15 mL), 
and the combined organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. The crude compound was purified by column chromatography us-
ing dichloromethane as eluents. Compounds were characterized by 1H NMR and 13C 
NMR spectrometry and their yields were in 40-60%. 
1-(4-cinnamoylphenyl)-1H-pyrrole-2,5-dione (D12) 
1H NMR (500 MHz, CDCl3): δ 7.19 (s, 3H), 7.37‒7.43 (m, 5H), 7.46 (d, J = 15.72 Hz, 
1H), 7.61‒7.64 (m, 2H), 7.78 (d, J = 15.8, 1H), 8.03‒8.07 (m, 2H); 13C NMR (126 
MHz, CDCl3): δ 121.6, 126.3, 128.5, 129.1, 129.3, 134.6, 135.2, 136.0, 
137.9,145.6,169.1,189.6. 
(E)-1-(4-(3-(4-fluorophenyl)acryloyl)phenyl)-1H-pyrrole-2,5-dione (D13) 
1H NMR (500 MHz, CDCl3): δ 6.90 (s, 2H), 7.08–7.15 (m, 2H), 7.43 (d, J = 15.72 Hz, 
1H), 7.54–7.59 (m, 2H), 7.61–7.66 (m, 2H), 7.78 (d, J = 15.56 Hz, 1H), 8.08–8.13 (m, 
2H); 13C NMR (126 MHz, CDCl3): δ 116.2, 116.3, 121.5, 125.5, 129.4, 130.4, 131.1, 
134.5, 135.3, 137.0, 144.0, 169.0, 189.3. 
 (E)-1-(4-(3-(4-chlorophenyl)acryloyl)phenyl)-1H-pyrrole-2,5-dione (D14) 
1H NMR (500 MHz, CDCl3): δ 6.91 (s, 2H), 7.36–7.42 (m, 2H), 7.48 (d, J = 15.56 Hz, 
1H), 7.53–7.60 (m, 4H), 7.76 (d, J = 15.72 Hz, 1H), 8.07–8.13 (m, 2H); 13C NMR 
(126 MHz, CDCl3): δ 122.2, 125.5, 129.3, 129.4, 129.7, 133.3, 134.5, 135.4, 136.7, 
136.9, 143.8, 169.0, 189.2. 
 
MATERIALS AND METHODS 
 
77 
 
(E)-1-(4-(3-(p-tolyl)acryloyl)phenyl)-1H-pyrrole-2,5-dione (D16) 
1H NMR (300 MHz, CDCl3): δ 2.39 (s, 3H), 6.87–6.90 (m, 2H), 7.19–7.27 (m, 2H), 
7.46 (d, J = 15.82 Hz, 1H), 7.50–7.59 (m, 4H), 7.80 (d, J = 15.64 Hz, 1H), 8.06–8.15 
(m, 2H); 13C NMR (75 MHz, CDCl3): δ 21.58, 120.83, 125.44 128.58, 129.37, 129.78, 
132.06, 134.46, 135.11, 137.3, 141.33, 145.47, 169.01, 198.6.  
 (E)-1-(4-(3-(4-methoxyphenyl)acryloyl)phenyl)-1H-pyrrole-2,5-dione (D17) 
1H NMR (500 MHz, CDCl3): δ 3.86 (s, 3H), 6.89 (s, 2H), 6.94 (d, J = 8.70 Hz, 2H), 
7.39 (d, J = 15.72 Hz, 1H), 7.53–7.57 (m, 2H), 7.60 (d, J = 8.54 Hz, 2H), 7.80 (d, J = 
15.56 Hz, 1H), 8.08–8.12 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 55.5, 114.5, 119.5, 
125.4, 127.5, 129.3, 130.4, 134.5, 135.0, 137.5, 145.3, 161.9, 169.0, 189.5. 
(E)-1-(4-(3-(3,4-dimethoxyphenyl)acryloyl)phenyl)-1H-pyrrole-2,5-dione (D18) 
1H NMR (500 MHz, CDCl3): δ 3.91–3.97 (m, 6H), 6.87–6.92 (m, 3H), 7.15 (d, J = 
1.83 Hz, 1H), 7.23 (dd, J = 8.32, 1.91 Hz, 1H), 7.36 (d, J = 15.56 Hz, 1H), 7.53–7.57 
(m, 2H), 7.76 (d, J = 15.56 Hz, 1H), 8.06–8.12 (m, 2H); 13C NMR (126 MHz, CDCl3): 
δ 56.0, 56.1, 110.2, 111.2, 119.9, 123.3, 125.4, 127.8, 129.3, 134.5, 135.0, 137.4, 
145.6, 149.4, 151.7, 169.0, 189.6. 
 (E)-1-(4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenyl)-1H-pyrrole-2,5-dione (D19) 
1H NMR (500 MHz, CDCl3): δ 3.88–3.93 (m, 9H), 6.85–6.87 (m, 2H), 6.90 (s, 2H), 
7.37 (d, J = 15.56 Hz, 1H), 7.54–7.59 (m, 2H), 7.72 (d, J = 15.72 Hz, 1H), 8.07–8.12 
(m, 2H); 13C NMR (126 MHz, CDCl3): δ 56.3, 61.0, 105.6, 121.4, 125.1, 129.4, 130.3, 
134.5, 135.2, 137.3, 145.6, 153.6, 169.0, 189.7. 
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(E)-1-(4-(3-(4-(methylthio)phenyl)acryloyl)phenyl)-1H-pyrrole-2,5-dione (D20) 
1H NMR (500 MHz, CDCl3): δ 2.51 (s, 3H), 6.89 (s, 2H), 7.22–7.28 (m, 2H), 7.46 (d, 
J = 15.72 Hz, 1H), 7.56 (d, J = 8.54 Hz, 4H), 7.78 (d, J = 15.56 Hz, 1H), 8.07–8.12 
(m, 2H); 13C NMR (126 MHz, CDCl3): δ 15.2, 120.7, 125.5, 126.0, 128.9, 129.5, 
131.3, 134.5, 135.1, 137.2, 142.7, 144.9, 169.0, 189.4. 
(E)-1-(4-(3-(3-nitrophenyl)acryloyl)phenyl)-1H-pyrrole-2,5-dione (D21) 
1H NMR (500 MHz, DMSO-d6): δ 7.24 (s, 2H), 7.56–7.62 (m, 2H), 7.73–7.79 (m, 1H), 
7.89 (d, J = 15.72 Hz, 1H), 8.20 (d, J = 15.72 Hz, 1H), 8.26–8.39 (m, 4H), 8.80 (t, J = 
1.91 Hz, 1H); 13C NMR (126 MHz, DMSO-d6): δ 123.1, 124.7, 124.8, 126.3, 129.4, 
130.4, 134.9, 135.2, 135.9, 136.0, 136.6, 141.7, 148.5, 169.6, 188.3. 
4.2.1.4.3. General procedure for the preparation of 4’-cinnamic-maleimides (D9-
D11) 
4-Amino-(E)-cinnamic acid (14, 3.1 mmol) was added to a solution of maleic anhy-
dride (2.76 mmol) in ethyl acetate (5 mL) and stirred at RT for 2 h. The resultant pre-
cipitate was filtered and dried under vacuum. The dried intermediate (15) was added 
to a mixture of NaOAc (1.5 mmol) and acetic anhydride (15.3 mmol), which was pre-
heated to 80 ºC and stirred at same temperature. After 1 h, the reaction mixture was 
diluted with ice-cold water (15 mL). The precipitated solid was filtered and washed 
with water. The obtained brown-coloured crude compound was purified by column 
chromatography using dichloromethane as eluent to yield the free acid (16). The acid 
(16, 0.12 m mol) was refluxed with a catalytic amount of sulfuric acid and molecular 
sieves (100 mg) in methanol or ethanol (5 mL) for overnight. Reaction was monitored 
by TLC and after completion of the reaction, the molecular sieves were filtered off 
and the solvent was evaporated from the reaction mixture under reduced pressure at 
MATERIALS AND METHODS 
 
79 
 
30 ºC. The remaining solid was neutralized with a saturated aqueous solution of Na-
HCO3. The aqueous layer was two times extracted with equal volumes of ethyl ace-
tate. The organic layers were combined, dried over Na2SO4.and the solvent was re-
moved under reduced pressure at 30 ºC. The crude compound was purified by col-
umn chromatography using ethyl acetate and petroleum ether as eluents. Com-
pounds were characterized by 1H NMR and 13C NMR spectrometry and their yields 
were in 45-60%. 
(E)-3-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)acrylic acid (D09) 
1H NMR (400 MHz, Acetone-d6): δ 6.58 (d, J = 16.28 Hz, 1H), 7.06 (s, 2H), 7.46–
7.51 (m, 2H), 7.71 (d, J = 16.28 Hz, 1H), 7.76–7.85 (m, 2H); 13C NMR (101 MHz, 
Acetone-d6): δ 120.0, 127.4, 129.4, 134.5, 135.4, 144.4, 167.5, 170.3. 
Methyl (E)-3-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)acrylate (D10) 
1H NMR (500 MHz, CDCl3): δ 3.86 (s, 3H), 6.89 (s, 2H), 6.94 (d, J = 8.70 Hz, 2H), 
7.39 (d, J = 15.72 Hz, 1H), 7.53–7.57 (m, 2H), 7.60 (d, J = 8.54 Hz, 2H), 7.80 (d, J = 
15.56 Hz, 1H), 8.08–8.12 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 51.8, 118.9, 126.0, 
128.8, 132.9, 133.8, 134.4, 143.6, 167.2, 169.2. 
Ethyl (E)-3-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)acrylate (D11) 
1H NMR (300 MHz, CDCl3): δ 1.34 (t, J = 7.16 Hz, 3H), 4.27 (q, J = 7.16 Hz, 2H), 
6.44 (d, J = 16.01 Hz, 1H), 6.86 (s, 2H), 7.38–7.44 (m, 2H), 7.58–7.63 (m, 2H), 7.68 
(d, J = 16.01 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 14.3, 57.3, 60.7, 118.9, 126.0, 
128.7, 132.8, 133.7, 134.4, 143.4, 167.0, 169.1. 
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4.2.1.4.4. Procedure for the synthesis of chromone-based maleimide (D22) 
 7-Amino-2-methylchromone (18, 2.9 mmol) was added to a solution of maleic anhy-
dride (1, 2.6 mmol) in ethyl acetate (10 mL). The mixture was stirred at RT for 1 h. 
The resultant solid precipitate was filtered and dried at RT under vacuum to get the 
intermediate, N-substituted aminobutenoic acid (19). A mixture of NaOAc (1.45 
mmol) and acetic anhydride (14.5 mmol) was heated to 80 ºC in an oil bath until all 
NaOAc had dissolved. The intermediate (19) was added to this solution and stirred 
at 80 ºC. After 1 h, the reaction was cooled to RT and diluted with ice cold water (10 
mL). The aqueous layer was extracted with ethyl acetate (2 x 10 mL). The organic 
layers were combined and dried over Na2SO4. The organic layer was evaporated at 
30 ºC under reduced pressure and obtained crude compound was purified by col-
umn chromatography using ethyl acetate and petroleum ether as eluents to obtain 
compound D22 in 70% yield. It was characterized by NMR and mass spectrometry. 
1-(2-methyl-4-oxo-4H-chromen-7-yl)-1H-pyrrole-2,5-dione (D22) 
1H NMR (300 MHz, CDCl3): δ 2.38 (s, 3 H), 6.11–6.21 (m, 1H), 6.87–6.93 (m, 2H), 
7.48 (dd, J = 8.67, 1.88 Hz, 1H), 7.56 (d, J = 1.70 Hz, 1H), 8.21–8.28 (m, 1H); 13C 
NMR (75 MHz, CDCl3): δ 20.61, 110.86, 114.34, 121.73, 122.4, 126.6, 134.5, 135.8, 
156.5, 166.6, 168.7, 177.5; NSI-MS: m/z 256.0607 (M+H)+ 
4.2.1.4.5. General procedure for the synthesis of amino-N-alkanoic acid 
maleimides (21) 
Maleic anhydride (1, 10.2 mmol) was mixed with an appropriate amino acid (10.2 
mmol) in acetic acid (10 mL) and the mixture was stirred at RT for 5 hours until a 
mono-coupled amide intermediate precipitated out. The intermediate was filtered and 
washed with water, followed by dissolution at reflux in water. Evaporation of water 
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under reduced pressure at 30 ºC and subsequent recrystalyzation in methanol gave 
the pure maleimide derivatives in good yields (55-70%). The compounds were char-
acterized by 1H NMR. 
4.2.1.4.6. Procedure for the protection of (1S-cis)-3-bromo-3,5-cyclohexadiene-
1,2-diol (22) 
2,2-Dimethoxypropane (1.1 mmol) and a catalytic amount of p-toluenesulfonic acid 
were added to a pre-cooled solution of the dienediol (22, 0.52 mmol) in dichloro-
methane (4 mL). The reaction mixture was allowed to warm to RT and stirred until 
the reaction was complete (monitored by TLC). The reaction mixture was neutralized 
with triethylamine (0.2 mmol), and dichloromethane was evaporated under reduced 
pressure at 25 ºC. The crude compound was purified by flash column chromatogra-
phy using ethylacetate and petroleum ether as eluents to obtain the pure compound 
in 90% yield.  
TLC: 1:9 ethyl acetate, petroleum ether, Rf 0.7. 
4.2.1.4.7. General procedure for [4+2] cycloadditions with protected (1S-cis)-3-
bromo-3,5-cyclohexadiene-1,2-diol (23) 
A mixture of the protected dienediol (23, 0.07 mmol) and a dienophile (0.08 mmol) in 
chloroform (4 mL) was refluxed under a drying tube for 2-4 days. Reaction progress 
was monitored by TLC. After the reaction was completed, the solvent was removed 
under reduced pressure at 25 ºC and the crude compound was purified by column 
chromatography using ethyl acetate and petroleum ether as eluents to afford 
cycloadducts in 40-70% yield. The compounds were characterized by 1H NMR, 13C 
NMR and mass spectrometry. 
TLC: 1:1 ethyl acetate, petroleum ether, Rf 0.3-0.6.  
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4-bromo-2,2-dimethyl-7-phenyl-3a,4,10,10a-tetrahydro-6H-4,10-etheno[1,3]dio-
xolo[4,5-d][1,2,4]triazolo[1,2-a]pyridazine-6,8(7H)-dione  
BrDPD01A (anti): 1H NMR (300 MHz, CDCl3): δ 1.36–1.44 (m, 6H), 4.64–4.79 (m, 
2H), 5.18 (ddd, J = 5.56, 4.05, 1.32 Hz, 1H), 6.29 (ddd, J = 8.43, 5.79, 0.85 Hz, 1H), 
6.58 (dt, J = 8.48, 1.32 Hz, 1H), 7.33–7.49 (m, 5H); 13C NMR (75 MHz, CDCl3): δ 
25.5, 25.6, 51.9, 68.0, 74.9, 81.3, 112.5, 125.8, 128.3, 128.8, 129.2, 130.9, 134.8, 
154.4, 154.9; NSI-MS: m/z 406, 408; HRMS (NSI): For C17H16BrN3O4+H (M+H)
+ m/z 
calcd., 406.0402; found, 406.0397. 
4-bromo-6-(4-fluorophenyl)-2,2-dimethyl-3a,4,4a,7a,8,8a-hexahydro-5H-4,8-eth-
eno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione  
BrDPD02S (endo-syn): 1H NMR (600 MHz, CDCl3): δ 1.41 (s, 3H), 1.57 (s, 3H), 
3.49–3.55 (m, 1H), 3.60–3.65 (m, 1H), 3.70–3.76 (m, 1H), 4.30 (dd, J = 8.25, 3.85 
Hz, 1H), 4.39 (d, J = 8.44 Hz, 1H), 6.17 (dd, J = 8.44, 6.24 Hz, 1H), 6.39 (d, J = 9.54 
Hz, 1H), 7.08–7.15 (m, 2H), 7.16–7.22 (m, 2H); 13C NMR (101 MHz, CDCl3): δ 24.4, 
26.3, 36.6, 40.2, 44.2, 57.1, 75.1, 82.0, 113.4, 116.0, 116.3, 128.2, 128.3, 131.0, 
137.1, 161.1, 163.5, 174.4, 176.6; NSI-MS: m/z 422, 424; HRMS (NSI): For 
C19H17BrFNO4+H (M+H)
+ m/z calcd., 422.0403; found, 422.0398. 
BrDPD02A (endo-anti): 1H NMR (600 MHz, CDCl3): δ 1.35 (s, 3H), 1.40 (s, 3H), 3.05 
(dd, J = 8.44, 2.93 Hz, 1H), 3.12–3.17 (m, 1H), 3.55–3.60 (m, 1H), 4.40–4.48 (m, 
2H), 6.07 (dd, J = 8.25, 6.42 Hz, 1H), 6.29 (d, J = 8.80 Hz, 1H), 7.10–7.15 (m, 2H), 
7.16–7.22 (m, 2H); 13C NMR (101 MHz, CDCl3): δ 25.1, 25.4, 35.9, 42.2, 46.7, 57.7, 
78.0, 83.7, 110.7, 116.1, 116.4, 128.2, 128.3, 129.7, 134.5, 160.7, 164.0, 172.4, 
174.7; NSI-MS: m/z 422, 424; HRMS (NSI): For C19H17BrFNO4+H (M+H)
+ m/z calcd., 
422.0403; found, 422.0398. 
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4-bromo-6-(4-bromophenyl)-2,2-dimethyl-3a,4,4a,7a,8,8a-hexahydro-5H-4,8-eth-
eno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione   
BrDPD03S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 1.41 (s, 3H), 1.57 (s, 3H), 
3.49–3.57 (m, 1H), 3.59–3.66 (m, 1H), 3.70–3.76 (m, 1H), 4.26–4.33 (m, 1H), 4.34–
4.43 (m, 1H), 6.16 (dd, J = 8.48, 6.59 Hz, 1H), 6.39 (d, J = 8.48 Hz, 1H), 7.07–7.15 
(m, 2H), 7.52–7.61 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 24.4, 26.3, 36.6, 40.3, 
44.2, 57.5, 85.0, 82.0, 113.4, 127.5, 127.9, 128.0, 131.8, 132.3, 137.1, 174.1, 176.3; 
NSI-MS: m/z 481, 483, 485; HRMS (NSI): For C19H17Br2NO4+H (M+H)
+ m/z calcd., 
481.9602; found, 481.9597. 
BrDPD03A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.35 (s, 3H), 1.40 (s, 3H), 
3.01–3.08 (m, 1H), 3.15 (d, J = 8.29 Hz, 1H), 3.54–3.61 (m, 1H), 4.44 (s, 2H), 6.04–
6.09 (m, 1H), 6.28 (d, J = 8.85 Hz, 1H), 7.07–7.14 (m, 2H), 7.53–7.61 (m, 2H); 13C 
NMR (75 MHz, CDCl3): δ 25.1, 25.4, 35.9, 42.3, 46.7, 57.6, 78.0, 83.7, 110.7, 122.8, 
127.9, 129.7, 130.4, 132.4, 134.5, 172.1, 174.4; NSI-MS: m/z 481, 483, 485; HRMS 
(NSI): For C19H17Br2NO4+H (M+H)
+ m/z calcd., 481.9602; found, 481.9597. 
6-(4-acetylphenyl)-4-bromo-2,2-dimethyl-3a,4,4a,7a,8,8a-hexahydro-5H-4,8-eth-
eno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione  
BrDPD04S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 1.42 (s, 3H), 1.57 (s, 3H), 2.60 
(s, 3H), 3.50–3.58 (m, 1H), 3.61–3.69 (m, 1H), 3.74 (s, 1H), 4.27–4.34 (m, 1H), 
4.36–4.43 (m, 1H), 6.18 (dd, J = 8.57, 6.50 Hz, 1H), 6.41 (d, J = 8.48 Hz, 1H), 7.35–
7.38 (m, 2H), 7.98–8.05 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 24.4, 26.3, 26.7, 36.6, 
40.3, 44.3, 57.4, 75.0, 82.0, 113.4, 126.4, 129.1, 131.0, 135.7, 136.9, 137.1, 174.0, 
176.2, 197.0; NSI-MS: m/z 446, 448; HRMS (NSI): For C21H20BrNO5+H (M+H)
+ m/z 
calcd., 446.0603; found, 446.0598. 
MATERIALS AND METHODS 
 
84 
 
BrDPD04A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.36 (s, 3H), 1.40 (s, 3H), 2.60 
(s, 3H), 3.05–3.11 (m, 1H), 3.18 (d, J = 8.48 Hz, 1H), 3.55–3.63 (m, 1H), 4.45 (s, 
2H), 6.08 (dd, J = 8.57, 6.31 Hz, 1H), 6.31 (d, J = 8.48 Hz, 1H), 7.33–7.38 (m, 2H), 
8.00–8.05 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 25.1, 25.4, 26.7, 35.9, 42.3, 46.8, 
57.6, 76.0, 83.7, 110.8, 126.4, 129.1, 129.8, 134.5, 135.4, 137.0, 172.0, 174.3, 
197.0; NSI-MS: m/z 446, 448; HRMS (NSI): For C21H20BrNO5+H (M+H)
+ m/z calcd., 
446.0603; found, 446.0598. 
4-bromo-6-(4-methoxyphenyl)-2,2-dimethyl-3a,4,4a,7a,8,8a-hexahydro-5H-4,8-
etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione  
BrDPD05S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 1.41 (s, 3H), 1.53 (s, 3H), 
3.49–3.57 (m, 1H), 3.58–3.65 (m, 1H), 3.69–3.75 (m, 1H), 3.80 (s, 3H), 4.26–4.33 
(m, 1H), 4.36–4.42 (m, 1H), 6.16 (dd, J = 8.57, 6.31 Hz, 1H), 6.39 (d, J = 8.67 Hz, 
1H), 6.89–6.98 (m, 2H), 7.06–7.15 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 24.4, 26.3, 
36.6, 40.2, 44.2, 55.5, 57.6, 75.1, 82.1, 113.3, 114.4, 124.3, 127.6, 130.1, 137.0, 
160.0, 174.7, 176.9; NSI-MS: m/z 434, 436; HRMS (NSI): For C20H20BrNO5+H 
(M+H)+ m/z calcd., 434.0603; found, 434.0598. 
BrDPD05A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.35 (s, 3H), 1.40 (s, 3H), 
2.99–3.07 (m, 1H), 3.09–3.18 (m, 1H), 3.50–3.63 (m, 1H), 3.81 (s, 3H), 4.39–4.50 
(m, 2H), 6.06 (dd, J = 8.48, 6.22 Hz, 1H), 6.28 (d, J = 8.48 Hz, 1H), 6.87–7.00 (m, 
2H), 7.05–7.15 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 25.1, 25.4, 35.9, 42.2, 46.6, 
55.6, 57.8, 78.1, 83.7, 110.7, 114.5, 124.1, 127.6, 129.7, 134.5, 159.8, 172.7, 175.0; 
NSI-MS: m/z 434, 436; HRMS (NSI): For C20H20BrNO5+H (M+H)
+ m/z calcd., 
434.0603; found, 434.0598. 
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4-bromo-2,2-dimethyl-6-(3,4,5-trimethoxyphenyl)-3a,4,4a,7a,8,8a-hexahydro-5H-
4,8-etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione  
BrDPD06S (endo-syn): 1H NMR (400 MHz, CDCl3): δ 1.42 (s, 3H), 1.57 (s, 3H), 1.73 
(s, 1H), 3.49–3.58 (m, 1H), 3.59–3.66 (m, 1H), 3.73 (d, J = 8.14 Hz, 1H), 3.78–3.86 
(m, 9H), 4.23–4.44 (m, 2H), 6.11–6.24 (m, 1H), 6.36–6.47 (m, 3H); 13C NMR (75 
MHz, CDCl3): δ 24.4, 26.3, 36.7, 40.3, 44.2, 55.4, 56.3, 58.8, 77.2, 82.0, 103.2, 
113.3, 126.9, 129.7, 136.5, 153.5, 174.0, 176.2; NSI-MS: m/z 494, 496; HRMS 
(NSI): For C22H24BrNO7+H (M+H)
+ m/z calcd., 494.0814; found, 494.0809. 
BrDPD06A (endo-anti): 1H NMR (400 MHz, CDCl3): δ 1.35 (s, 3H), 1.40 (s, 3H), 3.03 
(dd, J = 8.39, 2.80 Hz, 1H), 3.14 (d, J = 8.65 Hz, 1H), 3.53–3.61 (m, 1H), 3.76–3.87 
(m, 9H), 4.38–4.50 (m, 2H), 6.08 (dd, J = 8.65, 6.61 Hz, 1H), 6.30 (d, J = 8.65 Hz, 
1H), 6.39 (s, 2H); 13C NMR (75 MHz, CDCl3): δ 25.1, 25.4, 35.9, 42.2, 46.7, 56.3, 
57.7, 60.9, 78.1, 83.7, 104.1, 110.7, 126.9, 129.7, 134.6, 153.5, 172.5, 174.7; NSI-
MS: m/z 494, 496; HRMS (NSI): For C22H24BrNO7+H (M+H)
+ m/z calcd., 494.0814; 
found, 494.0809. 
3-(4-bromo-2,2-dimethyl-5,7-dioxo-3a,4,4a,5,7,7a,8,8a-octahydro-6H-4,8-etheno-
[1,3]dioxolo[4,5-f]isoindol-6-yl)phenyl acetate  
BrDPD07S (endo-syn): 1H NMR (600 MHz, CDCl3): δ 1.41 (s, 3H), 1.57 (s, 3H), 2.27 
(s, 3H), 3.49–3.55 (m, 1H), 3.60–3.65 (m, 1H), 3.72 (d, J = 8.44 Hz, 1H), 4.29 (dd, J 
= 8.25, 3.85 Hz, 1H), 4.38 (d, J = 8.07 Hz, 1H), 6.13–6.18 (m, 1H), 6.38 (d, J = 8.80 
Hz, 1H), 7.03–7.08 (m, 1H), 7.10–7.16 (m, 2H), 7.39–7.45 (m, 1H); 13C NMR (75 
MHz, CDCl3): δ 21.1, 24.4, 26.3, 36.6, 40.2, 44.2, 57.5, 75.1, 82.0, 113.4, 119.6, 
121.9, 123.4, 129.6, 131.0, 132.5, 137.1, 150.1, 168.9, 174.1, 176.2; NSI-MS: m/z 
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462, 464; HRMS (NSI): For C21H20BrNO6+H (M+H)
+ m/z calcd., 462.0548; found, 
462.0547. 
BrDPD07A (endo-anti): 1H NMR (600 MHz, CDCl3): δ 1.35 (s, 4H), 1.40 (s, 4H), 2.28 
(s, 3H), 2.99–3.06 (m, 1H), 3.11–3.16 (m, 1H), 3.53–3.60 (m, 1H), 4.38–4.48 (m, 
2H), 6.03–6.09 (m, 1H), 6.24–6.31 (m, 1H), 7.03–7.08 (m, 1H), 7.10–7.17 (m, 2H), 
7.40–7.47 (m, 1H); 13C NMR (75 MHz, CDCl3): δ 21.1, 25.1, 25.4, 35.9, 42.2, 46.6, 
57.7, 78.0, 83.7, 110.7, 119.7, 122.1, 123.4, 129.6, 129.7, 132.2, 134.5, 150.8, 
168.9, 172.1, 174.3; NSI-MS: m/z 462, 464; HRMS (NSI): For C21H20BrNO6+H 
(M+H)+ m/z calcd., 462.0548; found, 462.0547. 
(E)-3-(4-(4-bromo-2,2-dimethyl-5,7-dioxo-3a,4,4a,5,7,7a,8,8a-octahydro-6H-4,8-
etheno[1,3]dioxolo[4,5-f]isoindol-6-yl)phenyl)acrylic acid  
BrDPD09S (endo-syn): 1H NMR (400 MHz, Acetone-d6): δ 1.41 (s, 3H), 1.55 (s, 3H), 
3.40–3.47 (m, 1H), 3.70 (dd, J = 8.65, 3.05 Hz, 1H), 3.80 (d, J = 8.65 Hz, 1H), 4.38–
4.49 (m, 2H), 6.30 (dd, J = 8.39, 6.36 Hz, 1H), 6.42 (d, J = 8.65 Hz, 1H), 6.57 (d, J = 
15.77 Hz, 1H), 7.26–7.33 (m, 2H), 7.69 (d, J = 15.77 Hz, 1H), 7.75–7.82 (m, 2H); 13C 
NMR (101 MHz, Acetone-d6): δ 24.6, 26.3, 37.6, 41.4, 45.6, 59.7, 76.0, 83.0, 113.6, 
120.4, 128.0, 129.3, 132.4, 135.0, 135.4, 137.4, 144.2, 167.5, 175.0, 177.2; NSI-MS: 
m/z 474, 476; HRMS (NSI): For C22H20BrNO6 (M+H)
+ m/z calcd.,474.0552; found, 
474.0547. 
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Methyl-(E)-3-(4-(4-bromo-2,2-dimethyl-5,7-dioxo-3a,4,4a,5,7,7a,8,8a-octahydro-
6H-4,8-etheno[1,3]dioxolo[4,5-f]isoindol-6-yl)phenyl)acrylate  
BrDPD10S (endo-syn): 1H NMR (400 MHz, CDCl3): δ 1.41 (s, 3H), 1.57 (s, 3H), 3.54 
(dt, J = 6.36, 3.43 Hz, 1H), 3.60–3.68 (m, 1H), 3.71–3.77 (m, 1H), 3.80 (s, 3H), 4.30 
(dd, J = 8.14, 4.07 Hz, 1H), 4.36–4.43 (m, 1H), 6.17 (dd, J = 8.39, 6.36 Hz, 1H), 
6.35–6.48 (m, 2H), 7.27 (d, J = 8.14 Hz, 2H), 7.58 (d, J = 8.65 Hz, 2H), 7.66 (d, J = 
15.77 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ 24.4, 26.3, 36.6, 40.3, 44.3, 51.9, 
57.5, 75.1, 82.0, 113.4, 119.2, 126.7, 128.6, 131.0, 133.1, 134.8, 137.1, 143.5, 
167.1, 174.2, 176.4; NSI-MS: m/z 488, 490; HRMS (NSI): For C23H22BrNO6+H 
(M+H)+ m/z calcd., 488.0709; found, 488.0703. 
BrDPD10A (endo-anti): 1H NMR (400 MHz, CDCl3): δ 1.35 (s, 3H), 1.40 (s, 3H), 3.06 
(dd, J = 8.39, 2.80 Hz, 1H), 3.12–3.19 (m, 1H), 3.56–3.61 (m, 1H), 3.80 (s, 3H), 
4.39–4.51 (m, 2H), 6.07 (dd, J = 8.65, 6.10 Hz, 1H), 6.29 (d, J = 8.65 Hz, 1H), 6.44 
(d, J = 16.28 Hz, 1H), 7.26–7.28 (m, 2H), 7.54–7.61 (m, 2H), 7.63–7.71 (m, 1H); 13C 
NMR (101 MHz, CDCl3): δ 25.4, 25.8, 36.3, 42.7, 47.1, 52.2, 58.0, 78.4, 84.1, 111.1, 
119.7, 127.1, 129.0, 130.1, 133.2, 134.9, 135.3, 143.8, 167.5, 172.6, 174.8; NSI-MS: 
m/z 488, 490; HRMS (NSI): For C23H22BrNO6+H (M+H)
+ m/z calcd., 488.0709; 
found, 488.0703. 
Ethyl-(E)-3-(4-(4-bromo-2,2-dimethyl-5,7-dioxo-3a,4,4a,5,7,7a,8,8a-octahydro-
6H-4,8-etheno[1,3]dioxolo[4,5-f]isoindol-6-yl)phenyl)acrylate 
BrDPD11A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.28–1.45 (m, 9H), 3.02–3.11 
(m, 1H), 3.12–3.20 (m, 1H), 3.55–3.62 (m, 1H), 4.21–4.31 (m, 2H), 4.40–4.52 (m, 
2H), 6.07 (dd, J = 8.57, 6.31 Hz, 1H), 6.29 (d, J = 8.67 Hz, 1H), 6.43 (d, J = 16.01 
Hz, 1H), 7.22–7.30 (m, 3H), 7.58 (d, J = 8.48 Hz, 2H), 7.66 (d, J = 16.01 Hz, 1H); 13C 
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NMR (75 MHz, CDCl3): δ 14.3, 25.1, 25.4, 35.9, 42.3, 46.7, 57.7, 60.7, 78.0, 83.7, 
110.7, 119.8, 126.7, 128.6, 129.7, 132.7, 134.5, 135.0, 143.1, 166.7, 172.2, 174.5; 
NSI-MS: m/z 502, 504; HRMS (NSI): For C24H24BrNO6+H (M+H)
+ m/z calcd., 
502.0865; found, 502.0860. 
(E)-4-bromo-6-(4-(3-(4-fluorophenyl)acryloyl)phenyl)-2,2-dimethyl-3a,4,4a,7a,8,-
8a-hexahydro-5H-4,8-etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione  
BrDPD13S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 1.42 (s, 3H), 1.58 (s, 2H), 
3.51–3.59 (m, 1H), 3.63–3.70 (m, 1H), 3.73–3.80 (m, 1H), 4.27–4.35 (m, 1H), 4.37–
4.44 (m, 1H), 6.20 (dd, J = 8.48, 6.59 Hz, 1H), 6.42 (d, J = 8.48 Hz, 1H), 7.06–7.15 
(m, 2H), 7.34–7.45 (m, 3H), 7.58–7.67 (m, 2H), 7.77 (d, J = 15.82 Hz, 1H), 8.02–8.10 
(m, 2H); 13C NMR (75 MHz, CDCl3): δ 24.4, 26.3, 36.7, 40.3, 44.4, 57.5, 75.0, 82.0, 
113.4, 116.1, 116.4, 121.6, 126.4, 130.6, 130.4, 129.3, 131.1, 135.4, 137.1, 138.0, 
144.2, 174.1, 176.3, 189.4; NSI-MS: m/z 552, 554; HRMS (NSI): For 
C28H23BrFNO5+H (M+H)
+ m/z calcd., 552.0822; found, 552.0816. 
BrDPD13A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.36 (s, 3H), 1.41 (s, 3H), 
3.00–3.24 (m, 2H), 3.55–3.66 (m, 1H), 4.40–4.51 (m, 2H), 6.05–6.15 (m, 1H), 6.27–
6.38 (m, 1H), 7.11 (t, J = 8.57 Hz, 2H), 7.35–7.45 (m, 3H), 7.63 (dd, J = 8.76, 5.37 
Hz, 2H), 7.77 (d, J = 15.82 Hz, 1H), 8.07 (d, J = 8.48 Hz, 2H); 13C NMR (75 MHz, 
CDCl3): δ 25.1, 25.4, 35.9, 42.4, 46.8, 57.6, 78.0, 83.7, 110.8, 116.2, 116.4, 121.5, 
126.4, 129.3, 129.8, 130.4, 130.6, 134.6, 135.1, 138.2, 144.3, 172.1, 174.3, 189.3; 
NSI-MS: m/z 552, 554; HRMS (NSI): For C28H23BrFNO5+H (M+H)
+ m/z calcd., 
552.0822; found, 552.0816. 
 
MATERIALS AND METHODS 
 
89 
 
(E)-4-bromo-6-(4-(3-(4-bromophenyl)acryloyl)phenyl)-2,2-dimethyl-3a,4,4a,7a,8,-
8a-hexahydro-5H-4,8-etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione  
BrDPD15S (endo-syn): 1H NMR (400 MHz, CDCl3): δ 1.42 (s, 3H), 1.58 (s, 3H), 
3.52–3.60 (m, 1H), 3.67 (dd, J = 8.65, 3.05 Hz, 1H), 3.74–3.81 (m, 1H), 4.22–4.44 
(m, 2H), 6.19 (dd, J = 8.39, 6.36 Hz, 1H), 6.42 (d, J = 8.65 Hz, 1H), 7.37–7.59 (m, 
7H), 7.73 (d, J = 15.77 Hz, 1H), 8.06 (d, J = 8.65 Hz, 2H); 13C NMR (101 MHz, 
CDCl3): δ 25.1, 25.4, 35.9, 42.2, 46.7, 57.8, 78.1, 83.8, 110.7, 114.5, 117.7, 120.2, 
124.8, 125.5, 127.1, 127.6, 129.1, 129.7, 134.5, 159.8, 172.7, 174.5, 189.2; NSI-MS: 
m/z 612, 614, 616; HRMS (NSI): For C28H23Br2NO5+H (M+H)
+ m/z calcd., 612.0021; 
found, 612.0021. 
BrDPD15A (endo-anti): 1H NMR (400 MHz, CDCl3): δ 1.36 (s, 3H), 1.41 (s, 3H), 
3.05–3.12 (m, 1H), 3.16–3.22 (m, 1H), 3.57–3.64 (m, 1H), 4.42–4.50 (m, 2H), 6.06–
6.13 (m, 1H), 6.31 (d, J = 8.65 Hz, 1H), 7.35–7.58 (m, 7H), 7.73 (d, J = 15.77 Hz, 
1H), 8.07 (d, J = 8.14 Hz, 2H); NSI-MS: m/z 612, 614, 616; HRMS (NSI): For 
C28H23Br2NO5+H (M+H)
+ m/z calcd., 612.0021; found, 612.0021. 
(E)-4-bromo-6-(4-(3-(4-methoxyphenyl)acryloyl)phenyl)-2,2-dimethyl-3a,4,4a,-
7a,8,8a-hexahydro-5H-4,8-etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione 
BrDPD17S (endo-syn): 1H NMR (600 MHz, CDCl3): δ 1.42 (s, 3H), 1.58 (s, 3H), 
3.53–3.58 (m, 1H), 3.66 (dd, J = 8.44, 2.93 Hz, 1H), 3.75–3.79 (m, 1H), 3.85 (s, 3H), 
4.31 (dd, J = 8.07, 3.67 Hz, 1H), 4.40 (d, J = 8.07 Hz, 1H), 6.19 (dd, J = 8.44, 6.60 
Hz, 1H), 6.42 (d, J = 8.44 Hz, 1H), 6.90–6.96 (m, 2H), 7.35 (d, J = 15.41 Hz, 1H), 
7.37–7.41 (m, 2H), 7.56–7.61 (m, 2H), 7.77 (d, J = 15.77 Hz, 1H), 8.04–8.07 (m, 2H); 
13C NMR (101 MHz, CDCl3): δ 24.4, 26.3, 36.7, 40.3, 44.3, 55.5, 57.5, 75.0, 82.0, 
113.4, 114.5, 119.6, 126.3, 129.2, 130.4, 131.1, 135.1, 137.1, 138.4, 145.2, 161.9, 
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174.1, 176.3, 189.6; NSI-MS: m/z 564, 566; HRMS (NSI): For C29H26BrNO6+H 
(M+H)+ m/z calcd., 564.1022; found, 564.1016. 
BrDPD17A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.42 (s, 3H), 1.58 (s, 3H), 
3.50–3.60 (m, 1H), 3.62–3.70 (m, 1H), 3.77 (d, J = 8.10 Hz, 1H), 3.85 (s, 3H), 4.25–
4.44 (m, 2H), 6.19 (dd, J = 8.48, 6.59 Hz, 1H), 6.42 (d, J= 8.48 Hz, 1H), 6.89–6.98 
(m, 2H), 7.31–7.42 (m, 3H), 7.55–7.63 (m, 2H), 7.77 (d, J = 15.64 Hz, 1H), 8.03–8.10 
(m, 2H); 13C NMR (75 MHz, CDCl3): δ 25.1, 25.4, 35.9, 42.3, 46.8, 55.5, 57.7, 78.0, 
83.7, 110.7, 114.5, 119.5, 126.2, 127.5, 129.2, 129.8, 130.4, 134.6, 134.9, 138.6, 
145.5, 161.9, 172.1, 174.4, 189.6; NSI-MS: m/z 564, 566; HRMS (NSI): For 
C29H26BrNO6+H (M+H)
+ m/z calcd., 564.1022; found, 564.1016. 
(E)-4-bromo-6-(4-(3-(3,4-dimethoxyphenyl)acryloyl)phenyl)-2,2-dimethyl-3a,4,-
4a,7a,8,8a-hexahydro-5H-4,8-etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione 
BrDPD18A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.36 (s, 3H), 1.41 (s, 3H), 
3.01–3.23 (m, 2H), 3.55–3.65 (m, 1H), 3.94 (d, J = 4.33 Hz, 6H), 4.38–4.52 (m, 2H), 
6.05–6.14 (m, 1H), 6.27–6.35 (m, 1H), 6.85–6.95 (m, 1H), 7.09–7.23 (m, 2H), 7.27–
7.44 (m, 4H), 7.74 (d, J = 15.64 Hz, 1H), 8.01–8.10 (m, 2H); 13C NMR (75 MHz, 
CDCl3): δ 25.1, 25.4, 35.9, 42.3, 46.8, 56.0, 57.6, 78.0, 83.7, 110.2, 110.8, 111.2, 
119.9, 123.4, 126.4, 127.7, 129.3, 129.8, 134.6, 134.9, 138.6, 145.9, 149.4, 151.7, 
172.1, 174.4, 189.9; NSI-MS: m/z 594, 596; HRMS (NSI): For C30H28BrNO7+H 
(M+H)+ m/z calcd., 594.1127; found, 594.1122. 
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(E)-4-bromo-2,2-dimethyl-6-(4-(3-(4-(methylthio)phenyl)acryloyl)phenyl)-
3a,4,4a,7a,8,8a-hexahydro-5H-4,8-etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-
dione 
 BrDPD20S (endo-syn): 1H NMR (400 MHz, CDCl3): δ 1.35–1.45 (m, 3H), 1.54 (s, 
3H), 2.48–2.53 (m, 3H), 3.55 (dt, J = 6.61, 3.31 Hz, 1H), 3.63–3.70 (m, 1H), 3.73–
3.79 (m, 1H), 4.26–4.47 (m, 2H), 6.14–6.24 (m, 1H), 6.42 (d, J = 8.14 Hz, 1H), 7.20–
7.30 (m, 2H), 7.36–7.48 (m, 3H), 7.54 (d, J = 8.65 Hz, 2H), 7.76 (d, J = 15.77 Hz, 
1H), 8.06 (d, J = 8.65 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 15.2, 24.3, 26.3, 30.7, 
40.3, 44.3, 57.5, 75.0, 82.0, 113.0, 120.0, 126.0, 126.4, 128.9, 129.2, 131.1, 135.3, 
137.1, 138.2, 142.8, 145.0, 174.1, 176.3, 189.5; NSI-MS: m/z 580, 582; HRMS 
(NSI): For C29H26BrNO5S+H (M+H)
+ m/z calcd., 580.0793; found, 580.0788. 
BrDPD20A (endo-anti): 1H NMR (400 MHz, CDCl3): δ 1.36 (s, 3H), 1.41 (s, 3H), 2.51 
(s, 3H), 3.09 (dd, J = 8.39, 2.80 Hz, 1H), 3.17–3.22 (m, 1H), 3.56–3.65 (m, 1H), 
4.40–4.52 (m, 2H), 6.05–6.13 (m, 1H), 6.31 (d, J = 8.65 Hz, 1H), 7.21–7.29 (m, 2H), 
7.36–7.46 (m, 3H), 7.54 (d, J = 8.14 Hz, 2H), 7.76 (d, J = 15.77 Hz, 1H), 8.06 (d, J = 
8.65 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 15.2, 25.1, 25.4, 35.9, 42.3, 46.8, 57.6, 
78.0, 83.7, 110.8, 120.7, 126.0, 126.4, 128.9, 129.3, 129.8, 113.2, 134.6, 138.4, 
142.8, 145.0, 172.1, 174.3, 189.5; NSI-MS: m/z 580, 582; HRMS (NSI): For 
C29H26BrNO5S+H (M+H)
+ m/z calcd., 580.0793; found, 580.0788. 
(E)-4-bromo-2,2-dimethyl-6-(4-(3-(3-nitrophenyl)acryloyl)phenyl)-3a,4,4a,7a,8,-
8a-hexahydro-5H-4,8-etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione   
BrDPD21A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.36 (s, 3H), 1.41 (s, 3H), 
3.07–3.26 (m, 2H), 3.49–3.53 (m, 1H), 3.49–3.67 (m, 1H), 4.32–4.54 (m, 2H), 6.04–
6.16 (m, 1H), 6.25–6.38 (m, 1H), 7.38–7.50 (m, 2H), 7.55–7.68 (m, 2H), 7.78–7.97 
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(m, 2H), 8.07–8.16 (m, 2H), 8.27 (dd, J = 9.32, 1.22 Hz, 1H), 8.50 (t, J = 1.88 Hz, 
1H); 13C NMR (75 MHz, CDCl3): δ 25.1, 25.4, 35.9, 42.4, 46.8, 57.6, 78.0, 83.7, 
110.8, 122.5, 124.3, 124.9, 126.6, 129.4, 129.7, 129.8, 130.1, 134.4, 134.6, 135.6, 
136.5, 142.4, 148.8, 172.1, 174.3, 188.7; NSI-MS: m/z 579, 581; HRMS (NSI): For 
C28H23BrN2O7+H (M+H)
+ m/z calcd., 579.0767; found, 579.0761. 
4-bromo-6-ethyl-2,2-dimethyl-3a,4,4a,7a,8,8a-hexahydro-5H-4,8-etheno[1,3]-
dioxolo[4,5-f]isoindole-5,7(6H)-dione  
BrDPD23S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 1.09 (t, J = 7.25 Hz, 3H), 1.39 
(s, 3H), 1.53 (s, 3H), 3.36–3.60 (m, 5H), 4.21–4.28 (m, 1H), 4.31–4.38 (m, 1H), 
5.97–6.11 (m, 1H), 6.27 (d, J = 9.04 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 13.0, 
24.4, 26.3, 34.0, 36.3, 40.1, 44.1, 57.7, 75.1, 82.1, 113.2, 130.7, 136.8, 175.3, 177.3; 
NSI-MS: m/z 356, 358; HRMS (NSI): For C15H18BrNO4+H (M+H)
+ m/z calcd., 
356.0497; found, 356.0492. 
BrDPD23A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.10 (t, J = 7.16 Hz, 3H), 1.33 
(s, 3H), 1.38 (s, 3H), 2.85 (dd, J = 8.29, 2.64 Hz, 1H), 2.93–3.01 (m, 1H), 3.43–3.56 
(m, 3H), 4.34–4.42 (m, 2H), 5.94 (dd, J = 8.57, 6.31 Hz, 1H), 6.17 (dd, J = 8.67, 0.94 
Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 12.9, 25.1, 25.4, 34.2, 35.6, 42.2, 46.6, 57.8, 
78.1, 83.7, 110.6, 129.4, 134.2, 173.3, 175.4; NSI-MS: m/z 356, 358; HRMS (NSI): 
For C15H18BrNO4+H (M+H)
+ m/z calcd., 356.0497; found, 356.0492. 
4-bromo-2,2-dimethyl-6-(2-morpholinoethyl)-3a,4,4a,7a,8,8a-hexahydro-5H-4,8-
etheno[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione  
BrDPD24S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 1.39 (s, 3H), 1.54 (s, 3H), 
2.35–2.53 (m, 6H), 3.38–3.49 (m, 2H), 3.51–3.71 (m, 7H), 4.22–4.29 (m, 1H), 4.31–
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4.38 (m, 1H), 6.03 (dd, J = 8.29, 6.78 Hz, 1H), 6.26 (d, J = 8.48 Hz, 1H); 13C NMR 
(75 MHz, CDCl3): δ 24.4, 26.3, 35.8, 36.3, 40.2, 44.1, 53.4, 55.3, 57.7, 67.1 75.1, 
82.1 113.3, 130.7, 136.8, 175.4, 177.5; NSI-MS: m/z 441, 443; HRMS (NSI): For 
C19H25BrN2O5+H (M+H)
+ m/z calcd., 441.1025; found, 441.1020. 
BrDPD24A (endo-anti): 1H NMR (400 MHz, CDCl3): δ 1.33 (s, 3H), 1.38 (s, 3H), 
2.36–2.51 (m, 6H), 2.88 (dd, J = 8.14, 2.54 Hz, 1H), 2.99 (d, J = 8.14 Hz, 1H), 3.47 
(dt, J = 5.85, 2.67 Hz, 1H), 3.55–3.67 (m, 6H), 4.35–4.42 (m, 2H), 5.94 (dd, J = 8.65, 
6.10 Hz, 1H), 6.16 (d, J = 8.65 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ 25.1, 25.4, 
35.6, 36.0, 42.3, 46.6, 53.4, 56.2, 57.8, 67.1, 78.1, 83.8, 110.6, 129.4, 134.2, 173.5, 
175.6; NSI-MS: m/z 441, 443; HRMS (NSI): For C19H25BrN2O5+H (M+H)
+ m/z calcd., 
441.1025; found, 441.1020. 
4.2.1.4.8. General procedure for [4+2] cycloadditions with unprotected (1S-cis)-
3-bromo-3,5-cyclohexadiene-1,2-diol (22) 
A mixture of dienediol (22, 0.07 mmol) and a dienophile (0.08 mmol) in toluene (5 
mL) was refluxed with a drying tube for 2-4 days. Reaction progress was monitored 
by TLC. After the reaction was completed, the solvent was removed under reduced 
pressure at 25 ºC and the crude compound was purified by column chromatography 
using ethyl acetate and petroleum ether as eluents to afford cycloadducts in 40-70% 
yield. The compounds were characterized by 1H NMR, 13C NMR and mass spec-
trometry. 
TLC: 3:7 ethyl acetate, dichloromethane, Rf 0.4-0.6.  
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5-bromo-10,11-dihydroxy-2-phenyl-5,8-dihydro-1H-5,8-ethano[1,2,4]triazolo[1,2-
a]pyridazine-1,3(2H)-dione  
BrDUD01A (anti): 1H NMR (300 MHz, Acetone-d6): δ 4.26 (d, J = 7.35 Hz, 1H), 4.50 
(dd, J = 7.16, 3.77 Hz, 1H), 4.98 (ddd, J = 5.60, 4.00, 1.51 Hz, 1H), 6.48 (ddd, J = 
8.48, 5.65, 0.75 Hz, 1H), 6.60–6.66 (m, 1H), 7.37–7.55 (m, 5H); 13C NMR (75 MHz, 
Acetone-d6): δ 54.4, 67.5, 72.3, 73.6, 127.1, 129.3, 129.8, 130.3, 132.5, 136.0, 
155.1, 155.6; NSI-MS: m/z 366, 368; HRMS (NSI): For C14H12BrN3O4+H (M+H)
+ m/z 
calcd., 366.0089; found, 366.0084. 
4-bromo-2-(4-fluorophenyl)-8,9-dihydroxy-3a,4,7,7a-tetrahydro-1H-4,7-ethano-
isoindole-1,3(2H)-dione   
BrDUD02S (endo-syn): 1H NMR (300 MHz, DMSO–d6): δ 3.01 - 3.11 (m, 1H), 3.45–
3.52 (m, 1H), 3.60 (d, J = 8.29 Hz, 1H), 3.64–3.74 (m, 2H), 5.41–5.60 (m, 2H), 6.19 
(dd, J = 8.67, 6.40 Hz, 1H), 6.33 (d, J = 8.48 Hz, 1H), 7.15–7.25 (m, 2H), 7.27–7.37 
(m, 2H); 13C NMR (75 MHz, CDCl3): δ 44.4, 64.3, 70.5, 115.7, 116.0, 128.0, 129.0, 
129.2, 131.2, 136.0, 159.8, 163.1, 175.0, 177.1; NSI-MS: m/z 382, 384; HRMS 
(NSI): For C16H13BrFNO4+H (M+H)
+ m/z calcd., 382.009; found, 382.0085. 
4-bromo-2-(4-bromophenyl)-8,9-dihydroxy-3a,4,7,7a-tetrahydro-1H-4,7-ethano-
isoindole-1,3(2H)-dione  
BrDUD03S (endo-syn): 1H NMR (300 MHz, Acetone-d6): δ 3.20–3.35 (m, 1H), 3.58–
3.68 (m, 1H), 3.70–3.80 (m, 1H), 3.83–3.96 (m, 2H), 4.83 (d, J = 3.39 Hz, 1H), 5.17 
(d, J = 3.58 Hz, 1H), 6.24 (dd, J = 8.67, 6.40 Hz, 1H), 6.33–6.40 (m, 1H), 7.13–7.23 
(m, 2H), 7.60–7.69 (m, 2H); 13C NMR (75 MHz, Acetone-d6): δ 40.2, 40.9, 45.3, 63.9, 
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65.5, 71.8, 122.2, 129.7, 132.1, 132.7, 132.9, 137.4, 175.3, 177.3; NSI-MS: m/z 441, 
443; HRMS (NSI): For C16H13Br2NO4 (M+H)
+ m/z calcd., 441.9289; found, 441.9284. 
2-(4-acetylphenyl)-4-bromo-8,9-dihydroxy-3a,4,7,7a-tetrahydro-1H-4,7-ethano-
isoindole-1,3(2H)-dione 
BrDUD04S (endo-syn): 1H NMR (400 MHz, DMSO-d6): δ 2.60 (s, 3H), 3.03–3.13 (m, 
1H), 3.51 (dd, J = 8.39, 2.80 Hz, 1H), 3.59–3.76 (m, 3H), 5.46 (d, J = 4.07 Hz, 1H), 
5.56 (d, J = 4.58 Hz, 1H), 6.20 (dd, J = 8.65, 6.61 Hz, 1H), 6.34 (d, J = 8.65 Hz, 1H), 
7.33 (d, J = 8.65 Hz, 2H), 8.05 (d, J = 8.65 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): 
δ 26.8, 39.1, 44.6, 64.2, 70.5, 127.0, 128.8, 131.3, 136.0, 136.1, 136.4, 174.8, 176.9, 
197.2; NSI-MS: m/z 406, 408; HRMS (NSI): For C18H16BrNO5+H (M+H)
+ m/z 
calcd.,406.029; found,406.024 . 
4-bromo-8,9-dihydroxy-2-(4-methoxyphenyl)-3a,4,7,7a-tetrahydro-1H-4,7-etha-
noisoindole-1,3(2H)-dione 
BrDUD05S (endo-syn): 1H NMR (500 MHz, Acetone-d6): δ 3.26–3.33 (m, 1H), 3.53–
3.60 (m, 1H), 3.64–3.69 (m, 1H), 3.75 (s, 3H), 3.86 (d, J = 3.20 Hz, 2H), 6.09–6.17 
(m, 1H), 6.31 (s, 1H), 6.85–6.93 (m, 2H), 7.02–7.08 (m, 2H); 13C NMR (126 MHz, 
Acetone-d6): δ 39.2, 39.9, 44.1, 55.3, 62.7, 64.5, 70.8, 114.2, 124.8, 127.9, 131.0, 
136.7, 160.5, 175.2, 177.2; NSI-MS: m/z 394, 396; HRMS (NSI): For 
C17H16BrNO5+H (M+H)
+ m/z calcd., 394.029; found, 394.0285. 
BrDUD05A (endo-anti): 1H NMR (300 MHz, Acetone-d6): δ 3.23–3.43 (m, 3H), 3.80–
3.84 (m, 3H), 4.02–4.16 (m, 1H), 4.22–4.33 (m, 1H), 4.59 (d, J = 4.33 Hz, 1H), 4.77 
(br. s, 1H), 6.08–6.30 (m, 2H), 6.92–7.15 (m, 4H); 13C NMR (75 MHz, Acetone-d6): δ 
39.6, 43.4, 48.6, 55.8, 64.8, 70.1, 75.2, 114.8, 126.2, 128.9, 131.3, 135.5, 160.4, 
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174.1, 176.3; NSI-MS: m/z 394, 396; HRMS (NSI): For C17H16BrNO5+H (M+H)
+ m/z 
calcd., 394.029; found, 394.0285. 
4-bromo-8,9-dihydroxy-2-(3,4,5-trimethoxyphenyl)-3a,4,7,7a-tetrahydro-1H-4,7-
ethanoisoindole-1,3(2H)-dione  
BrDUD06S (endo-syn): 1H NMR (400 MHz, Acetone-d6): δ 3.19–3.28 (m, 1H), 3.59 
(dd, J = 8.39, 2.80 Hz, 1H), 3.68–3.81 (m, 10H), 3.84–3.94 (m, 2H), 4.76–4.86 (m, 
1H), 5.16 (d, J = 4.07 Hz, 1H), 6.24 (dd, J = 8.90, 6.36 Hz, 1H), 6.37 (d, J = 8.65 Hz, 
1H), 6.49 (s, 2H); 13C NMR (101 MHz, Acetone-d6): δ 40.2, 40.8, 45.2, 56.6, 60.6, 
64.0, 65.5, 71.8, 106.0, 129.2, 132.0, 137.4, 139.3, 154.3, 175.5, 177.5; NSI-MS: 
m/z 454, 456; HRMS (NSI): For C19H20BrNO7+H (M+H)
+ m/z calcd., 454.0501; 
found, 454.0496. 
BrDUD06A (endo-anti): 1H NMR (300 MHz, Acetone-d6): δ 3.26–3.35 (m, 2H), 3.36–
3.42 (m, 1H), 3.74 (s, 3H), 3.76–3.81 (m, 6H), 4.03–4.13 (m, 1H), 4.23–4.30 (m, 1H), 
4.59 (d, J = 4.52 Hz, 1H), 4.78 (d, J = 6.22 Hz, 1H), 6.10–6.19 (m, 1H), 6.23–6.30 
(m, 1H), 6.46–6.49 (m, 2H); 13C NMR (75 MHz, Acetone-d6): δ 39.6, 43.4, 48.7, 56.6, 
60.6, 64.8, 70.1, 75.2, 105.9, 129.1, 131.3, 134.7, 135.5, 154.3, 178.8, 176.1; NSI-
MS: m/z 454, 456; HRMS (NSI): For C19H20BrNO7+H (M+H)
+ m/z calcd., 454.0501; 
found, 454.0496. 
3-(4-bromo-8,9-dihydroxy-1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-ethanoiso-
indol-2-yl)phenyl acetate   
BrDUD07S (endo-syn): 1H NMR (300 MHz, Acetone-d6): δ 2.25–2.29 (m, 3H), 3.25 
(dtd, J = 6.29, 3.03, 3.03, 1.41 Hz, 1H), 3.60–3.67 (m, 1H), 3.72–3.79 (m, 1H), 3.82–
3.97 (m, 2H), 4.82–4.87 (m, 1H), 5.12–5.20 (m, 1H), 6.19–6.28 (m, 1H), 6.38 (d, J = 
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8.67 Hz, 1H), 7.03 (t, J = 2.17 Hz, 1H), 7.15 (dddd, J = 12.24, 8.10, 2.07, 0.94 Hz, 
2H), 7.42–7.54 (m, 1H); 13C NMR (75 MHz, Acetone-d6): δ 20.9, 40.2, 40.9, 45.3, 
47.4, 65.5, 71.8, 121.2, 122.6, 124.9, 130.1, 132.1, 134.4, 137.4, 151.9, 169.4, 
175.3, 177.3; NSI-MS: m/z 422, 424; HRMS (NSI): For C18H16BrNO6+H (M+H)
+ m/z 
calcd.,422.0239; found, 422.0234 . 
BrDUD07A (endo-anti): 1H NMR (300 MHz, Acetone-d6): δ 2.26 (s, 3H), 3.25–3.47 
(m, 3H), 4.04–4.16 (m, 1H), 4.27 (d, J = 4.33 Hz, 1H), 4.60 (d, J = 4.90 Hz, 1H), 
4.73–4.82 (m, 1H), 6.10–6.20 (m, 1H), 6.22–6.31 (m, 1H), 6.98–7.05 (m, 1H), 7.08–
7.23 (m, 2H), 7.42–7.55 (m, 1H); 13C NMR (75 MHz, Acetone-d6): δ 20.9, 39.6, 40.2, 
43.5, 48.7, 70.1, 75.2, 121.2, 122.7, 124.8, 130.2, 131.4, 134.3, 135.5, 151.9, 170.4, 
173.6, 175.9; NSI-MS: m/z 422, 424; HRMS (NSI): For C18H16BrNO6+H (M+H)
+ m/z 
calcd., 422.0239; found, 422.0234 . 
4-bromo-8,9-dihydroxy-2-(4-nitrophenyl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoiso-
indole-1,3(2H)-dione 
BrDUD08S (endo-syn): 1H NMR (300 MHz, Acetone-d6): δ 3.23–3.34 (m, 1H), 3.64–
3.72 (m, 1H), 3.77–3.84 (m, 1H), 3.86–3.97 (m, 2H), 4.85 (d, J = 3.96 Hz, 1H), 5.17–
5.22 (m, 1H), 6.27 (dd, J = 8.67, 6.40 Hz, 1H), 6.36–6.44 (m, 1H), 7.53–7.63 (m, 2H), 
8.32–8.39 (m, 2H); 13C NMR (Acetone-d6): δ 40.3, 41.1, 45.5, 63.8, 65.5, 71.7, 
124.8, 126.3, 128.5, 132.2, 137.5, 139.1, 175.1, 177.2; NSI-MS: m/z 409, 411; 
HRMS (NSI): For C16H13BrN2O6+H (M+H)
+ m/z calcd.,409.0035; found,409.0029 . 
BrDUD08A (endo-syn): 1H NMR (300 MHz, Acetone-d6): δ 0.97–1.06 (m, 3H), 3.07–
3.13 (m, 1H), 3.17–3.34 (m, 2H), 3.40 (q, J = 7.16 Hz, 2H), 4.02 (ddd, J = 7.39, 5.89, 
1.22 Hz, 1H), 4.16–4.24 (m, 1H), 4.54 (d, J = 4.90 Hz, 1H), 4.69–4.75 (m, 1H), 5.99 
(dd, J = 8.57, 6.31 Hz, 1H), 6.08–6.15 (m, 1H); 13C NMR (75 MHz, Acetone-d6): δ 
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39.1, 43.3, 48.4, 69.5, 74.6, 74.7, 124.4, 128.0, 131.0, 131.7, 135.1, 138.5, 173.0, 
175.7; NSI-MS: m/z 409, 411; HRMS (NSI): For C16H13BrN2O6+H (M+H)
+ m/z 
calcd.,409.0035; found,409.0029 . 
Methyl-(E)-3-(4-(4-bromo-2,2-dimethyl-5,7-dioxo-3a,4,4a,5,7,7a,8,8a-octahydro-
6H-4,8-etheno[1,3]dioxolo[4,5-f]isoindol-6-yl)phenyl)acrylate  
BrDUD10S (endo-syn): 1H NMR (400 MHz, Acetone-d6): δ 3.26 (dtd, J = 6.36, 2.92, 
2.92, 1.53 Hz, 1H), 3.64 (dd, J = 8.14, 3.05 Hz, 1H), 3.71–3.79 (m, 4H), 3.85–3.95 
(m, 2H), 4.83 (d, J = 4.07 Hz, 1H), 5.13–5.21 (m, 1H), 6.25 (dd, J = 8.65, 6.61 Hz, 
1H), 6.39 (d, J = 8.65 Hz, 1H), 6.59 (d, J = 16.28 Hz, 1H), 7.28–7.35 (m, 2H), 7.69 
(d, J = 16.28 Hz, 1H), 7.74–7.82 (m, 2H); 13C NMR (101 MHz, Acetone-d6): δ 40.2, 
40.9, 45.4, 47.5, 51.8, 64.0, 65.5, 71.8, 119.8, 128.1, 129.3, 132.1, 135.2, 137.4, 
144.2, 167.3, 175.3, 177.4; NSI-MS: m/z 448, 450; HRMS (NSI): For C20H18BrNO6 
+H (M+H)+ m/z calcd., 448.0395; found, 448.0390. 
BrDUD10A (endo-anti) : 1H NMR (300 MHz, Acetone-d6): δ 3.27–3.48 (m, 3H), 3.76 
(s, 3H), 4.06–4.17 (m, 1H), 4.28 (d, J = 7.35 Hz, 1H), 4.52–4.67 (m, 1H), 4.79 (br. s, 
1H), 6.10–6.21 (m, 1H), 6.24–6.33 (m, 1H), 6.59 (d, J = 16.01 Hz, 1H), 7.26–7.34 (m, 
2H), 7.69 (d, J = 16.20 Hz, 1H), 7.74–7.82 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 
39.6, 43.6, 48.8, 51.8, 64.7, 70.1, 75.2, 119.9, 128.1, 129.3, 131.4, 135.0, 135.3, 
135.5, 144.2, 167.3, 173.8, 176.0; NSI-MS: m/z 448, 450; HRMS (NSI): For 
C20H18BrNO6 +H (M+H)
+ m/z calcd., 448.0395; found, 448.0390. 
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4-bromo-2-(4-cinnamoylphenyl)-8,9-dihydroxy-3a,4,7,7a-tetrahydro-1H-4,7-eth-
anoisoindole-1,3(2H)-dione 
BrDUD12S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.45–3.49 (m, 1H), 3.67–3.72 
(m, 2H), 3.91–3.99 (m, 2H), 6.17–6.23 (m, 1H), 6.41 (dd, J = 8.70, 1.22 Hz, 1H), 
7.39–7.44 (m, 5H), 7.47 (d, J = 15.72 Hz, 1H), 7.61–7.68 (m, 2H), 7.80 (d, J = 15.72 
Hz, 1H), 8.03–8.11 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 38.7, 40.0, 44.0, 62.7, 
64.8, 71.1, 121.8, 126.4, 128.6, 129.0, 129.3, 130.8, 131.3, 134.7, 135.4, 136.3, 
138.1, 145.6, 174.3, 176.3, 189.7; NSI-MS: m/z 494, 496; HRMS (NSI): For 
C25H20NO5Br+H (M+H)
+ m/z calcd., 494.0603; found, 494.0598. 
(E)-4-bromo-2-(4-(3-(4-fluorophenyl)acryloyl)phenyl)-8,9-dihydroxy-3a,4,7,7a-
tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione  
BrDUD13S (endo-syn): 1H NMR (300 MHz, Acetone-d6): δ 3.21–3.36 (m, 1H), 3.55–
3.98 (m, 4H), 4.74–4.93 (m, 1H), 5.19 (t, J = 3.39 Hz, 1H), 6.19–6.52 (m, 2H), 7.11–
7.54 (m, 4H), 7.77–8.01 (m, 4H), 8.17–8.29 (m, 2H); NSI-MS: m/z 512, 514; HRMS 
(NSI): For C25H19BrFNO5 +H (M+H)
+ m/z calcd., 512.0509; found, 512.0503. 
(E)-4-bromo-2-(4-(3-(4-chlorophenyl)acryloyl)phenyl)-8,9-dihydroxy-3a,4,7,7a-
tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
BrDUD14S (endo-syn): 1H NMR (500 MHz, CDCl3): 3.26–3.5 (m, 1H), 3.62–3.87 (m, 
4H), 6.24–6.3 (m, 1H), 6.37–6.44 (m, 1H), 7.33–7.46 (m, 3H), 7.53–7.60 (m, 4H), 
7.74 (d, J = 15.72 Hz, 1H), 8.05–8.11 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 38.6, 
40.1, 44.0, 62.7, 64.8, 71.1, 131.8, 132.6, 122.2, 125.5, 129.3, 129.4, 129.7, 133.3, 
134.5, 135.4, 136.7, 136.9, 143.8, 174.5, 176.6, 189.7; HRMS (NSI): For 
C25H19BrClNO5 +H (M+H)
+ m/z calcd.,528.0213; found, 528.0207. 
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(E)-4-bromo-8,9-dihydroxy-2-(4-(3-(p-tolyl)acryloyl)phenyl)-3a,4,7,7a-
tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
BrDUD16S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 2.39 (s, 3H), 3.44–3.50 (m, 
1H), 3.67–3.73 (m, 2H), 3.89–4.01 (m, 2H), 6.17–6.23 (m, 1H), 6.41 (dd, J = 8.62, 
1.30 Hz, 1H), 7.22 (d, J = 7.93 Hz, 2H), 7.37–7.45 (m, 3H), 7.53 (d, J = 8.24 Hz, 2H), 
7.79 (d, J = 16.02 Hz, 1H), 8.04–8.09 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 21.6, 
38.7, 40.0, 44.0, 62.7, 64.8, 71.1, 120.8, 126.4, 128.6, 129.3, 129.8, 131.2, 132.0, 
135.3, 136.3, 138.2, 141.4, 145.7, 174.3, 176.3, 189.8; NSI-MS: m/z 508, 510; 
HRMS (NSI): For C26H22NO5Br+H (M+H)
+ m/z calcd., 508.0759; found, 508.0754. 
(E)-4-bromo-8,9-dihydroxy-2-(4-(3-(4-methoxyphenyl)acryloyl)phenyl)-3a,4,7,7a-
tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione  
BrDUD17S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 3.21–3.30 (m, 2H), 3.47 (ddd, 
J = 4.76, 3.16, 1.51 Hz, 1H), 3.70 (d, J = 1.51 Hz, 2H), 3.85 (s, 3H), 3.88–4.01 (m, 
2H), 6.20 (dd, J = 8.67, 6.40 Hz, 1H), 6.41 (dd, J = 8.67, 1.13 Hz, 1H), 6.89–6.98 (m, 
2H), 7.29–7.43 (m, 3H), 7.54–7.63 (m, 2H), 7.78 (d, J = 15.64 Hz, 1H), 8.01–8.10 (m, 
2H); 13C NMR (75 MHz, CDCl3): δ 38.7, 40.0, 44.0, 55.5, 62.7, 64.8, 71.1, 114.5, 
119.6, 126.4, 127.5, 129.2, 130.4, 131.2, 135.2, 136.4, 138.4, 145.5, 161.9, 174.2, 
176.4, 189.7; NSI-MS: m/z 524, 526; HRMS (NSI): For C26H22BrNO6+H (M+H)
+ m/z 
calcd., 524.0709; found, 524.0703. 
(E)-4-bromo-2-(4-(3-(3,4-dimethoxyphenyl)acryloyl)phenyl)-8,9-dihydroxy-3a,4,-
7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
BrDUD18S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 3.31–3.50 (m, 3H), 3.60–3.71 
(m, 3H), 3.74–3.87 (m, 1H), 3.93 (d, J = 4.71 Hz, 6H), 6.15–6.23 (m, 1H), 6.38–6.44 
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(m, 1H), 6.90 (d, J = 8.67 Hz, 1H), 7.11–7.24 (m, 2H), 7.27–7.43 (m, 3H), 7.74 (d, J 
= 15.64 Hz, 1H), 8.01–8.08 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 38.7, 40.0, 44.0, 
55.8, 56.1, 62.6, 64.8, 71.1, 110.2, 111.2, 120.0, 123.4, 126.4, 127.7, 129.2, 131.2, 
135.4, 136.4, 138.4, 145.9, 149.3, 151.7, 174.3, 176.4, 189.9; NSI-MS: m/z 554, 
556; HRMS (NSI): For C27H24BrNO7+H (M+H)
+ m/z calcd., 554.0814; found, 
554.0809. 
(E)-4-bromo-8,9-dihydroxy-2-(4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenyl)-
3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione  
BrDUD19S (endo-syn): 1H NMR (300 MHz, CDCl3): δ 3.29–3.37 (m, 2H), 3.47 (td, J 
= 3.16, 1.22 Hz, 1H), 3.66–3.72 (m, 2H), 3.82–4.03 (m, 11H), 6.11–6.28 (m, 1H), 
6.41 (dd, J = 8.67, 1.13 Hz, 1H), 6.85 (s, 2H), 7.27–7.45 (m, 3H), 7.69 (d, J = 15.64 
Hz, 1H), 8.00–8.09 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 38.7. 40.0. 44.0. 56.3. 
61.1. 62.6. 64.8. 71.1. 105.8. 107.4. 121.5. 126.4. 129.3. 130.2. 131.2. 135.3. 136.4. 
138.2. 145.9. 153.6. 174.3. 176.4. 190.0; NSI-MS: m/z 584, 586; HRMS (NSI): For 
C28H26NO8Br+H (M+H)
+ m/z calcd., 584.092; found, 584.0915. 
(E)-4-bromo-8,9-dihydroxy-2-(4-(3-(4-(methylthio)phenyl)acryloyl)phenyl)-3a,4,-
7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
 BrDUD20S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 2.49–2.53 (m, 3H), 3.43–3.48 
(m, 1H), 3.66–3.72 (m, 2H), 3.89–3.99 (m, 2H), 6.16–6.22 (m, 1H), 6.41 (dd, J = 
8.70, 1.07 Hz, 1H), 7.23–7.28 (m, 2 H) 7.37–7.45 (m, 3H), 7.51–7.57 (m, 2H), 7.75 
(d, J = 15.72 Hz, 1H), 8.03–8.08 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 15.1, 38.7, 
40.0, 44.0, 62.6, 64.8, 71.0, 120.7, 126.0, 126.4, 129.0, 129.2, 131.1, 131.2, 135.3, 
136.4, 138.2, 142.8, 145.2, 174.3, 176.4, 189.7; NSI-MS: m/z 540, 542; HRMS 
(NSI): For C26H22BrNO5S+H (M+H)
+ m/z calcd., 540.048; found, 540.0475. 
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(E)-4-bromo-8,9-dihydroxy-2-(4-(3-(3-nitrophenyl)acryloyl)phenyl)-3a,4,7,7a-tet-
rahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione  
BrDUD21S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.46–3.51 (m, 1H), 3.68–3.72 
(m, 2H), 3.89–4.02 (m, 2H), 6.17–6.24 (m, 1H), 6.39–6.44 (m, 1H), 7.41–7.48 (m, 
2H), 7.56–7.66 (m, 2H), 7.83 (d, J = 15.72 Hz, 1H), 7.92 (d, J = 7.78 Hz, 1H), 8.07–
8.13 (m, 2H), 8.26 (ddd, J = 8.20, 2.25, 0.99 Hz, 1H), 8.50 (t, J = 1.91 Hz, 1H); 13C 
NMR (126 MHz, CDCl3): δ 38.7, 40.1, 44.0, 62.6, 64.8, 71.1, 122.5, 124.3, 124.9, 
126.6, 129.4, 130.2, 131.2, 134.4, 135.8, 136.4, 136.5, 137.4, 142.4, 148.8, 174.2, 
176.3, 188.7; NSI-MS: m/z 539, 541; HRMS (NSI): For C25H19N2O7Br+H (M+H)
+ m/z 
calcd., 539.0454; found, 539.0448. 
4-bromo-8,9-dihydroxy-2-(2-methyl-4-oxo-4H-chromen-7-yl)-3a,4,7,7a-tetra-
hydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
BrDUD22S (endo-syn): 1H NMR (300 MHz, Acetone-d6): δ 2.42 (s, 3H), 3.29 (dtd, J 
= 6.22, 3.01, 3.01, 1.32 Hz, 1H), 3.64–3.73 (m, 1H), 3.76–3.83 (m, 1H), 3.85–3.97 
(m, 2H), 4.86 (d, J = 4.14 Hz, 1H), 5.17–5.23 (m, 1H), 6.18 (d, J = 0.75 Hz, 1H), 6.29 
(dd, J = 8.67, 6.40 Hz, 1H), 6.38–6.46 (m, 1H), 7.33 (dd, J = 8.48, 1.88 Hz, 1H), 7.44 
(d, J = 1.70 Hz, 1H), 8.12 (d, J = 8.48 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 20.3, 
40.3, 41.1, 45.5, 63.9, 65.5, 71.8, 111.1, 117, 123.8, 124.2, 126.4, 132.2, 137.5, 
137.8, 157, 167.8, 175.1, 177, 177.2; NSI-MS: m/z 446, 448; HRMS (NSI): For 
C20H16BrNO6 (M+H)
+ m/z calcd.,446.0239; found, 446.0235. 
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4-bromo-2-ethyl-8,9-dihydroxy-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-
1,3(2H)-dione  
BrDUD23S (endo-syn): 1H NMR (400 MHz, Acetone-d6): δ 1.02 (t, J = 7.12 Hz, 3H), 
3.08–3.19 (m, 1H), 3.33–3.45 (m, 3H), 3.49–3.58 (m, 1H), 3.77–3.92 (m, 2H), 4.75 
(br. s, 1H), 5.09 (br. s, 1H), 6.08 (dd, J = 8.65, 6.10 Hz, 1H), 6.23 (d, J = 8.65 Hz, 
1H); 13C NMR (101 MHz, Acetone-d6): δ 13.1, 33.9, 39.9, 40.5, 44.9, 64.0, 65.5, 
71.8, 131.8, 137.1, 176.0, 178.0; NSI-MS: m/z 356,358; HRMS (NSI): For 
C15H18BrNO4+H (M+H)
+ m/z calcd.,356.0497; found,356.0491. 
1-bromo-9,10-dihydroxy-1,4,4a,8a-tetrahydro-1,4-ethanonaphthalene-5,8-dione  
BrDUD25S (endo-syn): 1H NMR (300 MHz, Acetone-d6): δ 3.22 (dtd, J = 6.33, 3.10, 
3.10, 1.41 Hz, 1H), 3.51–3.68 (m, 2H), 3.73–3.87 (m, 2H), 4.75 (br. s., 1H), 5.13 (br. 
s., 1H), 6.15 (dd, J = 8.67, 6.59 Hz, 1H), 6.33 (dd, J = 8.57, 1.22 Hz, 1H), 6.61–6.83 
(m, 2H); 13C NMR (75 MHz, Acetone-d6): δ 43.3, 45.7, 49.0, 65.0, 71.0, 72.4, 132.7, 
138.6, 142.6, 143.8, 196.0, 199.0; NSI-MS: m/z 298, 300; HRMS (NSI): For 
C12H11BrO4+H (M+H)
+ m/z calcd., 298.9919; found, 298.9913. 
1-bromo-11,12-dihydroxy-1,4,4a,9a-tetrahydro-1,4-ethanoanthracene-9,10-
dione 
BrDUD26S (endo-syn): 1H NMR (300 MHz, Acetone-d6): δ 3.21–3.39 (m, 1H), 3.69–
3.92 (m, 4H), 4.73–4.90 (m, 1H), 5.11–5.27 (m, 1H), 5.90–6.15 (m, 2H), 7.67–7.91 
(m, 4H); 13C NMR (75 MHz, Acetone-d6): δ 43.8, 46.8, 49.8, 65.0, 66.6, 72.4, 126.5, 
127.1, 132.7, 134.4, 135.0, 137.6, 138.6, 195.5, 197.6; NSI-MS: m/z 349, 351; 
HRMS (NSI): For C16H13BrO4+H (M+H)
+ m/z calcd., 349.0048; found, 349.0070. 
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4.2.1.4.9. General procedure for [4+2] cycloadditions with protected hetero-aryl 
dienediols 
The appropriate dienophile (0.04 mmol) was added to a solution of a dienediol (0.03 
mmol) in methanol (0.2 mL) and chloroform (3 mL). This mixture was heated to 100-
110 °C in a sealed vessel and stirred for 3-4 days until the dienediols had reacted 
completely (monitored by TLC). Subsequently, the solvent was evaporated under 
reduced pressure at 25 ºC and the crude compound was purified by flash column 
column chromatography using methanol and dichloromethane as eluents to obtain 
pure compounds in 22-45% yields. Compounds were characterized by 1H NMR, 13C 
NMR and high resolution mass spectroscopy.  
TLC: 1:9 methanol, dichloromethane, Rf 0.4-0.6.  
10,11-dihydroxy-2-phenyl-5-(pyridin-2-yl)-5,8-dihydro-1H-5,8-ethano[1,2,4]-
triazolo[1,2-a]pyridazine-1,3(2H)-dione 
Py2DUD01A (endo-anti):  1H NMR (500 MHz, CDCl3): δ 4.09–4.14 (m, 1H), 4.44 (d, 
J = 8.39 Hz, 1H), 5.12 (ddd, J = 6.22, 2.71, 1.45 Hz, 1H), 6.65–6.69 (m, 1H), 6.72–
6.76 (m, 1H), 7.26–7.45 (m, 6H), 7.69–7.75 (m, 1H), 7.84–7.91 (m, 1H), 8.55–8.62 
(m, 1H); 13C NMR (126 MHz, Methanol-d4): δ 58.6, 64.3, 68.6, 70.4, 124.6, 127.2, 
129.1, 130.2, 131.0, 132.3, 135.1, 126.5, 155.0, 160.1, 156.3, 157.2; NSI-MS: m/z 
365; HRMS (NSI): For C19H16N4O4+H (M+H)
+ m/z calcd., 365.125; found, 365.1244. 
10,11-dihydroxy-2-phenyl-5-(pyridin-3-yl)-5,8-dihydro-1H-5,8-ethano-
[1,2,4]triazo-lo-[1,2-a]pyridazine-1,3(2H)-dione  
Py3DUD01A (anti): 1H NMR (500 MHz, Methanol-d4) δ ppm 4.10 (s, 2H), 5.02–5.13 
(m, 1H), 6.72–6.81 (m, 2H), 7.32–7.60 (m, 6H), 8.15–8.28 (m, 1H), 8.51–8.65, (m, 
1H), 8.94 (s, 1H); 13C NMR (126 MHz, Methanol-d4): δ 58.4, 64.2, 68.1, 68.4, 124.4, 
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127.5, 129.6, 130.1, 131.1, 132.8, 134.3, 135.9, 138.0, 149.2, 149.9, 156.2, 156.8; 
NSI-MS: m/z 365; HRMS (NSI): For C19H16N4O4+H (M+H)
+ m/z calcd., 365.125; 
found, 365.1244. 
8,9-dihydroxy-4-(pyridin-3-yl)-2-(3,4,5-trimethoxyphenyl)-3a,4,7,7a-tetrahydro-
1H-4,7-ethanoisoindole-1,3(2H)-dione 
Py3DUD06S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.27 (dd, J = 8.32, 2.52 Hz, 
1H), 3.75–3.89 (m, 11H), 3.92–4.00 (m, 2H), 5.06–5.14 (m, 2H), 6.27–6.33 (m, 2H), 
6.60 (dd, J = 8.70, 6.26 Hz, 1H), 6.74 (d, J = 8.70 Hz, 1H), 7.50–7.56 (m, 1H), 8.03 
(d, J = 7.78 Hz, 1H), 8.59–8.66 (m, 1H), 9.15 (br. s, 1H); NSI-MS: m/z 453; HRMS 
(NSI): For C24H24N2O7+H (M+H)
+ m/z calcd., 453.1662; found, 453.1656. 
Methyl-(E)-3-(4-(8,9-dihydroxy-1,3-dioxo-4-(pyridin-3-yl)-1,3,3a,4,7,7a-hexahyd-
ro-2H-4,7-ethanoisoindol-2-yl)phenyl)acrylate  
Py3DUD10S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.44–3.55 (m, 2H), 3.67–
3.77 (m, 5H), 3.82–3.88 (m, 1H), 4.07–4.16 (m, 1H), 6.30–6.52 (m, 3H), 7.09–7.19 
(m, 2H), 7.45–7.65 (m, 3H), 7.75 (dd, J = 8.24, 5.34 Hz, 1H), 8.42 (d, J = 8.24 Hz, 
1H), 8.58 (d, J = 5.03 Hz, 1H), 8.95 (s, 1H); 13C NMR (126 MHz, CDCl3): δ 38.7, 
39.3, 40.3, 50.3, 51.8, 63.7, 70.4, 119.1, 122.1, 125.1, 126.6, 128.6, 132.5, 132.9, 
133.4, 134.7, 140.7, 141.2, 143.0, 143.5, 167.3, 176.8, 177.6; NSI-MS: m/z 447; 
HRMS (NSI): For C25H22N2O6+H (M+H)
+ m/z calcd., 447.1556; found, 447.1551.  
(E)-2-(4-(3-(4-fluorophenyl)acryloyl)phenyl)-8,9-dihydroxy-4-(pyridin-3-yl)-3a,4,-
7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
Py3DUD13S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 2.95–3.09 (m, 1H), 3.34–
3.47 (m, 2H), 3.79 (dd, J = 8.54, 3.36 Hz, 1H), 4.10 (d, J = 8.39 Hz, 1H), 6.43 (s, 
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2H), 7.01 (s, 2H), 7.22 (d, J = 8.70 Hz, 2H), 7.30 (d, J = 15.72 Hz, 1H), 7.53 (dd, J = 
8.70, 5.34 Hz, 2H), 7.64 (d, J = 15.87 Hz, 2H), 7.93 (d, J = 8.70 Hz, 2H), 8.31–8.41 
(m, 1H), 8.49–8.59 (m, 1 H) 8.85–8.93 (m, 1H); 13C NMR (126 MHz, CDCl3): δ 38.6, 
39.3, 40.3, 46.0, 63.5, 70.4, 116.0, 116.1, 121.2, 125.0, 126.3, 129.1, 130.4, 131.4, 
132.7, 133.0, 135.3, 137.7, 139.6, 142.4, 144.5, 163.1, 165.2, 176.7, 177.7, 190.0; 
NSI-MS: m/z 511; HRMS (NSI): For C30H23N2O5F+H (M+H)
+ m/z calcd., 511.1669; 
found, 511.1664. 
(E)-8,9-dihydroxy-2-(4-(3-(4-methoxyphenyl)acryloyl)phenyl)-4-(pyridin-3-yl)-
3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione  
Py3DUD17S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.34–3.39 (m, 2H), 3.61–
3.65 (m, 1H), 3.72 (s, 3H), 3.74–3.79 (m, 1H), 4.05–4.09 (m, 1H), 6.35–6.43 (m, 2H), 
6.78–6.83 (m, 2H), 7.15–7.24 (m, 3H), 7.44–7.48 (m, 2H), 7.57–7.64 (m, 1H), 7.86–
7.91 (m, 2H), 8.29 (d, J = 8.24 Hz, 1H), 8.48 (d, J = 5.04 Hz, 1H), 8.84 (s, 1H); 13C 
NMR (126 MHz, CDCl3): δ 38.6, 39.3, 40.3, 46.0, 50.0, 63.4, 70.4, 114.3, 119.1, 
124.8, 126.2, 127.1, 129.0, 130.3, 131.5, 132.8, 132.9, 135.0, 138.1, 140.0, 142.1, 
144.2, 145.9, 161.9, 176.7, 177.7, 190.2; NSI-MS: m/z 523; HRMS (NSI): For 
C31H26N2O6+H (M+H)
+ m/z calcd., 523.1869; found, 523.1864. 
(E)-8,9-dihydroxy-4-(pyridin-3-yl)-2-(4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phen-
yl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
Py3DUD19S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.53–3.66 (m, 2H), 3.76 (dd, 
J = 8.16, 2.82 Hz, 1H), 3.85–3.94 (m, 9H), 3.97 (dd, J = 8.32, 3.28 Hz, 1H), 4.23 (d, 
J = 8.39 Hz, 1H), 6.42–6.59 (m, 3H), 6.78–6.86 (m, 2H), 7.26–7.32 (m, 4H), 7.65 (d, 
J = 15.56 Hz, 1H), 7.72–7.83 (m, 1H), 7.94–8.05 (m, 2H), 8.40 (d, J = 8.24 Hz, 1H), 
8.51 (d, J = 4.58 Hz, 1H), 9.08–9.18 (m, 1H); 13C NMR (126 MHz, CDCl3): δ 38.9, 
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39.2, 40.2, 50.5, 56.3, 61.1, 63.9, 71.0, 105.8, 121.4, 125.5, 126.4, 129.3, 130.1, 
132.5, 133.7, 135.1, 138.3, 140.7, 142.6, 144.0, 144.4, 145.9, 153.6, 176.6, 177.0, 
189.8; NSI-MS: m/z 583; HRMS (NSI): For C33H30N2O8+H (M+H)
+ m/z calcd., 
583.208; found, 583.2075. 
(E)-8,9-dihydroxy-2-(4-(3-(4-(methylthio)phenyl)acryloyl)phenyl)-4-(pyridin-3-
yl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
Py3DUD20S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 2.58 (s, 3H), 3.48–3.57 (m, 
2H), 3.72–3.79 (m, 1H), 3.86 (dd, J = 8.47, 3.43 Hz, 1H), 4.11–4.16 (m, 1H), 6.42–
6.54 (m, 2H), 7.18–7.31 (m, 3H), 7.36 (d, J = 15.56 Hz, 1H), 7.45–7.53 (m, 2H), 
7.63–7.79 (m, 3H), 7.95–8.03 (m, 2H), 8.60–8.68 (m, 2H), 9.05 (m, 1H); 13C NMR 
(126 MHz, CDCl3): δ 15.0, 38.7, 39.4, 40.3, 50.4, 63.5, 70.3, 120.5, 123.5, 124.2, 
125.9, 126.3, 128.9, 129.2, 131.0, 131.7, 133.9, 135.0, 138.6, 141.4, 142.9, 143.7, 
145.4, 145.6, 176.7, 177.3, 185.7; NSI-MS: m/z 539; HRMS (NSI): For 
C31H26N2O5S+H (M+H)
+ m/z calcd., 539.164; found, 539.1635. 
(E)-8,9-dihydroxy-2-(4-(3-(3-nitrophenyl)acryloyl)phenyl)-4-(pyridin-3-yl)-3a,4,-
7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
Py3DUD21S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.54–3.65 (m, 2H), 3.76–
3.82 (m, 1H), 3.94–3.99 (m, 1H), 4.23–4.27 (m, 1H), 6.47–6.52 (m, 2H), 7.34–7.39 
(m, 2H), 7.56 (d, J = 15.72 Hz, 1H), 7.58–7.63 (m, 1H), 7.79 (d, J = 15.8 Hz, 1H), 
7.89 (d, J = 7.63 Hz, 1H), 7.92–7.99 (m, 2H), 8.02–8.07 (m, 2H), 8.10–8.14 (m, 1H), 
8.22–8.27 (m, 1H), 8.48 (t, J = 1.91 Hz, 1H), 8.75 (d, J = 2.14 Hz, 1H); 13C NMR (126 
MHz, CDCl3): δ 38.8, 39.4, 40.4, 50.7, 63.8, 70.6, 122.5, 124.2, 124.9, 126.5, 128.4, 
129.3, 129.6, 130.1, 132.4, 134.4, 133.6, 135.0, 135.7, 135.9, 137.3, 138.2, 142.4, 
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143.5, 148.7, 176.6, 176.7, 188.8; NSI-MS: m/z 538; HRMS (NSI): For 
C30H23N3O7+H (M+H)
+ m/z calcd., 538.1614; found, 538.1609. 
10,11-dihydroxy-2-phenyl-5-(pyridin-4-yl)-5,8-dihydro-1H-5,8-ethano[1,2,4]-
triazolo-[1,2-a]pyridazine-1,3(2H)-dione 
Py4DUD01A (anti): 1H NMR (500 MHz, Methanol-d4): δ 3.78–3.84 (m, 1H), 4.08 (s, 
1H), 4.98–5.04 (m, 1H), 6.77–6.86 (m, 1H), 6.98–7.04 (m, 1H), 7.23–7.64 (m, 5H), 
7.80–7.87 (m, 2 H), 8.63 (d, J = 5.95 Hz, 2H); 13C NMR (126 MHz, Methanol-d4): δ 
59.8, 68.2, 76.2, 78.9, 124.9, 127.3, 129.7, 130.0, 130.2, 130.3, 132.1, 149.8, 158.2, 
156.4; NSI-MS: m/z 365; HRMS (NSI): For C19H16N4O4+H (M+H)
+ m/z calcd., 
365.125; found, 365.1244.  
(E)-8,9-dihydroxy-2-(4-(3-(4-methoxyphenyl)acryloyl)phenyl)-4-(pyridin-4-yl)-
3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
Py4DUD17S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.46– 3.52 (m, 1H), 3.75– 
3.90 (m, 7H), 4.26 (s, 1H) ,6.51–6.58 (m, 1 H), 6.73 (d, J = 8.70 Hz, 1H), 6.93 (d, J = 
8.70 Hz, 2H), 7.28–7.36 (m, 4 H) 7.55–7.61 (m, 3H), 7.75 (d, J = 15.7 Hz, 1H), 7.99–
8.06 (m, 2H), 8.78 (d, J = 5.34 Hz, 1H), 9.25–9.33 (m, 1H); 13C NMR (126 MHz, 
CDCl3): δ 38.3, 41.4, 46.5, 53.1, 55.5, 65.1, 79.9, 114.5, 119.5, 121.0, 126.3, 127.5, 
129.2, 130.1, 130.4, 131.1, 135.0, 138.4, 145.5, 157.2, 158.8, 161.9, 174.6, 176.9, 
189.6; NSI-MS: m/z 523; HRMS (NSI): For C31H26N2O6+H (M+H)
+ m/z calcd., 
523.1869; found, 523.1864. 
PmDUD06S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.55 (dt, J = 6.33, 2.56 Hz, 
1H), 3.67–3.72 (m, 1H), 3.77–3.83 (m, 9H), 3.86–3.92 (m, 3H), 6.31 (s, 2H), 6.48–
6.55 (m, 1H), 6.60 (d, J = 8.54 Hz, 1H), 7.57–7.64 (m, 1H), 8.75–8.82 (m, 1H), 9.23 
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(d, J = 1.37 Hz, 1H); 13C NMR (126 MHz, CDCl3): δ 38.1, 40.5, 43.0, 49.6, 56.3, 
60.9, 65.1, 67.7, 104.1, 120.9, 127.1, 130.4, 133.0, 138.4, 153.6, 157.1, 157.5, 
176.9, 177.6; NSI-MS: m/z 454; HRMS (NSI): For C23H23N3O7+H (M+H)
+ m/z calcd., 
454.1614; found, 454.1609. 
Methyl-(E)-3-(4-(8,9-dihydroxy-1,3-dioxo-4-(pyrimidin-4-yl)-1,3,3a,4,7,7a-hexa-
hydro-2H-4,7-ethanoisoindol-2-yl)phenyl)acrylate 
PmDUD10S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.51–3.57 (m, 1H), 3.68–3.73 
(m, 1H), 3.75–3.81 (m, 3H), 3.86–3.96 (m, 3H), 6.41 (d, J = 16.02 Hz, 1H), 6.45–6.51 
(m, 1H), 6.55–6.61 (m, 1H), 7.15–7.23 (m, 2H), 7.51–7.60 (m, 3H), 7.64 (d, J = 16.02 
Hz, 1H), 8.73–8.81 (m, 1H), 9.20 (s, 1H); 13C NMR (126 MHz, CDCl3): δ 38.2, 40.5, 
42.9, 49.7, 51.9, 64.9, 67.7, 119.2, 120.9, 126.7, 128.6, 130.4, 133.0, 134.7, 143.4, 
157.3, 157.6, 167.1, 168.8, 176.3, 177.3; NSI-MS: m/z 448; HRMS (NSI): For 
C24H21N3O6+H (M+H)
+ m/z calcd., 448.1508; found, 448.1503. 
(E)-2-(4-(3-(4-fluorophenyl)acryloyl)phenyl)-8,9-dihydroxy-4-(pyrimidin-4-yl)-
3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
PmDUD13S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.55–3.59 (m, 1H), 3.74 (dd, 
J = 8.54, 2.90 Hz, 1H), 3.88–3.94 (m, 3H), 6.49–6.54 (m, 1H), 6.60 (d, J = 8.54 Hz, 
1H), 7.08–7.14 (m, 2H), 7.31–7.40 (m, 3H), 7.56–7.64 (m, 3H), 7.75 (d, J = 15.72 Hz, 
1H), 8.01–8.06 (m, 2H), 8.81 (d, J = 5.34 Hz, 1H), 9.24 (d, J = 1.22 Hz, 1H); 13C 
NMR (126 MHz, CDCl3): δ 38.3, 40.6, 43.2, 49.6, 65.0, 67.6, 116.3, 120.8, 121.5, 
120.4, 129.3, 130.4, 131.1, 133.1, 135.4, 138.0, 144.3, 157.4, 157.7, 163.2, 165.3, 
168.7, 176.2, 177.1, 189.3; NSI-MS: m/z 512; HRMS (NSI): For C29H22N3O5F+H 
(M+H)+ m/z calcd., 512.1621; found, 512.1616. 
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(E)-8,9-dihydroxy-2-(4-(3-(4-methoxyphenyl)acryloyl)phenyl)-4-(pyrimidin-4-yl)-
3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione  
PmDUD17S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.54–3.59 (m, 1H), 3.73 (dd, 
J = 8.54, 2.90 Hz, 1H), 3.85 (s, 3H), 3.89–3.94 (m, 3H), 6.51 (dd, J = 8.62, 6.49 Hz, 
1H), 6.60 (d, J = 8.24 Hz, 1H), 6.90–6.96 (m, 2H), 7.29–7.36 (m, 3H), 7.55–7.61 (m, 
3H), 7.76 (d, J = 15.56 Hz, 1H), 7.99–8.05 (m, 2H), 8.80 (d, J = 5.34 Hz, 1H), 9.23 
(d, J = 1.22 Hz, 1H); 13C NMR (126 MHz, CDCl3): δ 38.3, 40.6, 43.1, 49.6, 55.5, 
65.0, 67.7, 114.5, 119.5, 120.8, 126.3, 127.4, 129.2, 130.3, 130.4, 133.1, 135.1, 
138.4, 145.5, 157.4, 157.7, 161.9, 168.8, 176.2, 177.2, 189.6; NSI-MS: m/z 524; 
HRMS (NSI): For C30H25N3O6+H (M+H)
+ m/z calcd., 524.1821; found, 524.1816. 
(E)-2-(4-(3-(3,4-dimethoxyphenyl)acryloyl)phenyl)-8,9-dihydroxy-4-(pyrimidin-4-
yl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
PmDUD18S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.54–3.59 (m, 1H), 3.71–3.76 
(m, 1H), 3.88–3.95 (m, 9H), 6.51 (dd, J = 8.62, 6.49 Hz, 1H), 6.60 (d, J = 8.54 Hz, 
1H), 6.87–6.91 (m, 1H), 7.13 (d, J = 1.98 Hz, 1H), 7.21 (dd, J = 8.39, 1.98 Hz, 1H), 
7.26–7.35 (m, 3H), 7.57–7.61 (m, 1H), 7.72 (d, J = 15.72 Hz, 1H), 8.00–8.04 (m, 2H), 
8.81 (d, J = 5.49 Hz, 1H), 9.24 (d, J = 1.22 Hz, 1H); 13C NMR (126 MHz, CDCl3): δ 
38.3, 40.6, 43.2, 49.6, 56.0, 65.0, 67.6, 110.2, 111.2, 119.9, 120.8, 123.3, 126.3, 
127.7, 129.2, 130.3, 133.1, 135.1, 138.4, 145.8, 149.4, 151.7, 157.4, 157.7, 176.2, 
177.2, 189.7; NSI-MS: m/z 554; HRMS (NSI): For C31H27N3O7+H (M+H)
+ m/z calcd., 
554.1927; found, 554.1922. 
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(E)-8,9-dihydroxy-4-(pyrimidin-4-yl)-2-(4-(3-(3,4,5-trimethoxyphenyl)acryloyl)-
phenyl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
PmDUD19S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.56 (dd, J = 3.81, 2.59 Hz, 
1H), 3.72–3.76 (m, 1H), 3.87–3.94 (m, 12H), 6.48–6.53 (m, 1H), 6.61 (d, J = 8.54 Hz, 
1H), 6.83 (s, 2H), 7.26–7.36 (m, 3H), 7.58 (dd, J = 5.42, 1.30 Hz, 1H), 7.67 (d, J = 
15.72 Hz, 1H), 7.99–8.04 (m, 2H), 8.78–8.82 (m, 1H), 9.23 (d, J = 1.22 Hz, 1H); 13C 
NMR (126 MHz, CDCl3): δ 38.3, 40.6, 48.0, 49.7, 56.3, 61.1, 64.9, 67.7, 105.8, 
120.8, 121.4, 126.3, 129.3, 130.1, 130.4, 133.0, 135.2, 138.2, 140.7, 145.8, 153.5, 
157.4, 157.7, 168.8, 176.2, 177.2, 189.8; NSI-MS: m/z 584; HRMS (NSI): For 
C32H29N3O8+H (M+H)
+ m/z calcd., 584.2033; found, 584.2027. 
(E)-8,9-dihydroxy-2-(4-(3-(4-(methylthio)phenyl)acryloyl)phenyl)-4-(pyrimidin-4-
yl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
PmDUD20S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 2.49–2.53 (m, 3H), 3.54–3.59 
(m, 1H), 3.70–3.76 (m, 1H), 3.87–3.95 (m, 3H), 6.51 (dd, J = 8.62, 6.48 Hz, 1H), 6.60 
(d, J = 8.54 Hz, 1H), 7.22–7.28 (m, 2H), 7.30–7.35 (m, 2H), 7.39 (d, J = 15.41 Hz, 
1H), 7.49–7.60 (m, 3H), 7.74 (d, J = 15.41 Hz, 1H), 8.00–8.05 (m, 2H); 13C NMR 
(126 MHz, CDCl3): δ 15.1, 38.3, 40.6, 43.1, 49.6, 65.0, 67.7, 120.7, 120.8, 126.0, 
126.3, 128.9, 129.2, 130.3, 131.2, 133.1, 135.2, 138.2, 142.8, 145.1, 157.4, 157.7, 
168.7, 176.2, 177.1, 189.5; NSI-MS: m/z 540; HRMS (NSI): For C30H25N3O5S (M+H)
+ 
m/z calcd., 540.1593; found, 540.1588. 
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(E)-8,9-dihydroxy-2-(4-(3-(3-nitrophenyl)acryloyl)phenyl)-4-(pyrimidin-4-yl)-
3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione 
PmDUD21S (endo-syn): 1H NMR (500 MHz, CDCl3): δ 3.54–3.60 (m, 1H), 3.71–3.77 
(m, 1H), 3.88–3.96 (m, 3H), 6.48–6.55 (m, 1H), 6.58–6.64 (m, 1H), 7.35–7.41 (m, 
2H), 7.51–7.66 (m, 3H), 7.78–7.85 (m, 1H), 7.90 (d, J=7.78 Hz, 1H), 8.04–8.10 (m, 
2H), 8.20–8.30 (m, 1H), 8.49 (t, J = 1.91 Hz, 1H), 8.75–8.85 (m, 1H), 9.21–9.26 (m, 
1H); 13C NMR (126 MHz, CDCl3): δ 38.3, 40.6, 43.2, 49.6, 65.0, 67.6, 120.8, 122.5, 
124.3, 124.9, 126.5, 129.4, 130.2, 130.3, 133.1, 134.4, 135.8, 136.5, 137.3, 142.4, 
148.8, 157.5, 157.8, 168.7, 176.1, 177.1, 188.6; NSI-MS: m/z 539; HRMS (NSI): For 
C29H22N4O7+H (M+H)
+ m/z calcd., 539.1566; found, 539.1561. 
Methyl-(E)-3-(4-(8,9-dihydroxy-4-(1H-imidazol-1-yl)-1,3-dioxo-1,3,3a,4,7,7a-
hexahydro-2H-4,7-ethanoisoindol-2-yl)phenyl)acrylate 
ImDUD10S (endo-syn): 1H NMR (500 MHz, Acetone-d6): δ 3.36 (dtd, J = 6.37, 3.07, 
3.07, 1.22 Hz, 1H), 3.69–3.77 (m, 5H), 3.96 (dd, J = 8.62, 3.13 Hz, 1H), 4.24 (d, J = 
8.39 Hz, 1H), 6.49 (dd, J = 8.77, 6.48 Hz, 1H), 6.58 (d, J = 15.87 Hz, 1H), 6.72 (d, J 
= 8.85 Hz, 1H), 6.90–6.97 (m, 1H), 7.25–7.29 (m, 2H), 7.41 (t, J = 1.30 Hz, 1H), 7.67 
(d, J = 16.02 Hz, 1H), 7.72–7.77 (m, 2H), 7.98 (t, J = 1.07 Hz, 1H); 13C NMR (126 
MHz, Acetone-d6): δ 30.7, 39.6, 41.3, 41.9, 51.8, 64.6, 65.6, 118.9, 119.8, 128.0, 
129.0, 129.3, 132.3, 133.4, 137.6, 144.1, 167.3, 175.7, 177.7; NSI-MS: m/z 436; 
HRMS (NSI): For C26H22NO5Br+H (M+H)
+ m/z calcd., 436.1508; found, 436.1503. 
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4.2.1.4.10. Modifications of bridged bicycles  
4.2.1.4.10.1. Debromination to obtain BzDPD01A and BzDPD10A 
Tributyltin hydride (0.019 mmol) and AIBN (0.006 mmol) were added to a solution of 
compound BrDPD01A or BrDPD10A (0.013 mmol) (Fig. 7) in dry benzene (3 mL). 
The resultant reaction mixture was refluxed in a flask with a drying tube. After 16h, 
the reaction was cooled to RT, an aqueous saturated KF solution (5 mL) was added 
and the mixture was stirred for 1h. Resultant tin fluoride salts were removed by filtra-
tion and the aqueous layer was extracted with ethyl acetate (2 x 5 mL). Organic lay-
ers were combined, dried over Na2SO4 and filtered. Solvent was evaporated under 
reduced pressure at 30 ºC, and the obtained crude product was purified by column 
chromatography using ethyl acetate and petroleum ether as eluents to obtain the 
compounds in 60-70% yield. Purified compounds were characterized by 1H NMR, 
13C NMR and mass spectrometry. 
TLC: 1:1 ethyl acetate, petroleum ether, Rf 0.4 and 0.6.  
2,2-dimethyl-7-phenyl-3a,4,10,10a-tetrahydro-6H-4,10-etheno[1,3]dioxolo[4,5-
d][1,2,4]triazolo[1,2-a]pyridazine-6,8(7H)-dione  
BzDPD01A (anti): 1H NMR (600 MHz, CDCl3): δ 1.35 (s, 6H), 4.63–4.68 (m, 2H), 
5.06–5.21 (m, 2H), 6.39–6.43 (m, 2H), 7.33–7.38 (m, 1H), 7.39–7.46 (m, 4H); 13C 
NMR (75 MHz, CDCl3): δ 25.4, 25.5, 52.4, 74.0, 112.2, 125.6, 128.5, 128.9, 129.2, 
131.3, 155.7; NSI-MS: m/z 328; HRMS (NSI): For C17H17N3O4+H (M+H)
+ m/z calcd., 
328.1297; found, 328.1292. 
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Methyl-(E)-3-(4-(2,2-dimethyl-5,7-dioxo-3a,4,4a,5,7,7a,8,8a-octahydro-6H-4,8-
ethe-no[1,3]dioxolo[4,5-f]isoindol-6-yl)phenyl)acrylate  
BzDPD10A (endo-anti): 1H NMR (300 MHz, CDCl3): δ 1.36 (s, 3H), 1.51 (s, 3H), 
3.50 (s, 4H), 3.80 (s, 3H), 4.18 (s, 2H), 6.23 (dd, J = 4.05, 2.73 Hz, 2H), 6.42 (d, J = 
16.01 Hz, 1H), 7.20–7.29 (m, 2H), 7.57 (d, J = 8.48 Hz, 2H), 7.67 (d, J = 16.01 Hz, 
1H); 13C NMR (75 MHz, CDCl3): δ 24.3, 26.4, 37.1, 37.9, 51.8, 74.0, 112.7, 119.1, 
126.8, 128.6, 131.8, 133.5, 134.6, 143.6, 167.2, 178.2; NSI-MS: m/z 410; HRMS 
(NSI): For C23H23NO6+H (M+H)
+ m/z calcd.410.1603,; found, 410.1608. 
4.2.1.4.10.2. Synthesis of BrDUD01AR and BrDUD02SR by reduction 
Activated palladium on charcoal (10 mg) was added to a solution of compounds 
BrDUD01A or BrDUD02S (0.025 mmol) in methanol (5 mL). The mixture was stirred 
at RT under hydrogen gas pressure with balloons. After 16 h, the reaction mixture 
was filtered through a celite bed and the filtrate was evaporated under reduced pres-
sure at RT. Pure compounds were obtained without any further purification in 75-
85% yield. These were analyzed by 1H NMR, 13C NMR and mass spectrometry. 
TLC: 1:1 ethyl acetate, petroleum ether, Rf 0.3 and 0.6. 
5-bromo-6,7-dihydroxy-2-phenyltetrahydro-1H-5,8-ethano[1,2,4]triazolo[1,2-
a]pyridazine-1,3(2H)-dione 
BrDUD01AR (anti) :1H NMR (500 MHz, CDCl3): δ 1.80–1.92 (m, 1H), 2.35 (dddd, J = 
13.81, 11.22, 5.04, 2.90 Hz, 1H), 2.47 (ddd, J = 14.11, 11.22, 2.90 Hz, 1H), 2.81 
(ddd, J = 14.15, 11.33, 6.41 Hz, 1H), 3.27–3.35 (m, 1H), 3.44 (s, 1H), 4.14 (d, J = 
7.78 Hz, 1H), 4.23 (dd, J = 7.63, 3.20 Hz, 1H), 4.52 (ddd, J = 4.81, 3.13, 1.53 Hz, 
1H), 7.32–7.39 (m, 1H), 7.41–7.51 (m, 4H); 13C NMR (126 MHz, CDCl3): δ 22.1, 
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35.8, 54.7, 69.5, 72.0, 73.2, 126.1, 126.6, 128.4, 129.4, 155.1, 155.3; NSI-MS: m/z 
368, 370; HRMS (NSI): For C14H14BrN3O4 (M+H)
+ m/z calcd.,368.0246; found, 
368.0241 . 
4-bromo-2-(4-fluorophenyl)-5,6-dihydroxyhexahydro-1H-4,7-ethanoisoindole-
1,3(2H)-dione   
BrDUD02SR (endo-syn): 1H NMR (500 MHz, Acetone–d6): δ 1.70–1.80 (m, 2H), 
2.09–2.36 (m, 3H), 3.57 (dd, J = 9.84, 2.98 Hz, 1H), 3.71–3.80 (m, 1H), 4.11–4.30 
(m, 2H), 4.82 (d, J = 3.66 Hz, 1H), 5.14 (br. s, 1H), 7.21–7.31 (m, 2H), 7.36–7.44 (m, 
2H); 13C NMR (126 MHz, Acetone–d6): δ 21.4, 31.1, 34.8, 41.5, 44.8, 69.3, 75.3, 
116.4, 116.6, 130.0, 161.9, 163.9, 176.3, 178.3; NSI-MS: m/z 468, 470; HRMS 
(NSI): For C20H19BrFNO6+H (M+H)
+ m/z calcd., 468.0458; found, 468.0453. 
4.2.1.4.10.3. Synthesis of BrDUD01ARAc and BrDUD02SRAc by O-acetylation 
Acetic anhydride (0.03 mmol) and a catalytic amount of 4-dimethylamino pyridine 
were added to a solution of BrDUD10AR or BrDUD02SR (0.014 mmol) in THF (3 
mL), pre-cooled to 0°C. The resultant reaction mixture was stirred at RT until the 
starting material completely reacted (monitored by TLC). After completion of the re-
action, ice-cold water (3 mL) was added. The organic layer was separated and satu-
rated brine solution (10 mL) was added to the aqueous layer which subsequently 
was extracted with ethyl acetate (2 x 5 mL). Organic layers were combined, dried 
over Na2SO4 and concentrated under vacuum at RT. The crude compounds were 
purified by column chromatography using ethyl acetate and petroleum ether as elu-
ents to afford pure compounds in 75-85% yield. The compounds were characterized 
by 1H NMR, 13C NMR and mass spectrometry. 
TLC: 1:1 ethyl acetate, petroleum ether, Rf 0.4-0.6. 
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5-bromo-1,3-dioxo-2-phenylhexahydro-1H-5,8-ethano[1,2,4]triazolo[1,2-a]pyrid-
azine-6,7-diyl diacetate 
BrDUD01ARAc (anti): 1H NMR (500 MHz, CDCl3): δ 1.96–2.06 (m, 4H), 2.14 (s, 
3H), 2.39 (ddt, J = 13.83, 11.65, 4.20, 4.20 Hz, 1H), 2.52 (ddd, J = 14.53, 11.18, 3.74 
Hz, 1H), 2.84 (ddd, J = 14.34, 11.52, 5.57 Hz, 1H), 4.59 (dt, J = 4.65, 2.10 Hz, 1H), 
5.24 (dd, J = 8.24, 2.44 Hz, 1H), 5.38 (d, J = 8.24 Hz, 1H), 7.36–7.41 (m, 1H), 7.44–
7.52 (m, 4H); 13C NMR (126 MHz, CDCl3): δ 20.3, 20.4, 22.7, 35.5, 51.7, 66.9, 69.2, 
72.3, 125.5, 128.4, 129.3, 131.4, 152.3, 153.7, 168.9, 169.0; NSI-MS: m/z 452, 454; 
HRMS (NSI): For C18H18BrN3O6 (M+H)
+ m/z calcd.,452.0457; found, 452.0452. 
4-bromo-2-(4-fluorophenyl)-1,3-dioxooctahydro-1H-4,7-ethanoisoindole-5,6-diyl 
diacetate 
BrDUD02SRAc (endo-syn): 1H NMR (400 MHz, CDCl3): δ 1.73–1.83 (m, 2H), 2.08 
(s, 3H), 2.11–2.21 (m, 4H), 2.31–2.42 (m, 1H), 2.47–2.53 (m, 1H), 3.55 (dt, J = 9.92, 
1.40 Hz, 1H), 3.74 (dd, J = 9.92, 2.29 Hz, 1H), 5.28 (dd, J = 8.39, 2.80 Hz, 1H), 5.39 
(d, J = 8.65 Hz, 1H), 7.14–7.22 (m, 2H), 7.26–7.32 (m, 2H); 13C NMR (101 MHz, 
CDCl3): δ 20.4, 20.6, 20.8, 30.0, 31.3, 40.1, 44.2, 56.9, 69.1, 73.7, 116.3, 116.6, 
128.1, 160.8, 164.1, 169.1, 174.3, 176.3; NSI-MS: m/z 468, 470; HRMS (NSI): For 
C20H19BrFNO6+H (M+H)
+ m/z calcd., 468.0458; found, 468.0453. 
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4.2.2. Biology 
 
4.2.2.1. Work with microorganisms 
4.2.2.1.1. Cultivation of microorganisms 
All assays with microorganisms were carried out under sterile conditions. The bacte-
rial and yeast cells were revived from frozen cultures (at -20 ºC), whenever neces-
sary. To start a new culture, fresh medium (20 mL) was added to a frozen culture (1 
mL) and shaken over night at 30 ºC. Subsequently, the OD of the new culture was 
determined at 600 nm, using a photometer. 
4.2.2.1.2. Agar diffusion assay 
Complete media were used for the agar diffusion assay, EBS medium for bacteria 
and M90 medium for yeasts media with agar were heated in a microwave oven until 
the agar had melted. Then they were cooled in a water bath, pre-heated to 50 ºC. 
The microorganisms were added to these media to obtain a final OD of 0.01 for bac-
teria and 0.1 for yeasts. The inoculated media (15 mL) were poured onto petri dishes 
and the agar was allowed to solidify. Paper discs (6 mm diameter) were placed on 
the agar surface and the test compounds, dissolved in DMSO, were added to the 
paper discs (20 µl). Thereafter, the petri dishes were incubated for 1 day in an incu-
bator at 30 ºC. After 24 hours of incubation time, the diameter of the inhibition zone 
(halo) was measured, if present.   
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4.2.2.2. Work with mammalian cell cultures 
4.2.2.2.1. Cultivation and trypsinisation of cells 
The whole work with mammalian cell cultures was carried out under sterile condi-
tions. Cells were grown in cell culture flasks at 37 ºC under 10% CO2 in appropriate 
media, with periodical passaging. The required media for the cultivation were pre-
warmed to 37 ºC prior to use. For harvesting, cultivated cells were trypsinised to split 
them for seeding the required number per well in a MTP. For trypsinisation the cell 
medium (10 mL) was removed from the culture flask, and the cell surface was rinsed 
once with EBSS (10 mL), followed by the addition of 1mL of trypsin. The flask was 
incubated at 37 ºC for 5-10 min, and the trypsination was terminated by adding 10 
mL of fresh medium.  
4.2.2.2.2. Cell viability assay (MTT assay) 
The Assay was carried out in 96 well plates. L929 cells (mouse fibroblast) were sus-
pended (50,000 cells/mL) in culture medium and 120 µl of cell suspension was 
added into each well. The peripheral rows were omitted. The test compounds, dis-
solved in either DMSO or DMSO/Methanol (1/1, v/v), were serially diluted with the 
same culture medium in a separate 96 well plate. The final compound dilution (60 µl) 
was transferred to the cells in two replicates to reach final concentrations in the 
range 37 µg/mL to 0.2 ng/mL. After 5 days of incubation at 37 ºC, the metabolic ac-
tivity of the cells was determined by using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). Twenty µl of MTT (0.5 mg/mL) in PBS was 
added to the cells. After 2h of incubation the micro-titre plates were centrifuged 
(1744 rcf/min) and the medium was removed by tapping. The precipitate was 
washed with 100 µl of PBS and the formazan crystals were dissolved by adding 100 
MATERIALS AND METHODS 
 
119 
 
µl of acidic isopropanol (0.4% hydrochloric acid). The absorbance of the colored so-
lution was measured in a plate reader at 595 nm. 
4.2.2.2.3. Impedance measurement assay 
A. Experimental procedure: The impedance assay was performed with L929 cells. 
These cells were grown in medium (DMEM, 10% FBS) at 37 ºC for 3 weeks. Two 
days before starting the assay, the cells were trypsinised and were split into equal 
volumes and growth was continued to confluency. Medium (60 µl) was added to 
each well of a 96 well plate equipped with gold electrodes for impedance measure-
ment (E-96 plate, Roche/Acea Biosciences) and of a normal micro-titre plate (MTP). 
Both plates were kept under a sterile bench for 30 minutes with the lids closed. 
Thereafter, the cells were trypsinized (see 4.2.2.1.1) and suspended in 30 mL of 
medium, pre-warmed to 37 ºC, to reach a density of 100000 cells/mL (calculated with 
a cell counter). A background impedance measurement (step 1) was carried out ap-
proximately over one minute in the incubator of the impedance reader at 37 ºC. After 
step 1, the E-plate was removed and 120 µL of cell suspension was added into each 
well of the E- and MT plate. Both plates were left for 30 minutes under the laminar-
flow hood to reach a homogenous distribution of the cells. After 30 minutes, the E-
plate was clamped back into the incubator of the impedance reader and step 2 of the 
schedule (2-1 to 2-3) with parameters as given in the Table 7 was initiated to start 
the second impedance measurement.  
After termination of step 2, both E-plate and MTP were placed under the ster-
ile bench and test compounds dissolved in DMSO/MeOH (1/1, v/v) were added to 
the cells in triplicates, in volumes of 1-3 µl to reach the IC90 of the MTT assay. The 
test compounds were added rapidly to start the measurement as soon as possible 
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after the compound addition in order to record the early effects of the compounds on 
the cellular processes. Subsequently, the E-plate was immediately placed back in 
the incubator of the impedance reader, and step 3 of the measurement schedule 
was started (Table 7). The measurement was terminated after 5 days. The recorded 
impedance data was analyzed. The MTP was used to observe the morphological 
changes of the cells under the microscope.  
Table 7. Parameters for the impedance monitoring for steps 2 and 3 of the measurement 
schedule 
Step 
Measurement 
interval (min) 
Duration (h) 
2-1 05 01 
2-2 15 03 
2-3 30 20 
3-1 05 01 
3-2 15 03 
3-3 30 20 
3-4 30 300 
 
B. Data analysis  
The so-called time-dependent cellular response profiles (TCRP) were recorded by 
Roche RTCA software. The statistical programming language R, Version 2.12.2 (R 
Development Core Team, 2011) was used for the execution of data mining and 
processing. The raw cell index (CI) data provided by RTCA software was normalized 
by dividing the cell indices for each time point after the compound addition, by the 
cell index at the reference point as suggested by Abassi and co-workers.82 The last 
measurement recorded before the addition of compounds was used as the reference 
point. Only the readings after compound addition were considered for subsequent 
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analysis. The outliers out of triplicates were detected and removed by the median 
polish method. Cubic smoothing splines fitting was used to reduce the dimensionality 
of the data set and to approximate the TCRPs. Spline basis coefficients were used 
as descriptors to construct the distance matrix which was used for hierarchical clus-
ter analysis to construct dendrograms. The distance matrix provided numerical val-
ues (Euclidean distance) to assess similarities between reference compounds with 
known biological activity and test compounds. These numerical values were used to 
select the compounds for further biological activity assays. A heat map was gener-
ated which displays the Z-transformed values of the 22 descriptors which correspond 
to the basis spline coefficients. Hierarchical cluster analysis was done for the refer-
ence compounds together with the test compounds. 
4.2.2.2.4. High content analysis with automated microscope 
A. Instrument and equipment  
ImageXpress Micro (IXM) 
High-Speed Laser Autofocus 
Digital CCD-Camera 
300 Watt Xenon-arc lamp 
Filter Sets:      -    DAPI 
- FITC 
- TRITC 
- Texas Red  
Nikon Objective:  - 4X Plan Apo, NA (Numerical Aperture) 0,20  
- 10X S Fluor, NA 0,50 
- 20X S Fluor, NA 0,75  
- 40X Plan Apo, NA 0,95 
- 60X Plan Fluor, NA 0,85 
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B. Experimental procedure 
Confluent KB 3‒1 cells were harvested according to the procedure mentioned in 
4.2.2.2.1. Cells (60 µl) were seeded into six 384 well MTPs with 2500 cells/well  and 
were incubated for 1h at RT, followed by 3h at 37 ºC. Compounds (100 µl), dissolved 
in DMSO/MeOH in a 1/1 ratio (v/v) were added to the MTPs to reach the IC50 of MTT 
assay, with the help of a robotic pin-tool. Cells were incubated for overnight at 37 ºC 
followed by washing and staining steps with appropriate reagents or antibodies de-
scribed in 4.2.2.2.5. All washing steps were done with PBS (50 µl). Additional details 
of the staining of the six plates are given in Table 8. After the staining step, cells 
were stored at 4 ºC, sealed with parafilm and wrapped in aluminum foil prior to image 
acquisition.  
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Table 8. Details of targeted proteins and their visualization 
Plate 
number 
Staining reagent or antibody Fixation 
reagents 
Dilution of 
stains or 
antibodies 
Incubation 
time (h) 
Primary Secondary 
I Alexa fluor phalloidin 
488 
Not required F a 1:400 1 
Monoclonal anti-α-
tubulin; Clone B-5-1-
2 
Anti-mouse IgG 
Atto 594 
F 1:6000 1 
II GRP 94 Labeled rabbit 
anti-rat IgG 
M/Ab 1:4000 1 
monoclonal anti-pan 
cytokeratin; clone C-
11 
Anti-mouse IgG 
Atto 594 
M/A 1:2000 1 
III Anillin Atto 488 goat 
anti-rabbit IgG 
F 1:1000 1 
Monoclonal anti-
splicing factor SC-35 
Anti-mouse IgG 
Atto 594 
F 1:4000 1 
IV Phospho-p38, MAP 
kinase 
(Thr180/Tyr182) 
Atto 488 goat 
anti-rabbit IgG 
F 1:400 O.N.c 
Phospho-44/42, MAP 
kinase (Erk 1/2) 
(Thr202/Tyr204) 
Anti-mouse IgG 
Atto 594 
F 1:400 O.N. 
V Anti-c-Fos Atto 488 goat 
anti-rabbit IgG 
F 1:3000 1 
Monoclonal Anti-p53 Anti-mouse IgG 
Atto 594 
F 1:1600 1 
VI Anti-phospho-CREB 
(pSer133) 
Atto 488 goat 
anti-rabbit IgG 
F 1:1000 O.N. 
Mouse anti-
calmodulin 
Anti-mouse IgG 
Atto 594 
F 1:400 O.N. 
F-Formalin, M/A-MeoH/Acetone, O.N.-Overnight  
C. Image analysis, software and application modules 
MetaXpress (2.0.0.13, Molecular Device) is the software used for the image acquisi-
tion with automated microscope. The important settings used for recording the im-
ages were mentioned below. 
Objective and camera: 10X was used with binning of 2 and gain of 1 
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Plate: Corning 384-well plastic 3683 and parameters for the plate type were already 
set and were not changed 
Wells to visit: Four sites were chosen for each well according to the cells distribution 
Time-lapse: only one time point 
Acquisition loop: 3 wavelengths selected and laser-based focusing enabled 
Autofocus: focus on well bottom for all sites 
Setting for each wavelength: W1for DAPI, W2 for FITC and W3 for Texas Red. Ex-
posure time was adjusted according to the staining intensity. 
Acquired images were analyzed in two ways, i) cell based and ii) image based 
with two application modules i) Transfluor for SC-35 staining ii) Multi wavelength cell 
scoring for all other staining.  
Cell and image-based analysis: Cell-based analysis takes individual cells into con-
sideration whereas image-based analysis takes an average of all the sites in one 
well. In this work both kinds of analyses were performed, but from the previous ex-
periences, output from image-based analysis was considered for the final evaluation.  
Multi wavelength cell scoring (MWCS):  This module is used to analyze cells with 
more than one staining. Size of the object (minimum and maximum width) and stain 
intensities for each wavelength were altered manually. In this experiment the three 
used wavelengths were W1: DAPI, W2: FITC and W3: Texas Red. Descriptors used 
for the image analysis in both ways were shown in Table 9.  
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Table 9. Descriptors used in Multi wavelength scoring for both image and cell-based analy-
sis 
 
Image-based analysis 
Total cells: Total number of cells based on DAPI. 
(%) Positive W2/W3: Number of cells stained for each wavelength (both absolute and 
relative) 
Scoring profile 1--/12-/1-3/123: absolute number of cells which are stained for differ-
ent wavelength, For example: 1-3 shows the number of cells stained only for 1(W1) 
and 3 (W3) but not 2 (W2) and so on. 
Cell-based analysis 
Total area: Nuclear surface 
Stained area W1/W2/W3: Coloured surface of respective staining 
Positive W2/W3: absolute number of cells stained for each wavelength 
Average/integrated intensity W1/W2/W3: average/integrated intensity of each stain 
 
Transfluor: This module was used for counting objects like pits and vesicles which 
were stained with SC-35. Parameters such as the nucleus size, vesicle and pit count 
were altered. Descriptors used in the Transfluor module for the analysis are show in 
Table 10. 
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Table 10. Descriptors used in the Transfluor application module for image analysis 
Image-based analysis 
Pit count per cell: Total number of pits per cell 
Pit average intensity: average intensity of all the pits in each well 
Vesicle count per cell: absolute number of vesicles per cell 
Vesicle average/integrated intensity: average or integrated intensity of all the vesicles in each 
well 
Nuclear count: Total number of cells based on W1 wavelength 
Nuclear average intensity: average intensity of all the cells in a well 
Same descriptors were used for Cell-based analysis 
 
D. Data analysis, software and methodology 
Data obtained from application modules are analyzed using AcuityXpress™. The 
flow of the analysis is shown below. 
Annotation: All micro-titre plates were annotated with compound labels in respec-
tive wells in an excel file. This file was imported to AcuityXpress™ in csv file format. 
Normalization: The data was normalized against the negative control 
(DMSO:MeOH, 1/1, v/v) with a linear scaling method, Control Mean Scaling. Each of 
the six plates was normalized separately based on cell- or image-based analysis. 
For this assay min-max scaling was used, which is independent of controls. All cell-
based parameters have a prefix of cell and image-based parameters have no prefix. 
Dataset creation: All the six plates used for HCIA experiment were combined into 
one dataset. Two kinds of dataset are possible and were created namely, cell-based 
and image-based. For each kind of dataset, their respective descriptors were used. 
MATERIALS AND METHODS 
 
127 
 
Centering and scaling of the data: For better comparison the data was centered 
and scaled, i.e., subtracting the mean from each data point and dividing each data 
point by the variance (average of squared difference from the mean), which gave Z-
values. 
Analysis method: After the data transformation, it was analysed using two different 
analysis methods, hierarchical and non-hierarchical clustering, with AcuityXpress™. 
In Hierarchical cluster, the number of clusters is derived from the analysis. 
Similarity metrics defined by the Euclidean squared metric was used to convert de-
scriptor rows into clusters. These clusters are linked together with the degree of simi-
larity to produce the dendrogram which determines the grouping of these descriptor 
rows in heat maps. This method was employed to construct the dendrograms asso-
ciated with a heat map with all of the test compounds and reference compounds.  
Match to mean profile: The data set can be sorted, based on similarity profiles of 
compounds of interest. This method was followed to obtain numerical correlation co-
efficient values, in addition to the two-dimensional visual representation. The profile 
of a test compounds was selected in the AcuityXpress interface, by clicking its row in 
the Data tab and the “Match to Mean Profile” command was executed. The output 
gave the distance values between the selected compound and the remaining com-
pounds in the data set.  This procedure was repeated for all test compounds and the 
generated file was exported each time to an excel data sheet. 
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4.2.2.2.5. Immuno-fluorescence assays for the inhibition of actin and tubulin 
polymerization 
Cells were cultivated on cover slips for fluorescence staining. Sterile cover slips (13 
mm diameter) were placed in each well of a 4-well MTP. PtK2 cells were harvested 
by trypsinising a confluent cell culture (see 4.2.2.2.1) and were diluted to 10-fold with 
medium. To each MTP well, 750 µl of the cell suspension was added and the cells 
were incubated for overnight at 37 ºC. Thereafter, the test compounds (1 µl), dis-
solved in DMSO, appropriate positive controls (1 µl in DMSO) or blank (DMSO, 1 µl) 
were added. The total concentration of DMSO in a well did not exceed 1%. Cells 
were incubated with the test compounds for overnight at 37 ºC.  
A. Fixation: After the incubation, medium was carefully aspirated under vacuum 
suction. The cells were incubated with 750 µl of formalin (3.7% (v/v) of formaldehyde 
in PBS) for 10 minutes. The cells were washed once with PBS (750 µl) and incu-
bated with 750 µl Triton X-100 (0.1% (v/v) in PBS) for 5 minutes to make the cells 
permeable. Triton X-100 was aspirated and cells were washed with PBS (750 µl).  
B. Staining: Appropriate antibodies were used for specific proteins staining. The 
cells were incubated with 240 µl of primary antibody dilution for one hour at 37 ºC 
and were subsequently washed twice with PBS (750 µl). Thereafter, the primary an-
tibodies were labeled with 240 µl of a dilution of the secondary antibody (containing a 
fluorescent reporter) by incubation for 1h at 37 ºC. Cells were washed twice with 
PBS (750 µl). Then, for the nucleolus staining, the cells were incubated with 20 µl 
DAPI (1 µg/mL in PBS) for 10 minutes at RT followed by a PBS (750 µl) washing. 
The cover slips were taken out of the wells, towel-dried and embedded onto a micro-
scopic glass slide with a drop of embedding medium (ProLong Antifade). The pri-
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mary and secondary antibodies used for staining of actin and tubulin protein struc-
tures are given in Table 11. 
Table 11. List of the antibodies used for the staining of actin and tublin structures in PtK2 
cells 
Stained structure Primary antibody Secondary antibody 
Actin Alexa Fluor Phalloidin 488 No secondary antibody needed 
α-Tubulin Anti- α-Tubulin Alexa Fluor 488 
 
C. Generation of images:  The images of stained protein structures in the cells 
were captured with the CCD camera mounted on the Axioplan fluorescence micro-
scope. Neofluor objectives with 63x and 100x magnification were used to view the 
images.  All images were taken with 63x magnification.  
4.2.2.2.6. Histone deacetylase inhibition assay 
Substrates provided in the commercial kit were thawed at room temperature and 
mixed to homogenize. Dilutions were made according to the assay protocol supplied 
with the kit. Reagents in the kit were added to the wells of 96 well MTPs according to 
Table 12.  
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Table 12. Reagent addition scheme for HDAC activity or inhibitor test 
Type of reac-
tion 
Assay 
Buffer (µl) 
HDAC Inhibitor 
Solution (µl) 
HeLa Lysate or 
Test Sample (µl) 
HDAC Substrate 
Solution (µl) 
100 % HDAC 
Sample 35 0 15 50 
Test-
compound 
 
30 
 
5 
 
15 
 
50 
No HDAC 50 0 0 50 
 
The MTP was incubated for 30 minutes at 30 ºC. Thereafter, 10 µl of devel-
oper solution was added to each well and the plate was incubated for 10 more min-
utes at RT. After the incubation time fluorescence at 460 nm was measured with the 
fluorimeter plate reader. 
4.2.2.2.7. Proteasome inhibition assay 
All contents supplied in the commercial kit were thawed at RT and used in the assay 
according to the instructions provided. All solid substrates or reagents supplied were 
dissolved in the appropriate buffer solution. The Proteasome reagent was prepared 
with a peptide substrate Suc-LLVY-GloTM, containing a luminescent reporter, and a 
luciferin detection reagent. The prepared reagent was kept at RT for 60 minutes be-
fore use to remove any contamination of free aminoluciferin.  
 Each reaction was done in duplicate. KB 3‒1 cells were harvested as de-
scribed in 4.2.2.2.1 and seeded (50 µl) into a 96 well white walled MTP with 15,000 
cells/well. Cells were incubated for 2 h at 37 ºC. Test compounds (1-2 µl), dissolved 
in DMSO/MeOH (1/1, v/v) were added to the cells, and the cells were incubated for 
another 2h at 37 ºC. The MTP was allowed to equilibrate to RT. The proteasome re-
agent (50 µl) was added to the cells and the contents of the wells were mixed using 
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a plate shaker for 2 minutes. Thereafter, the MTP was incubated for 20 minutes at 
RT with the lid closed. Subsequently, the luminescence of each well was measured 
with a plate reader.  
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5. Abbreviations 
AIBN   Azoisobutyronitrile 
ARHDO  Aryl hydroxy dioxygenase 
CI   Cell index 
DAPI   4',6-diamidino-2-phenylindole 
DMEM   Dulbecco’s modified eagle’s medium 
DMSO  Dimethyl sulfoxide 
EBSS   Earle's balanced salt solution 
FBS   Fetal bovine serum 
FDA   Food and drug administration 
FITC   Fluorescein isothiocyanate 
HCIA   High content image analysis 
HDAC   Histone deacetylase 
HOMO  Highest occupied molecular orbital 
HPLC   High pressure liquid chromatography 
HRMS  High-resolution mass spectrum 
LC-MS  Liquid chromatography-mass spectrum 
LUMO   Lowest unoccupied molecular orbital 
MEM    Minimum essential media 
MTP   Microtitre plate 
MTT    3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid 
MWCS  Multi wavelength cell scoring 
NME   New molecular entity 
NMR   Nuclear magnetic resonance 
NOE   Nuclear overhauser effect 
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NSI   Nanospray Ionization  
OD   Optical density 
O.N   Over night 
PBS   Phosphate buffered saline 
rcf   Relative centrifugal force 
RT   Room temperature 
TCRP   Time-dependent cellular response profile 
TLC   Thin layer chromatography 
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Table 3 Numerical distance values obtained from the impedance measurement performed  with bridged bicyclic compounds derived from dienediols 22 and 23 (1st experiment) 
 Bridged bicyclic compound 
Reference 
compound 
BrDPD17
A 
BrDPD20
A 
BrDPD13
A 
BrDPD10S BrDPD10A BzDPD01
A 
BzDPD10
A 
BrDUD17S BrDUD19S BrDUD01A BrDUD21S BrDUD20S BrDUD18S BrDUD26S BrDUD12S BrDUD16S 
Epothilon 5,488 4,489 2,491 1,387 1,332 3,769 4,674 2,394 3,019 1,084 5,638 3,572 3,733 5,520 5,914 6,051 
Mevastatin 2,223 1,157 2,544 4,677 3,945 7,429 4,642 4,735 4,880 4,149 2,281 2,495 3,269 1,770 2,620 2,550 
Simvastatin 2,224 1,194 2,626 4,725 4,003 7,481 4,628 4,797 4,897 4,200 2,283 2,489 3,260 1,794 2,621 2,540 
Myxothiazol 3,339 1,903 2,129 3,763 3,089 6,558 3,561 3,672 3,613 3,265 3,414 1,532 2,195 2,732 3,750 3,770 
Neopeltolid 3,172 1,756 2,157 3,907 3,222 6,701 3,716 3,841 3,836 3,406 3,244 1,685 2,365 2,549 3,582 3,582 
Oligomycin 2,972 1,552 2,360 4,206 3,509 6,997 3,801 4,118 4,062 3,699 3,027 1,747 2,467 2,320 3,365 3,350 
CruentarenA 3,194 1,750 2,244 4,005 3,319 6,798 3,622 3,907 3,846 3,507 3,254 1,652 2,352 2,532 3,587 3,580 
GephyronicAci
dA 
5,492 4,195 2,543 1,940 1,713 4,490 3,311 2,044 2,011 1,666 5,610 2,642 2,703 5,090 5,920 6,019 
Cycloheximid 5,181 3,983 2,302 1,913 1,532 4,541 3,501 2,051 2,172 1,511 5,311 2,505 2,676 4,890 5,619 5,733 
Anisomycin 5,217 3,965 2,140 1,685 1,421 4,354 3,787 2,195 2,537 1,367 5,338 2,844 3,025 4,900 5,643 5,735 
MG132 4,714 3,458 1,238 1,909 1,247 4,654 4,011 2,112 3,059 1,471 4,824 2,741 3,175 4,169 5,145 5,227 
Velcade 4,507 3,245 1,628 2,477 1,858 5,217 3,522 2,228 2,697 2,019 4,624 2,152 2,521 4,126 4,931 5,011 
SB202190 3,615 2,486 1,307 2,895 2,234 5,670 4,108 3,203 3,648 2,393 3,735 2,327 2,921 3,354 4,051 4,079 
SB203580 3,683 2,631 1,274 2,683 2,010 5,439 4,257 3,085 3,571 2,148 3,817 2,412 2,991 3,549 4,127 4,194 
Vioprolid 5,413 4,261 2,325 1,492 1,238 4,070 3,932 2,020 2,452 1,121 5,545 3,035 3,191 5,228 5,839 5,957 
CytochalasinD 9,711 8,678 6,293 3,922 4,598 2,092 7,501 4,425 5,270 4,340 9,857 7,416 7,284 9,632 10,117 10,313 
RhizopodinA 11,02 10,371 7,850 5,685 6,368 3,192 10,160 6,885 8,055 6,116 11,19 9,685 9,761 11,225 11,401 11,59 
LatrunculinB 8,939 8,475 6,053 4,465 4,841 2,852 9,262 5,595 7,170 4,671 9,098 8,229 8,464 9,308 9,288 9,508 
Nocodazol 5,239 4,184 1,998 1,252 0,950 3,851 4,571 2,280 3,089 0,822 5,373 3,438 3,703 5,173 5,650 5,778 
Griseofulvin 5,156 4,080 1,810 1,191 0,786 3,914 4,478 2,179 3,069 0,722 5,291 3,317 3,617 4,993 5,581 5,696 
TubulysinB 5,199 4,135 1,929 1,192 0,846 3,881 4,509 2,195 3,040 0,721 5,339 3,336 3,618 5,060 5,630 5,749 
Etoposid 6,641 5,506 3,241 1,068 1,599 2,816 4,810 2,079 2,907 1,310 6,776 4,293 4,338 6,408 7,066 7,208 
Camptothecin 7,530 6,554 4,026 1,608 2,353 1,530 6,093 2,880 4,092 2,065 7,678 5,581 5,662 7,437 7,946 8,098 
Saframycin 6,574 5,597 3,116 0,814 1,457 2,386 5,491 2,383 3,612 1,136 6,722 4,722 4,878 6,490 6,995 7,139 
Oxamflatin 5,576 4,485 2,079 0,834 0,689 3,492 4,686 2,025 3,146 0,563 5,709 3,671 3,939 5,311 6,006 6,129 
Scriptaid 5,720 4,585 2,225 0,877 0,927 3,478 4,613 2,090 3,112 0,795 5,849 3,717 3,960 5,387 6,150 6,263 
DMSO 6,307 5,307 2,834 0,619 1,187 2,657 5,273 2,224 3,463 0,857 6,452 4,448 4,623 6,195 6,729 6,868 
Taxol 5,646 4,606 2,460 1,090 1,158 3,594 4,584 2,337 3,025 0,880 5,793 3,649 3,837 5,544 6,077 6,188 
 140 
 
Table 2. Numerical distance values obtained from the impedance measurement performed with bridged bicyclic compounds derived from dienediols 22 and 23 (repetition experiment) 
 
Bridged bicyclic compound 
Reference 
compound BrDPD17A BrDPD20A BrDPD13A BrDPD10S BrDPD10A BzDPD01A BzDPD10A BrDUD17S BrDUD19S BrDUD01A BrDUD21S BrDUD20S BrDUD18S BrDUD26S BrDUD12S BrDUD16S BrDUD14S 
EpothilonB 3.590 5.436 1.768 1.536 1.247 4.968 3.829 2.242 3.217 1.399 3.384 2.405 4.021 2.539 3.418 2.173 2.590 
Mevastatin 0.987 2.169 4.100 4.863 4.427 8.712 3.922 4.880 3.131 4.638 2.146 3.523 1.987 5.974 1.843 5.549 6.081 
Simvastatin 1.076 2.176 4.168 4.916 4.482 8.765 3.923 4.937 3.142 4.690 2.159 3.548 1.985 6.033 1.880 5.604 6.137 
MyxothiazolA 1.429 3.262 3.365 3.978 3.506 7.841 2.750 3.803 1.926 3.760 1.219 2.252 1.395 5.088 1.105 4.621 5.197 
Neopeltolid 1.310 3.098 3.479 4.121 3.656 7.988 2.922 3.976 2.127 3.899 1.356 2.473 1.450 5.235 1.189 4.773 5.345 
Oligomycin 1.282 2.899 3.745 4.415 3.949 8.283 3.063 4.260 2.291 4.195 1.441 2.717 1.397 5.523 1.236 5.065 5.637 
CruentarenA 1.387 3.114 3.574 4.219 3.752 8.086 2.863 4.038 2.116 4.001 1.381 2.504 1.414 5.323 1.218 4.859 5.438 
GephyronicAcidA 3.411 5.418 2.253 2.171 1.772 5.723 2.475 1.980 2.100 2.021 2.649 1.258 3.221 3.135 2.766 2.639 3.220 
Cycloheximid 3.111 5.120 2.074 2.100 1.659 5.781 2.630 2.005 2.142 1.940 2.486 1.295 3.075 3.110 2.553 2.628 3.206 
Anisomycin 3.154 5.144 1.897 1.954 1.557 5.612 2.928 2.123 2.372 1.767 2.719 1.645 3.290 3.010 2.754 2.546 3.086 
MG132 2.499 4.642 1.522 2.091 1.700 5.948 3.051 2.219 2.424 1.886 2.548 1.874 2.989 3.150 2.308 2.690 3.269 
Velcade 2.342 4.446 2.103 2.659 2.199 6.489 2.570 2.264 2.079 2.488 2.047 1.547 2.555 3.625 2.002 3.201 3.785 
SB202190 1.543 3.565 2.467 3.109 2.695 6.958 3.216 3.265 2.489 2.884 2.024 2.322 2.403 4.229 1.801 3.799 4.335 
SB203580 1.635 3.637 2.260 2.873 2.455 6.714 3.351 3.143 2.538 2.650 2.093 2.275 2.531 4.004 1.886 3.585 4.101 
Vioprolid 3.377 5.349 1.810 1.680 1.271 5.308 3.093 1.899 2.620 1.532 2.949 1.759 3.555 2.705 2.988 2.244 2.797 
CytochalasinD 7.784 9.651 4.688 3.736 4.069 1.983 6.911 4.148 6.717 3.954 7.357 5.759 7.981 2.908 7.408 3.216 2.821 
RhizopodinA 9.394 10.982 6.318 5.486 5.962 2.222 9.479 6.652 9.113 5.665 9.509 8.176 10.136 4.715 9.429 5.114 4.518 
LatrunculinB 7.487 8.912 4.705 4.153 4.551 2.747 8.434 5.495 7.829 4.319 7.939 6.946 8.533 3.621 7.751 4.000 3.530 
Nocodazol 3.257 5.163 1.366 1.422 1.051 5.102 3.698 2.159 3.071 1.239 3.218 2.308 3.826 2.511 3.193 2.120 2.586 
Griseofulvin 3.114 5.086 1.240 1.394 1.019 5.188 3.577 2.095 2.956 1.179 3.109 2.200 3.688 2.528 3.037 2.104 2.602 
TubulysinB 3.176 5.136 1.320 1.382 1.018 5.146 3.613 2.099 2.974 1.177 3.138 2.211 3.716 2.516 3.080 2.096 2.581 
Etoposid 4.608 6.572 1.976 1.124 1.176 4.008 4.041 1.854 3.669 1.156 4.208 2.734 4.814 1.713 4.224 1.326 1.721 
Camptothecin 5.582 7.470 2.467 1.437 1.886 2.706 5.338 2.633 4.989 1.626 5.452 4.029 6.066 1.076 5.409 1.170 0.935 
Saframycin 4.615 6.515 1.669 0.693 1.042 3.624 4.668 2.171 4.207 0.792 4.560 3.284 5.165 1.280 4.501 1.037 1.259 
Oxamflatin 3.515 5.509 1.103 1.010 0.770 4.765 3.789 1.958 3.206 0.803 3.481 2.396 4.045 2.124 3.356 1.684 2.181 
Scriptaid 3.651 5.649 1.294 1.115 0.950 4.752 3.738 2.017 3.191 0.919 3.547 2.393 4.098 2.171 3.436 1.717 2.204 
DMSO 4.326 6.247 1.452 0.569 0.815 3.907 4.430 2.035 3.949 0.588 4.278 3.043 4.879 1.448 4.209 1.115 1.467 
Taxol 3.674 5.584 1.664 1.321 1.097 4.840 3.746 2.171 3.228 1.149 3.501 2.401 4.099 2.379 3.517 1.965 2.402 
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Table 3. Numerical distance values obtained from the impedance measurement performed with bridged bicyclic compounds derived from hetero-aryl dienediols (1
st
 experiment). 
 Bridged bicyclic compound  
Reference 
Compound 
PmDUD06
S 
PmDUD19
S 
PmDUD
20S 
PmDUD13
S 
PmDUD21S Py3DUD01A Py3DUD17S Py3DUD19
S 
Py3DUD20S Py3DUD13S Py3DUD21S Py3DUD10S Py4DUD01A ImDUD10S 
Epothilon 1,257 2,334 1,727 2,195 1,761 1,238 1,946 1,713 1,909 2,633 2,149 1,776 1,012 1,305 
Mevastatin 3,404 3,694 3,335 2,943 3,466 3,412 3,000 5,202 2,922 2,309 2,747 2,635 3,638 3,206 
Simvastatin 3,454 3,728 3,381 2,988 3,515 3,462 3,049 5,249 2,971 2,345 2,795 2,684 3,681 3,253 
MyxothiazolA 2,434 2,449 2,212 1,773 2,354 2,437 1,927 4,171 1,876 1,130 1,659 1,671 2,693 2,212 
Neopeltolid 2,588 2,654 2,399 1,962 2,537 2,594 2,090 4,343 2,037 1,302 1,827 1,816 2,842 2,372 
Oligomycin 2,877 2,911 2,681 2,230 2,812 2,884 2,367 4,641 2,309 1,545 2,088 2,090 3,135 2,659 
CruentarenA 2,673 2,681 2,458 2,011 2,589 2,684 2,140 4,426 2,087 1,341 1,876 1,888 2,929 2,456 
GephyronicAc
id A 
1,180 1,211 1,012 1,367 1,075 1,184 1,243 2,002 1,297 1,852 1,470 1,411 1,217 1,124 
Cycloheximid 0,942 1,318 0,876 1,266 1,004 0,929 1,063 2,028 1,075 1,700 1,237 1,150 1,023 0,852 
Anisomycin 0,887 1,567 1,044 1,431 1,085 0,900 1,225 1,998 1,230 1,890 1,488 1,148 0,894 0,827 
MG132 0,791 1,765 1,007 1,245 1,024 0,791 0,862 2,368 0,880 1,677 1,219 0,703 1,142 0,716 
Velcade 1,204 1,488 0,978 0,926 1,163 1,206 0,644 2,748 0,544 1,056 0,494 0,919 1,465 1,107 
SB202190 1,663 2,375 1,781 1,632 1,916 1,685 1,448 3,430 1,359 1,328 1,351 0,993 1,857 1,487 
SB203580 1,467 2,348 1,673 1,624 1,810 1,473 1,428 3,220 1,320 1,462 1,361 0,869 1,650 1,283 
CytochalasinD 5,056 5,522 5,320 5,876 5,213 5,034 5,675 3,384 5,714 6,604 5,999 5,811 4,840 5,225 
RhizopodinA 6,978 7,973 7,506 8,101 7,410 6,974 7,779 5,547 7,789 8,739 8,133 7,705 6,709 7,163 
LatrunculinB 5,521 6,758 6,122 6,667 6,035 5,498 6,331 4,536 6,312 7,235 6,629 6,142 5,313 5,674 
Nocodazol 0,823 2,183 1,434 1,925 1,444 0,849 1,591 1,730 1,544 2,390 1,868 1,361 0,594 0,915 
Griseofulvin 0,598 2,078 1,284 1,783 1,301 0,625 1,409 1,726 1,377 2,259 1,727 1,185 0,452 0,713 
TubulysinB 0,694 2,104 1,333 1,833 1,354 0,691 1,491 1,702 1,461 2,323 1,798 1,269 0,529 0,777 
Etoposid 1,835 2,547 2,164 2,745 2,084 1,824 2,495 0,824 2,534 3,411 2,853 2,554 1,639 1,979 
Camptothecin 2,877 3,800 3,342 3,952 3,249 2,872 3,627 1,407 3,651 4,620 4,002 3,647 2,627 3,070 
Saframycin 1,958 3,082 2,500 3,102 2,431 1,951 2,757 1,000 2,767 3,729 3,122 2,709 1,703 2,143 
Oxamflatin 0,907 2,250 1,526 2,074 1,470 0,903 1,724 1,381 1,733 2,656 2,102 1,587 0,843 1,058 
Scriptaid 1,061 2,243 1,595 2,137 1,524 1,066 1,812 1,392 1,836 2,730 2,209 1,704 0,998 1,200 
DMSO 1,664 2,842 2,229 2,821 2,163 1,657 2,469 0,976 2,480 3,434 2,835 2,410 1,419 1,846 
Taxol2 1,149 2,284 1,666 2,197 1,686 1,163 1,873 1,508 1,864 2,686 2,182 1,745 0,831 1,257 
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Table 4. Numerical distance values obtained from the impedance measurement performed with bridged bicyclic compounds derived from hetero-aryl dienediols (repetition experiment). 
 Bridged bicyclic compound 
Reference 
compound 
PmDUD06
S 
PmDUD19S PmDUD20S PmDUD13S PmDUD21S Py3DUD01A Py3DUD17S Py3DUD19S Py3DUD20S Py3DUD13S Py3DUD21S Py3DUD10S Py4DUD01A ImDUD10S 
Epothilon 1,928 2,950 2,520 2,567 2,423 2,160 2,598 1,957 2,567 3,079 2,643 2,491 1,671 2,121 
Mevastatin 2,658 2,733 2,739 2,681 2,749 2,310 2,504 3,305 2,249 1,992 2,176 2,094 2,904 2,324 
Simvastatin 2,717 2,758 2,787 2,726 2,800 2,359 2,548 3,334 2,307 2,027 2,230 2,150 2,954 2,374 
MyxothiazolA 1,768 1,540 1,626 1,538 1,683 1,340 1,362 2,047 1,306 0,909 1,245 1,197 1,974 1,370 
Neopeltolid 1,896 1,731 1,806 1,722 1,854 1,481 1,534 2,262 1,443 1,048 1,367 1,324 2,114 1,505 
Oligomycin 2,159 1,926 2,046 1,969 2,095 1,738 1,779 2,529 1,669 1,230 1,581 1,534 2,384 1,768 
CruentarenA 1,961 1,730 1,841 1,768 1,886 1,531 1,559 2,300 1,483 1,060 1,393 1,350 2,174 1,562 
GephyronicAc
id A 
1,601 1,932 1,678 1,721 1,639 1,657 1,734 0,837 1,978 2,296 2,046 1,987 1,375 1,643 
Cycloheximid 1,348 1,868 1,511 1,582 1,498 1,418 1,594 0,845 1,746 2,145 1,809 1,734 1,128 1,404 
Anisomycin 1,343 2,137 1,774 1,811 1,637 1,464 1,796 1,136 1,890 2,320 1,987 1,845 1,094 1,429 
MG132 0,653 2,034 1,370 1,454 1,116 0,948 1,404 1,439 1,305 1,984 1,508 1,315 0,696 0,863 
Velcade 0,826 1,473 0,989 1,131 1,035 0,841 0,939 1,231 0,880 1,420 0,842 0,961 0,810 0,851 
SB202190 1,067 1,971 1,648 1,660 1,566 0,837 1,439 1,900 1,192 1,480 1,159 0,971 1,205 0,800 
SB203580 0,985 2,055 1,661 1,681 1,565 0,849 1,538 1,840 1,249 1,660 1,279 1,030 1,091 0,802 
CytochalasinD 5,858 6,656 6,208 6,277 6,100 6,205 6,409 5,574 6,482 7,073 6,615 6,523 5,611 6,169 
RhizopodinA 7,745 8,970 8,409 8,489 8,228 8,123 8,573 7,856 8,516 9,190 8,656 8,475 7,515 8,069 
LatrunculinB 6,150 7,563 6,912 6,991 6,730 6,548 7,083 6,577 6,898 7,635 7,039 6,822 5,996 6,485 
Nocodazol 1,471 2,747 2,229 2,299 2,065 1,752 2,293 1,792 2,210 2,815 2,308 2,115 1,207 1,707 
Griseofulvin 1,280 2,622 2,062 2,136 1,881 1,586 2,126 1,690 2,043 2,672 2,166 1,976 1,031 1,530 
TubulysinB 1,382 2,663 2,117 2,181 1,948 1,674 2,194 1,715 2,117 2,734 2,247 2,059 1,141 1,619 
Etoposid 2,651 3,544 3,079 3,146 2,938 2,948 3,228 2,403 3,311 3,867 3,448 3,316 2,389 2,907 
Camptothecin 3,686 4,812 4,269 4,355 4,100 4,058 4,426 3,697 4,427 5,076 4,564 4,418 3,429 4,005 
Saframycin 2,759 3,977 3,411 3,493 3,236 3,125 3,551 2,893 3,515 4,174 3,653 3,491 2,509 3,070 
Oxamflatin 1,648 2,951 2,347 2,422 2,138 1,993 2,460 1,944 2,410 3,063 2,581 2,384 1,447 1,933 
Scriptaid 1,774 2,986 2,419 2,488 2,195 2,093 2,526 1,957 2,514 3,131 2,693 2,497 1,566 2,034 
DMSO 2,463 3,703 3,131 3,210 2,956 2,827 3,259 2,631 3,224 3,878 3,360 3,197 2,218 2,771 
Taxol2 1,886 2,969 2,515 2,573 2,370 2,137 2,583 1,936 2,586 3,125 2,682 2,526 1,599 2,087 
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Table 5. Numerical correlation values of 30 bridged bicyclic compounds obtained from the high content analysis (1
st
 experiment). The similarity values with first 30 reference compounds are shown. 
BrDPD17A 1.000 BrDPD20A 1.000 BrDPD110S 1.000 ImDUD10S 1.000 Py3DUD10S 1.000 PmDUD06S 1.000 BrDPD10A 1.000 Py3DUD01A 1.000 
Amanitin 0.857 Anisomycin 0.913 Chivosazol A 0.928 Mevastatin 0.884 H89 0.927 Staurosporine 0.917 Tunicamycin 0.895 Myxothiazol A 0.900 
Anisomycin 0.795 Griseofulvin 0.835 DMSO:MeOH 0.896 SB203580 0.877 SB203580 0.925 Simvastatin 0.906 Oligomycin 0.880 LY294002 0.885 
SB202190 0.787 Amanitin 0.833 SB202190 0.878 DMSO:MeOH 0.864 Saframycin  0.911 Saframycin  0.877 Myxothiazol A 0.879 SB203580 0.878 
Actinomycin D 0.766 SB202190 0.787 Griseofulvin 0.874 Saframycin  0.850 Oligomycin 0.876 Soraphen A 0.876 Soraphen A 0.876 Mevastatin 0.868 
Apicidin 0.763 Gephyronsäure A 0.766 Mevastatin 0.854 Chivosazol A 0.845 Mevastatin 0.865 DMSO:MeOH 0.875 Mevastatin 0.872 PD169316 0.857 
Griseofulvin 0.750 Mevastatin 0.761 Colchicine 0.851 LY294002 0.845 DMSO:MeOH 0.864 H89 0.868 SB203580 0.867 Tunicamycin 0.857 
Alsterpaullone 0.742 Podophyllotoxin 0.749 Saframycin  0.849 Amanitin 0.822 Staurosporine 0.819 Tunicamycin 0.859 Cruentaren A 0.864 Oligomycin 0.846 
Chelerythrine 0.720 Chivosazol A 0.744 Archazolid B 0.848 SB202190 0.813 PD169316 0.817 Rapamycin 0.858 Podophyllotoxin 0.861 Velcade 0.846 
Chivosazol A 0.682 DMSO:MeOH 0.742 Anisomycin 0.844 Oligomycin 0.812 Methotrexate 0.817 Oligomycin 0.850 Staurosporine 0.860 Podophyllotoxin 0.823 
Mevastatin 0.673 LY294002 0.738 Podophyllotoxin 0.834 Podophyllotoxin 0.803 Rapamycin 0.813 Nocodazole 0.848 Simvastatin 0.855 DMSO:MeOH 0.811 
DMSO:MeOH 0.662 
Indirubin 
monoxime 0.737 Amanitin 0.814 H89 0.795 Tunicamycin 0.807 SB203580 0.848 DMSO:MeOH 0.845 Dexamethasone 0.804 
LY294002 0.661 Alsterpaullone 0.717 SB203580 0.807 Archazolid B 0.794 Chivosazol A 0.800 Mevastatin 0.833 Dexamethasone 0.843 Soraphen A 0.800 
Saframycin  0.650 Actinomycin D 0.710 Staurosporine 0.805 Tunicamycin 0.793 Soraphen A 0.799 Podophyllotoxin 0.832 Velcade 0.841 Rapamycin 0.793 
SB203580 0.648 Purvalanol A 0.699 Soraphen A 0.803 PD169316 0.784 Simvastatin 0.798 Archazolid B 0.828 PD169316 0.840 Cruentaren A 0.790 
A23187 free 
acid 0.625 Tunicamycin 0.696 Apicularen 0.803 Anisomycin 0.783 LY294002 0.798 Emetine 0.823 Rapamycin 0.840 Saframycin  0.780 
Methotrexate 0.623 Colchicine 0.696 Actinomycin D 0.803 Velcade 0.778 Nocodazole 0.793 PD169316 0.819 LY294002 0.833 Staurosporine 0.774 
H89 0.619 SB203580 0.695 LY294002 0.797 Griseofulvin 0.775 Archazolid B 0.789 Chivosazol A 0.796 Saframycin  0.812 Simvastatin 0.770 
Emetine 0.615 Staurosporine 0.691 Purvalanol A 0.794 Soraphen A 0.774 Podophyllotoxin 0.787 Methotrexate 0.795 H89 0.811 H89 0.769 
Podophyllotoxin 0.614 Saframycin  0.689 Tunicamycin 0.794 Colchicine 0.774 SB202190 0.786 Dexamethasone 0.789 Archazolid B 0.786 Archazolid B 0.746 
PD169316 0.612 Apicidin 0.688 Chelerythrine 0.792 Actinomycin D 0.768 Dexamethasone 0.774 Cruentaren A 0.787 Camptothecin 0.776 Purvalanol A 0.736 
Apicularen 0.612 Velcade 0.684 
Gephyronsäure 
A 0.784 Staurosporine 0.764 Myxothiazol A 0.769 Colchicine 0.778 Myriaporon 0.768 Chivosazol A 0.734 
Colchicine 0.609 Soraphen A 0.679 Nocodazole 0.783 Apicidin 0.764 Emetine 0.751 Myxothiazol A 0.770 Nocodazole 0.759 Camptothecin 0.733 
Velcade 0.598 Chelerythrine 0.676 Apicidin 0.780 Methotrexate 0.754 Velcade 0.749 LY294002 0.768 Trichostatin 0.757 Myriaporon 0.732 
Purvalanol A 0.591 Archazolid B 0.674 Simvastatin 0.776 Chelerythrine 0.752 Colchicine 0.742 Apicularen 0.764 Cycloheximide 0.747 
Indirubin 
monoxime 0.731 
Tunicamycin 0.590 PD169316 0.672 Emetine 0.773 Nocodazole 0.748 Apicularen 0.738 SB202190 0.758 MG132 0.746 Doxorubicin 0.730 
Archazolid B 0.590 Emetine 0.665 Methotrexate 0.771 Myxothiazol A 0.746 Amanitin 0.733 Vinblastine 0.757 Chivosazol A 0.746 Nocodazole 0.716 
Staurosporine 0.586 Apicularen 0.657 H89 0.759 Purvalanol A 0.745 Cruentaren A 0.721 Purvalanol A 0.755 MeOH 0.734 Colchicine 0.708 
Gephyronsäure 
A 0.583 Argyrin A 0.646 Oligomycin 0.756 Simvastatin 0.743 Anisomycin 0.716 Camptothecin 0.752 Doxorubicin 0.733 Amanitin 0.704 
Soraphen A 0.580 Simvastatin 0.643 Velcade 0.742 Rapamycin 0.741 Apicidin 0.714 Velcade 0.742 Purvalanol A 0.730 Gephyronsäure A 0.704 
Continued on next page 
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PmDUD21S 1.000 BrDUD14S 1.000 BrDUD12S 1.000 Py3DUD19S 1.000 PmDUD13S 1.000 Py4DUD01A 1.000 BrDUD26S 1.000 BrDPD13A 1.000 
Tunicamycin 0.900 Cycloheximide 0.901 MG132 0.932 Camptothecin 0.909 Soraphen A 0.863 Simvastatin 0.876 Simvastatin 0.856 
Gephyronsäure 
A 0.870 
Myxothiazol A 0.880 MG132 0.900 Cycloheximide 0.895 Tunicamycin 0.864 Podophyllotoxin 0.850 Staurosporine 0.876 Staurosporine 0.849 Podophyllotoxin 0.820 
Cruentaren A 0.871 Camptothecin 0.882 Myriaporon 0.867 Soraphen A 0.858 Simvastatin 0.849 Soraphen A 0.848 Archazolid B 0.847 Brefeldin A 0.810 
Soraphen A 0.854 Cruentaren A 0.879 Cruentaren A 0.860 Simvastatin 0.856 Chondramid C 0.843 Tunicamycin 0.836 
Gephyronsäure 
A 0.837 Chondramid C 0.806 
Velcade 0.852 Myriaporon 0.877 Camptothecin 0.841 Ratjadon C 0.856 Purvalanol A 0.838 Podophyllotoxin 0.833 Podophyllotoxin 0.826 Archazolid B 0.805 
Camptothecin 0.848 Ratjadon C 0.847 MeOH 0.822 Cruentaren A 0.850 Tunicamycin 0.837 Brefeldin A 0.812 Nocodazole 0.823 Colchicine 0.799 
PD169316 0.845 MeOH 0.836 Ratjadon C 0.820 MeOH 0.838 Staurosporine 0.837 Cruentaren A 0.801 DMSO:MeOH 0.814 Staurosporine 0.796 
Podophyllotoxin 0.836 Tunicamycin 0.835 Tunicamycin 0.820 Doxorubicin 0.822 Brefeldin A 0.834 MG132 0.800 Colchicine 0.810 Simvastatin 0.791 
LY294002 0.831 Soraphen A 0.826 Trichostatin 0.814 Dexamethasone 0.816 Tubulysin B 0.825 Cycloheximide 0.798 Brefeldin A 0.805 Soraphen A 0.786 
MG132 0.826 Trichostatin 0.820 Soraphen A 0.808 Purvalanol A 0.813 Camptothecin 0.819 Myriaporon 0.795 Soraphen A 0.800 Cytochalasin D 0.785 
Rapamycin 0.819 Myxothiazol A 0.802 Brefeldin A 0.785 MG132 0.812 
Gephyronsäure 
A 0.818 Trichostatin 0.793 Cytochalasin D 0.793 DMSO:MeOH 0.779 
Myriaporon 0.819 Podophyllotoxin 0.796 Podophyllotoxin 0.784 Myriaporon 0.812 Colchicine 0.802 Puromycin 0.791 Wortmannin 0.791 Chivosazol A 0.769 
Dexamethasone 0.814 Simvastatin 0.793 Myxothiazol A 0.783 Staurosporine 0.812 Archazolid B 0.802 MeOH 0.789 Vinblastine 0.790 Puromycin 0.759 
Cycloheximide 0.809 Brefeldin A 0.786 Simvastatin 0.777 Rapamycin 0.812 Ratjadon C 0.800 DMSO:MeOH 0.785 Chivosazol A 0.787 Purvalanol A 0.758 
Simvastatin 0.800 Velcade 0.780 
Indirubin 
monoxime 0.772 Podophyllotoxin 0.809 Cycloheximide 0.795 Rapamycin 0.782 Apicularen 0.779 Tunicamycin 0.754 
Oligomycin 0.799 Dexamethasone 0.778 Velcade 0.762 Cycloheximide 0.803 DMSO:MeOH 0.789 Camptothecin 0.782 Tunicamycin 0.776 Wortmannin 0.749 
Doxorubicin 0.797 Chondramid C 0.767 Rapamycin 0.760 PD169316 0.794 
Indirubin 
monoxime 0.788 
Gephyronsäure 
A 0.779 Saframycin  0.775 Nocodazole 0.742 
Purvalanol A 0.795 Staurosporine 0.765 Staurosporine 0.758 Myxothiazol A 0.792 MG132 0.782 Archazolid B 0.761 Puromycin 0.774 Tubulysin B 0.740 
Mevastatin 0.794 Rapamycin 0.761 Chondramid C 0.756 Oligomycin 0.789 Myriaporon 0.776 Nocodazole 0.758 Mevastatin 0.756 
Indirubin 
monoxime 0.731 
Indirubin 
monoxime 0.791 
Indirubin 
monoxime 0.759 PD169316 0.748 Nocodazole 0.788 Puromycin 0.772 Ratjadon C 0.756 Chondramid C 0.748 Griseofulvin 0.730 
Ratjadon C 0.788 PMA 0.758 PMA 0.744 Trichostatin 0.787 MeOH 0.770 Mevastatin 0.755 Purvalanol A 0.746 Cycloheximide 0.726 
Staurosporine 0.785 PD169316 0.754 Tubulysin B 0.738 Archazolid B 0.786 Nocodazole 0.764 Emetine 0.755 Myriaporon 0.739 Mevastatin 0.726 
SB203580 0.775 Doxorubicin 0.750 Dexamethasone 0.737 DMSO:MeOH 0.778 Cruentaren A 0.763 
Indirubin 
monoxime 0.755 Camptothecin 0.739 Apicularen 0.726 
DMSO:MeOH 0.773 Purvalanol A 0.749 Purvalanol A 0.731 Colchicine 0.764 Emetine 0.762 PMA 0.754 Emetine 0.738 Vinblastine 0.722 
MeOH 0.767 LY294002 0.740 Doxorubicin 0.721 Brefeldin A 0.763 Trichostatin 0.757 PD169316 0.752 Cycloheximide 0.730 Camptothecin 0.716 
Trichostatin 0.746 Oligomycin 0.735 LY294002 0.720 Chondramid C 0.758 Chivosazol A 0.754 Purvalanol A 0.747 MeOH 0.724 Myriaporon 0.711 
Chondramid C 0.744 Tubulysin B 0.725 Puromycin 0.714 PMA 0.754 Rapamycin 0.747 Myxothiazol A 0.739 PMA 0.720 Saframycin  0.709 
Archazolid B 0.742 DMSO:MeOH 0.723 
Gephyronsäure 
A 0.707 Aphidicolin 0.752 Mevastatin 0.747 Tubulysin B 0.736 SB203580 0.719 Emetine 0.702 
Gephyronsäure 
A 0.721 Mevastatin 0.723 Oligomycin 0.706 Mevastatin 0.751 Wortmannin 0.734 Saframycin  0.736 Ratjadon C 0.719 Ratjadon C 0.702 
Continued on next page… 
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PmDUD20S 1.000 Py3DUD20S 1.000 Py3DUD13S 1.000 BrDUD19S 1.000 Py3DUD17S 1.000 PmDUD19S 1.000 BrDUD21S 1.000 BrDUD16S 1.000 
Puromycin 0.859 Brefeldin A 0.838 Vioprolid A 0.909 Brefeldin A 0.899 MeOH 0.870 Rhizopodin A 0.803 Taxol 0.806 Scriptaid 0.807 
Brefeldin A 0.839 Puromycin 0.824 Brefeldin A 0.811 Vioprolid A 0.843 Cycloheximide 0.849 Vioprolid A 0.786 Rhizopodin A 0.788 Vioprolid A 0.784 
Taxol 0.776 Vioprolid A 0.814 Puromycin 0.793 Puromycin 0.833 Trichostatin 0.838 Brefeldin A 0.742 Okadaic acid 0.727 Brefeldin A 0.756 
Vioprolid A 0.759 Scriptaid 0.789 Scriptaid 0.767 Wortmannin 0.808 Brefeldin A 0.833 Cycloheximide 0.735 Tubulysin B 0.725 Puromycin 0.752 
Chondramid C 0.743 Ratjadon C 0.758 Oxamflatin 0.731 Scriptaid 0.803 Ratjadon C 0.833 Puromycin 0.717 Brefeldin A 0.712 Tubulysin B 0.709 
Cycloheximide 0.743 Cycloheximide 0.748 Rhizopodin A 0.728 Ratjadon C 0.801 MG132 0.833 MeOH 0.707 Epothilon B 0.712 Taxol 0.691 
Tubulysin B 0.740 Tubulysin B 0.747 PMA 0.726 MeOH 0.789 PMA 0.814 Ratjadon C 0.699 Puromycin 0.699 Wortmannin 0.686 
Rhizopodin A 0.733 MeOH 0.736 MeOH 0.721 Cycloheximide 0.773 Myriaporon 0.805 MG132 0.697 Cycloheximide 0.690 Ratjadon C 0.672 
Gephyronsäure A 0.720 Chondramid C 0.731 Cycloheximide 0.719 PMA 0.769 Oxamflatin 0.801 Myriaporon 0.695 Chondramid C 0.688 Rhizopodin A 0.666 
Myriaporon 0.712 Wortmannin 0.721 Ratjadon C 0.711 Chondramid C 0.764 Camptothecin 0.786 PMA 0.689 Vioprolid A 0.671 Chondramid C 0.662 
Scriptaid 0.702 Taxol 0.713 Wortmannin 0.696 Camptothecin 0.758 Puromycin 0.774 Oxamflatin 0.686 Ratjadon C 0.659 MeOH 0.646 
MG132 0.693 Myriaporon 0.712 Trichostatin 0.696 Oxamflatin 0.757 Vioprolid A 0.768 Trichostatin 0.682 MG132 0.659 Cycloheximide 0.640 
Epothilon B 0.692 PMA 0.707 Myriaporon 0.691 Trichostatin 0.753 Cruentaren A 0.745 Scriptaid 0.658 Myriaporon 0.636 Oxamflatin 0.638 
Ratjadon C 0.685 Oxamflatin 0.706 MG132 0.661 Myriaporon 0.753 Neopeltolid 0.721 Taxol 0.638 Scriptaid 0.620 Trichostatin 0.618 
MeOH 0.678 Rhizopodin A 0.695 Chondramid C 0.657 Tubulysin B 0.742 Tubulysin B 0.715 Camptothecin 0.634 MeOH 0.616 PMA 0.617 
Wortmannin 0.673 Trichostatin 0.695 Tubulysin B 0.654 Simvastatin 0.731 Scriptaid 0.709 Tubulysin B 0.631 Camptothecin 0.595 Camptothecin 0.607 
Trichostatin 0.670 Camptothecin 0.694 Camptothecin 0.651 MG132 0.716 Aphidicolin 0.701 Okadaic acid 0.625 Trichostatin 0.589 MG132 0.600 
PMA 0.661 MG132 0.694 Taxol 0.640 Cytochalasin D 0.714 Simvastatin 0.698 Chondramid C 0.618 
Indirubin 
monoxime 0.584 Myriaporon 0.598 
Okadaic acid 0.659 Simvastatin 0.651 Neopeltolid 0.612 Archazolid B 0.702 Chondramid C 0.694 Neopeltolid 0.598 Gephyronsäure A 0.564 Okadaic acid 0.587 
Podophyllotoxin 0.655 
Gephyronsäure 
A 0.638 Simvastatin 0.608 
Gephyronsäure 
A 0.694 Soraphen A 0.681 Cruentaren A 0.586 PMA 0.563 Cytochalasin D 0.575 
Simvastatin 0.653 Epothilon B 0.634 Okadaic acid 0.597 Nocodazole 0.692 Tunicamycin 0.666 Simvastatin 0.548 Oxamflatin 0.551 Epothilon B 0.574 
Indirubin 
monoxime 0.650 Cytochalasin D 0.629 Cruentaren A 0.585 Staurosporine 0.692 Rhizopodin A 0.664 Aphidicolin 0.540 Wortmannin 0.535 Simvastatin 0.560 
Camptothecin 0.646 Soraphen A 0.620 
Gephyronsäure 
A 0.582 Soraphen A 0.690 Wortmannin 0.663 Epothilon B 0.573 Argyrin A 0.534 
Gephyronsäure 
A 0.551 
Staurosporine 0.644 Staurosporine 0.615 Cytochalasin D 0.578 Colchicine 0.684 Staurosporine 0.657 Wortmannin 0.570 Purvalanol A 0.531 Vinblastine 0.544 
Oxamflatin 0.637 Podophyllotoxin 0.612 Aphidicolin 0.575 Podophyllotoxin 0.681 Podophyllotoxin 0.644 Soraphen A 0.528 Podophyllotoxin 0.527 Purvalanol A 0.534 
Soraphen A 0.632 Cruentaren A 0.610 Staurosporine 0.571 Vinblastine 0.674 Dexamethasone 0.642 Gephyronsäure A 0.518 Soraphen A 0.526 Soraphen A 0.533 
Cytochalasin D 0.625 Archazolid B 0.607 Soraphen A 0.568 Taxol 0.674 Taxol 0.637 Tunicamycin 0.516 Cruentaren A 0.526 Colchicine 0.531 
Tunicamycin 0.614 Purvalanol A 0.607 Epothilon B 0.563 Cruentaren A 0.670 Doxorubicin 0.623 Podophyllotoxin 0.515 Simvastatin 0.520 Archazolid B 0.527 
Archazolid B 0.609 Colchicine 0.602 Podophyllotoxin 0.561 Purvalanol A 0.666 Myxothiazol A 0.622 
Indirubin 
monoxime 0.513 Tunicamycin 0.513 Staurosporine 0.526 
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BrDUD17S 1.000 BzDPD10A 1.000 Py3DUD21S 1.000 BrDUD01A 1.000 BzDPD01A 1.000 BrDUD18S 1.000 BrDUD20S 1.000 
Apicularen 0.912 Actinomycin D 0.924 Griseofulvin 0.884 Podophyllotoxin 0.846 Velcade 0.862 Wortmannin 0.801 Okadaic acid -0.493 
Chivosazol A 0.883 Chelerythrine 0.901 Anisomycin 0.872 LY294002 0.840 Indirubin monoxime 0.851 Puromycin 0.798 Rhizopodin A -0.500 
Colchicine 0.857 Apicidin 0.885 Purvalanol A 0.850 Mevastatin 0.830 LY294002 0.842 Scriptaid 0.797 Vioprolid A -0.573 
Archazolid B 0.841 Alsterpaullone 0.849 SB202190 0.830 Chivosazol A 0.825 Tunicamycin 0.797 Brefeldin A 0.771 Puromycin -0.592 
Griseofulvin 0.831 SB202190 0.833 Colchicine 0.805 DMSO:MeOH 0.822 PD169316 0.795 Cytochalasin D 0.722 Taxol -0.609 
Cytochalasin D 0.825 Griseofulvin 0.825 Chivosazol A 0.801 Purvalanol A 0.821 Podophyllotoxin 0.783 Vinblastine 0.719 Scriptaid -0.609 
SB202190 0.819 Chivosazol A 0.803 Amanitin 0.782 Anisomycin 0.811 Myxothiazol A 0.767 Tubulysin B 0.714 Cycloheximide -0.613 
Vinblastine 0.812 Apicularen 0.769 Emetine 0.768 Griseofulvin 0.809 Mevastatin 0.764 Vioprolid A 0.710 Epothilon B -0.616 
DMSO:MeOH 0.811 Anisomycin 0.752 DMSO:MeOH 0.762 Gephyronsäure A 0.807 Soraphen A 0.760 Chondramid C 0.693 Brefeldin A -0.618 
Nocodazole 0.807 Amanitin 0.752 Podophyllotoxin 0.760 Colchicine 0.807 Anisomycin 0.750 Gephyronsäure A 0.687 Oxamflatin -0.636 
Chelerythrine 0.805 Colchicine 0.744 Indirubin monoxime 0.748 Tunicamycin 0.803 Purvalanol A 0.747 Taxol 0.665 Myriaporon -0.637 
Saframycin  0.802 Methotrexate 0.727 Alsterpaullone 0.747 Velcade 0.800 Rapamycin 0.736 Colchicine 0.664 PMA -0.638 
Methotrexate 0.783 A23187 free acid 0.721 Argyrin A 0.747 Archazolid B 0.793 Amanitin 0.729 Simvastatin 0.659 Ratjadon C -0.640 
Actinomycin D 0.778 DMSO:MeOH 0.717 Gephyronsäure A 0.744 Soraphen A 0.785 DMSO:MeOH 0.718 Archazolid B 0.654 Tubulysin B -0.650 
Emetine 0.772 Saframycin  0.714 LY294002 0.743 Indirubin monoxime 0.783 Gephyronsäure A 0.710 Apicularen 0.651 MeOH -0.652 
Apicidin 0.768 Archazolid B 0.709 Tunicamycin 0.742 Amanitin 0.782 SB203580 0.708 Staurosporine 0.646 Chondramid C -0.658 
Gephyronsäure A 0.767 Cytochalasin D 0.683 Soraphen A 0.742 SB203580 0.761 Cruentaren A 0.702 Nocodazole 0.645 MG132 -0.661 
Staurosporine 0.763 Emetine 0.677 Archazolid B 0.741 Chondramid C 0.753 Staurosporine 0.701 Ratjadon C 0.632 Wortmannin -0.662 
Podophyllotoxin 0.754 Etoposide 0.671 Mevastatin 0.736 SB202190 0.747 MG132 0.693 Emetine 0.632 Trichostatin -0.678 
Anisomycin 0.747 Mevastatin 0.671 Actinomycin D 0.720 Staurosporine 0.746 Chondramid C 0.688 Podophyllotoxin 0.621 Camptothecin -0.686 
Simvastatin 0.747 Nocodazole 0.670 Chondramid C 0.718 Saframycin  0.744 Oligomycin 0.686 MeOH 0.621 Indirubin monoxime -0.688 
Mevastatin 0.740 Purvalanol A 0.656 Apicularen 0.715 PD169316 0.736 Simvastatin 0.678 Soraphen A 0.617 Neopeltolid -0.689 
Purvalanol A 0.734 Vinblastine 0.653 Staurosporine 0.712 Simvastatin 0.732 Griseofulvin 0.675 Purvalanol A 0.616 Gephyronsäure A -0.693 
Soraphen A 0.725 Cyclosporin A 0.649 PD169316 0.709 Myxothiazol A 0.724 Cycloheximide 0.673 Oxamflatin 0.615 Simvastatin -0.711 
SB203580 0.709 SB203580 0.647 Saframycin  0.705 Oligomycin 0.722 Camptothecin 0.672 Cycloheximide 0.615 Cytochalasin D -0.713 
Alsterpaullone 0.708 Podophyllotoxin 0.643 Etoposide 0.703 Cytochalasin D 0.716 Doxorubicin 0.668 Trichostatin 0.611 Cruentaren A -0.719 
Wortmannin 0.706 Gephyronsäure A 0.633 Cytochalasin D 0.697 Argyrin A 0.715 Myriaporon 0.667 PMA 0.610 Argyrin A -0.720 
Tunicamycin 0.701 LY294002 0.629 Velcade 0.694 Actinomycin D 0.709 Chivosazol A 0.664 Camptothecin 0.606 Podophyllotoxin -0.728 
H89 0.686 H89 0.627 Simvastatin 0.693 Nocodazole 0.705 Dexamethasone 0.655 Chivosazol A 0.605 Vinblastine -0.730 
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 Table 6. Numerical correlation values of 30 bridged bicyclic compounds obtained from the high content analysis (repetition experiment). The similarity values with first 30 reference compounds are shown. 
BzDPD10A 1 BrDPD17A 1 BrDPD20A 1 BrDUD01A 1 BrDPD10S 1 BrDPD10A 1 BzDPD01A 1 Py3DUD01A 1 
Chelerythrine 0.863 
A23187 free 
acid 0.831 Amanitin 0.792 DMSO:MeOH 0.799 Amanitin 0.874 Amanitin 0.837 Amanitin 0.837 Apicularen 0.860 
Amanitin 0.782 Chelerythrine 0.813 DMSO:MeOH 0.778 Chivosazol A 0.779 Chivosazol A 0.739 Anisomycin 0.783 Anisomycin 0.795 PD169316 0.837 
Chivosazol A 0.774 Amanitin 0.792 Chivosazol A 0.743 Apicularen 0.776 Anisomycin 0.731 Alsterpaullone 0.737 Chivosazol A 0.749 Archazolid B 0.812 
A23187 free 
acid 0.759 Apicidin 0.751 Mevastatin 0.732 Mevastatin 0.758 Colchicine 0.724 Chivosazol A 0.718 Archazolid B 0.741 SB202190 0.804 
Mevastatin 0.737 Chivosazol A 0.687 Cyclosporin A 0.725 PD169316 0.755 DMSO:MeOH 0.712 Colchicine 0.716 Colchicine 0.737 SB203580 0.795 
DMSO:MeOH 0.736 Colchicine 0.680 Colchicine 0.724 Colchicine 0.748 Apicularen 0.704 Apicularen 0.700 Apicularen 0.733 H89 0.777 
Apicidin 0.736 DMSO:MeOH 0.630 Chelerythrine 0.713 Archazolid B 0.747 PD169316 0.700 DMSO:MeOH 0.699 Alsterpaullone 0.723 Oligomycin 0.777 
Colchicine 0.734 Mevastatin 0.629 Apicularen 0.702 Emetine 0.734 Chelerythrine 0.694 Archazolid B 0.688 Emetine 0.709 DMSO:MeOH 0.762 
PD169316 0.697 PD169316 0.625 Brefeldin A 0.692 Chelerythrine 0.724 Archazolid B 0.690 Mevastatin 0.677 Mevastatin 0.707 Chivosazol A 0.756 
Cyclosporin A 0.689 Cyclosporin A 0.605 Alsterpaullone 0.687 Simvastatin 0.721 Mevastatin 0.687 Cyclosporin A 0.663 DMSO:MeOH 0.703 Amanitin 0.744 
Apicularen 0.663 Apicularen 0.581 Simvastatin 0.680 Cyclosporin A 0.720 Alsterpaullone 0.681 Chelerythrine 0.652 PD169316 0.681 Soraphen A 0.735 
Oligomycin 0.639 Anisomycin 0.564 Podophyllotoxin 0.675 Oligomycin 0.703 Emetine 0.664 Emetine 0.652 Cyclosporin A 0.665 Simvastatin 0.716 
Simvastatin 0.630 Actinomycin D 0.559 Anisomycin 0.672 H89 0.687 Cyclosporin A 0.656 SB203580 0.650 SB203580 0.663 Emetine 0.709 
Emetine 0.627 Archazolid B 0.557 PD169316 0.670 SB202190 0.687 
A23187 free 
acid 0.654 PD169316 0.647 H89 0.660 Mevastatin 0.707 
Archazolid B 0.624 Emetine 0.544 Emetine 0.664 SB203580 0.680 SB203580 0.647 Brefeldin A 0.625 SB202190 0.655 Colchicine 0.657 
SB202190 0.617 Alsterpaullone 0.541 Archazolid B 0.660 Podophyllotoxin 0.670 SB202190 0.643 SB202190 0.624 Oligomycin 0.643 LY294002 0.652 
Brefeldin A 0.615 Brefeldin A 0.541 
A23187 free 
acid 0.659 Brefeldin A 0.663 H89 0.638 H89 0.621 Chelerythrine 0.635 Cyclosporin A 0.651 
Podophyllotoxin 0.610 Simvastatin 0.538 Oligomycin 0.659 Anisomycin 0.661 Oligomycin 0.637 
A23187 free 
acid 0.617 Simvastatin 0.629 Methotrexate 0.651 
H89 0.596 Oligomycin 0.532 H89 0.651 Soraphen A 0.660 Simvastatin 0.635 Simvastatin 0.610 Brefeldin A 0.604 Chelerythrine 0.637 
SB203580 0.594 SB202190 0.530 SB203580 0.647 Alsterpaullone 0.649 Apicidin 0.616 Oligomycin 0.605 Soraphen A 0.582 Anisomycin 0.633 
Soraphen A 0.583 SB203580 0.522 Apicidin 0.645 Apicidin 0.632 Brefeldin A 0.615 Apicidin 0.558 
A23187 free 
acid 0.572 Podophyllotoxin 0.621 
Actinomycin D 0.573 Podophyllotoxin 0.509 SB202190 0.637 
A23187 free 
acid 0.626 Soraphen A 0.583 Soraphen A 0.557 Cytochalasin D 0.565 Saframycin  0.617 
Anisomycin 0.569 H89 0.500 Soraphen A 0.609 LY294002 0.615 Podophyllotoxin 0.560 Podophyllotoxin 0.546 Podophyllotoxin 0.538 Neopeltolid 0.607 
Alsterpaullone 0.564 Soraphen A 0.484 Nocodazole 0.606 Nocodazole 0.579 LY294002 0.537 Cytochalasin D 0.525 Purvalanol A 0.538 Brefeldin A 0.598 
LY294002 0.561 LY294002 0.467 LY294002 0.581 Methotrexate 0.573 Methotrexate 0.518 Nocodazole 0.525 Apicidin 0.532 Alsterpaullone 0.590 
Methotrexate 0.550 Methotrexate 0.452 Saframycin  0.561 PMA 0.565 Saframycin  0.510 Saframycin  0.513 Methotrexate 0.522 PMA 0.565 
Nocodazole 0.547 Nocodazole 0.439 Methotrexate 0.553 Saframycin Mx1 0.560 Nocodazole 0.505 Methotrexate 0.510 Saframycin  0.517 Cycloheximide 0.549 
Saframycin  0.520 Saframycin  0.421 Actinomycin D 0.540 Griseofulvin 0.542 Cytochalasin D 0.500 LY294002 0.504 Nocodazole 0.517 Griseofulvin 0.543 
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Continued from previous page… 
PmDUD06S 1 ImDUD10S 1 Py4DUD01A 1 BrDUD12S 1 Py3DUD19S 1 PmDUD21S 1 BrDUD14S 1 BrDUD26S 1 
Apicularen 0.795 SB203580 0.881 Soraphen A 0.834 H89 0.799 H89 0.799 H89 0.780 Purvalanol A 0.786 Purvalanol A 0.679 
H89 0.775 Apicularen 0.847 H89 0.813 Oligomycin 0.734 SB203580 0.774 Purvalanol A 0.778 Archazolid B 0.699 MG132 0.661 
Archazolid B 0.759 SB202190 0.824 Simvastatin 0.812 Saframycin  0.730 SB202190 0.769 SB203580 0.774 Apicularen 0.696 Myriaporon 0.643 
Oligomycin 0.754 H89 0.814 SB203580 0.799 Purvalanol A 0.729 Saframycin  0.754 Apicularen 0.737 Cycloheximide 0.681 Cycloheximide 0.618 
SB202190 0.751 Oligomycin 0.794 Oligomycin 0.787 SB203580 0.729 Oligomycin 0.749 SB202190 0.734 SB203580 0.670 Griseofulvin 0.533 
Emetine 0.737 DMSO:MeOH 0.784 Apicularen 0.781 SB202190 0.725 Methotrexate 0.744 Oligomycin 0.726 H89 0.669 Saframycin  0.526 
DMSO:MeOH 0.734 Archazolid B 0.766 SB202190 0.769 Soraphen A 0.712 Soraphen A 0.734 Griseofulvin 0.722 Anisomycin 0.662 H89 0.521 
PD169316 0.732 Methotrexate 0.765 Saframycin  0.766 Apicularen 0.707 Apicularen 0.725 Saframycin  0.704 Myriaporon 0.638 Indirubin monoxime 0.512 
SB203580 0.723 Soraphen A 0.761 LY294002 0.765 Methotrexate 0.691 Purvalanol A 0.702 Cycloheximide 0.703 Alsterpaullone 0.637 Chondramid C 0.509 
Soraphen A 0.701 Saframycin  0.751 DMSO:MeOH 0.761 Cruentaren A 0.669 Dexamethasone 0.669 DMSO:MeOH 0.699 SB202190 0.636 SB203580 0.508 
Chivosazol A 0.699 PD169316 0.744 Neopeltolid 0.748 Archazolid B 0.669 Neopeltolid 0.668 Soraphen A 0.683 Cytochalasin D 0.630 Apicularen 0.502 
Simvastatin 0.688 Chivosazol A 0.729 Cruentaren A 0.735 Cycloheximide 0.666 Archazolid B 0.662 Methotrexate 0.676 Emetine 0.627 Cytochalasin D 0.500 
Mevastatin 0.677 Simvastatin 0.727 Methotrexate 0.731 Myxothiazol A 0.665 DMSO:MeOH 0.645 Archazolid B 0.675 Griseofulvin 0.606 SB202190 0.499 
Amanitin 0.660 Mevastatin 0.713 Archazolid B 0.730 Simvastatin 0.656 Cycloheximide 0.639 Cytochalasin D 0.673 DMSO:MeOH 0.599 Methotrexate 0.475 
Cyclosporin A 0.635 Amanitin 0.677 PD169316 0.720 Neopeltolid 0.651 Myxothiazol A 0.639 Nocodazole 0.663 Oligomycin 0.599 Soraphen A 0.463 
Podophyllotoxin 0.625 Cyclosporin A 0.673 Podophyllotoxin 0.702 DMSO:MeOH 0.648 Simvastatin 0.627 Mevastatin 0.660 Mevastatin 0.576 DMSO:MeOH 0.461 
LY294002 0.620 LY294002 0.673 PMA 0.702 LY294002 0.616 LY294002 0.626 Myriaporon 0.647 Chivosazol A 0.574 Archazolid B 0.458 
Anisomycin 0.613 Podophyllotoxin 0.672 Brefeldin A 0.701 Chondramid C 0.614 Cruentaren A 0.620 Emetine 0.647 Soraphen A 0.568 Oligomycin 0.455 
Colchicine 0.610 Brefeldin A 0.668 Myxothiazol A 0.654 Nocodazole 0.614 PD169316 0.614 Chivosazol A 0.632 Cyclosporin A 0.561 Epothilon B 0.453 
Cycloheximide 0.609 Nocodazole 0.648 Mevastatin 0.628 MG132 0.608 Griseofulvin 0.599 Simvastatin 0.625 Saframycin  0.556 Nocodazole 0.452 
Neopeltolid 0.605 Emetine 0.644 Nocodazole 0.624 Myriaporon 0.601 Nocodazole 0.597 Cyclosporin A 0.621 Simvastatin 0.553 Neopeltolid 0.445 
Alsterpaullone 0.595 Cruentaren A 0.643 Cycloheximide 0.621 Mevastatin 0.598 MG132 0.595 Podophyllotoxin 0.616 Methotrexate 0.536 Myxothiazol A 0.445 
Purvalanol A 0.594 Neopeltolid 0.640 Emetine 0.618 Griseofulvin 0.598 Mevastatin 0.587 Myxothiazol A 0.611 Amanitin 0.533 Gephyronsäure A 0.434 
Griseofulvin 0.590 Anisomycin 0.633 Chivosazol A 0.615 Dexamethasone 0.591 Chondramid C 0.584 MG132 0.605 PD169316 0.532 Cruentaren A 0.431 
Methotrexate 0.588 Colchicine 0.625 Cyclosporin A 0.613 PD169316 0.590 Chivosazol A 0.580 Neopeltolid 0.604 Cruentaren A 0.531 Dexamethasone 0.426 
Saframycin  0.580 Myxothiazol A 0.621 Amanitin 0.598 Emetine 0.589 Podophyllotoxin 0.573 Cruentaren A 0.601 MG132 0.527 Cyclosporin A 0.424 
Cytochalasin D 0.570 Alsterpaullone 0.616 Anisomycin 0.578 Aphidicolin 0.588 Aphidicolin 0.573 Chondramid C 0.599 Nocodazole 0.524 Emetine 0.417 
Brefeldin A 0.562 Chelerythrine 0.606 Chondramid C 0.565 Cytochalasin D 0.587 Emetine 0.568 PD169316 0.586 Colchicine 0.516 Alsterpaullone 0.396 
Continued on next page… 
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PmDUD13S 1 BrDUD20S 1 BrDUD17S 1 Py3DUD13S 1 BrDPD13A 1 Py3DUD10S 1 BrDUD21S 1 BrDUD16S 1 
Chondramid C 0.784 
Indirubin 
monoxime 0.049 Colchicine 0.803 Rhizopodin A 0.514 Brefeldin A 0.833 Chivosazol A 0.869 Chondramid C 0.673 
Indirubin 
monoxime 0.642 
MG132 0.736 Rhizopodin A -0.058 Mevastatin 0.795 Okadaic acid 0.326 Cyclosporin A 0.687 Mevastatin 0.808 Cruentaren A 0.636 Purvalanol A 0.528 
Myxothiazol A 0.694 Okadaic acid -0.138 Cyclosporin A 0.790 Vioprolid A 0.324 Alsterpaullone 0.681 Colchicine 0.797 Brefeldin A 0.626 MG132 0.512 
Myriaporon 0.691 Oxamflatin -0.225 DMSO:MeOH 0.765 Epothilon B 0.230 Colchicine 0.679 Amanitin 0.792 Ratjadon C 0.625 Myriaporon 0.440 
Cycloheximide 0.684 Vioprolid A -0.256 Chivosazol A 0.744 
Indirubin 
monoxime 0.213 DMSO:MeOH 0.679 Apicularen 0.775 Nocodazole 0.609 Epothilon B 0.406 
Cruentaren A 0.682 Vinblastine -0.256 Amanitin 0.738 Ratjadon C 0.209 Nocodazole 0.669 Archazolid B 0.770 Myxothiazol A 0.572 Chondramid C 0.363 
Saframycin  0.676 Scriptaid -0.260 Emetine 0.726 Chondramid C 0.209 Simvastatin 0.666 Emetine 0.757 Argyrin A 0.548 Cycloheximide 0.349 
Nocodazole 0.665 Epothilon B -0.282 Chelerythrine 0.724 Tubulysin B 0.206 Mevastatin 0.658 Cyclosporin A 0.745 Wortmannin 0.538 Tubulysin B 0.336 
Purvalanol A 0.659 Chondramid C -0.287 Brefeldin A 0.716 MG132 0.174 Podophyllotoxin 0.656 Chelerythrine 0.732 Myriaporon 0.530 Myxothiazol A 0.324 
H89 0.644 MG132 -0.308 Podophyllotoxin 0.689 Puromycin 0.146 Anisomycin 0.636 DMSO:MeOH 0.719 Podophyllotoxin 0.523 Saframycin  0.300 
Griseofulvin 0.606 Tubulysin B -0.328 Simvastatin 0.678 Oxamflatin 0.129 Actinomycin D 0.632 PD169316 0.694 Cycloheximide 0.513 H89 0.292 
Oligomycin 0.591 Neopeltolid -0.389 Apicularen 0.673 Wortmannin 0.044 Amanitin 0.623 SB203580 0.653 Simvastatin 0.509 Gephyronsäure A 0.286 
Soraphen A 0.587 Saframycin  -0.396 Archazolid B 0.659 Myriaporon 0.032 Emetine 0.608 Anisomycin 0.644 PMA 0.499 Cytochalasin D 0.285 
Cytochalasin D 0.580 Myriaporon -0.417 Nocodazole 0.655 Trichostatin 0.028 Cruentaren A 0.585 SB202190 0.637 Staurosporine 0.478 Etoposide 0.283 
Neopeltolid 0.573 Myxothiazol A -0.417 Alsterpaullone 0.654 Taxol 0.022 Chivosazol A 0.580 Oligomycin 0.621 Alsterpaullone 0.466 Doxorubicin 0.279 
Methotrexate 0.571 Cruentaren A -0.447 Apicidin 0.649 Myxothiazol A 0.012 Apicidin 0.580 Alsterpaullone 0.620 Saframycin  0.464 Cruentaren A 0.276 
Simvastatin 0.568 Taxol -0.448 
A23187 free 
acid 0.640 Cruentaren A 0.009 Chelerythrine 0.564 H89 0.605 DMSO:MeOH 0.461 Camptothecin 0.254 
Podophyllotoxin 0.566 Trichostatin -0.451 Actinomycin D 0.634 Scriptaid 0.006 Apicularen 0.561 Simvastatin 0.605 Velcade 0.458 SB203580 0.250 
DMSO:MeOH 0.564 Cycloheximide -0.462 Anisomycin 0.624 Cycloheximide -0.009 Archazolid B 0.560 Cytochalasin D 0.601 Cytochalasin D 0.455 SB202190 0.244 
SB203580 0.557 Etoposide -0.472 PD169316 0.618 Neopeltolid -0.029 
A23187 free 
acid 0.546 
A23187 free 
acid 0.585 MG132 0.443 Griseofulvin 0.242 
Brefeldin A 0.555 Ratjadon C -0.477 Oligomycin 0.601 Saframycin  -0.036 PMA 0.545 Griseofulvin 0.585 Griseofulvin 0.435 Methotrexate 0.236 
SB202190 0.545 Methotrexate -0.487 Cytochalasin D 0.581 Gephyronsäure A -0.051 Cytochalasin D 0.541 Podophyllotoxin 0.572 Cyclosporin A 0.429 Aphidicolin 0.221 
PMA 0.545 H89 -0.496 H89 0.578 Tunicamycin -0.052 Staurosporine 0.533 Brefeldin A 0.565 H89 0.428 Oligomycin 0.221 
Apicularen 0.543 Soraphen A -0.498 SB203580 0.573 PMA -0.069 Oligomycin 0.531 Soraphen A 0.565 Epothilon B 0.425 Dexamethasone 0.218 
LY294002 0.531 Purvalanol A -0.500 Griseofulvin 0.570 Nocodazole -0.098 H89 0.529 Nocodazole 0.557 LY294002 0.409 Apicularen 0.214 
Staurosporine 0.517 Puromycin -0.502 Soraphen A 0.561 Velcade -0.099 Myxothiazol A 0.516 Methotrexate 0.538 Soraphen A 0.402 Soraphen A 0.209 
Epothilon B 0.511 LY294002 -0.505 SB202190 0.557 LY294002 -0.118 Soraphen A 0.511 Apicidin 0.534 Emetine 0.400 Nocodazole 0.206 
Archazolid B 0.503 Dexamethasone -0.528 Staurosporine 0.554 Soraphen A -0.127 Saframycin  0.509 Purvalanol A 0.503 Mevastatin 0.399 Anisomycin 0.206 
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BrDUD18S 1 Py3DUD17S 1 PmDUD19S 1 BrDUD19S 1 Py3DUD21S 1 Py3DUD20S 1 PmDUD20S 1 
Rhizopodin A 0.524 Oxamflatin 0.524 Chondramid C 0.639 Epothilon B 0.616 PmDUD19 0.820 Ratjadon C 0.565 Rhizopodin A 0.667 
Indirubin monoxime 0.517 Chondramid C 0.512 MG132 0.578 Chondramid C 0.596 Apicularen 0.782 Trichostatin 0.536 Chondramid C 0.516 
Chondramid C 0.445 MG132 0.487 Indirubin monoxime 0.556 Tubulysin B 0.572 SB203580 0.762 Oxamflatin 0.515 Oxamflatin 0.501 
Epothilon B 0.361 Rhizopodin A 0.483 Rhizopodin A 0.530 Myriaporon 0.555 Chivosazol A 0.753 Chondramid C 0.469 Ratjadon C 0.431 
Oxamflatin 0.350 Indirubin monoxime 0.459 Cruentaren A 0.490 MG132 0.531 SB202190 0.752 Rhizopodin A 0.465 Cruentaren A 0.338 
MG132 0.299 Neopeltolid 0.403 Oxamflatin 0.484 Argyrin A 0.468 Mevastatin 0.750 PMA 0.457 Myxothiazol A 0.335 
Myxothiazol A 0.293 Scriptaid 0.400 Epothilon B 0.476 Myxothiazol A 0.446 H89 0.737 Neopeltolid 0.436 MG132 0.334 
Cruentaren A 0.280 Cruentaren A 0.388 Myxothiazol A 0.475 Indirubin monoxime 0.436 Oligomycin 0.731 MG132 0.409 Scriptaid 0.330 
Tubulysin B 0.279 Myxothiazol A 0.370 Myriaporon 0.465 Purvalanol A 0.435 Methotrexate 0.713 Scriptaid 0.392 Neopeltolid 0.317 
Myriaporon 0.276 Saframycin  0.356 Saframycin  0.438 Nocodazole 0.414 DMSO:MeOH 0.711 Vioprolid A 0.392 Vioprolid A 0.311 
Saframycin  0.251 Ratjadon C 0.335 Cycloheximide 0.437 Cycloheximide 0.414 Archazolid B 0.709 Cruentaren A 0.384 Epothilon B 0.308 
Okadaic acid 0.240 Trichostatin 0.331 Neopeltolid 0.431 Cruentaren A 0.413 Griseofulvin 0.705 LY294002 0.360 Trichostatin 0.302 
Ratjadon C 0.205 Epothilon B 0.323 Ratjadon C 0.425 Wortmannin 0.396 Purvalanol A 0.699 Velcade 0.337 Saframycin  0.298 
Neopeltolid 0.201 Cycloheximide 0.319 H89 0.375 Ratjadon C 0.379 Cyclosporin A 0.675 Cycloheximide 0.332 Indirubin monoxime 0.297 
Cycloheximide 0.200 Myriaporon 0.312 Tubulysin B 0.368 Cytochalasin D 0.373 Saframycin  0.672 Tunicamycin 0.326 PMA 0.272 
Scriptaid 0.197 Vioprolid A 0.301 Purvalanol A 0.361 Griseofulvin 0.355 Cytochalasin D 0.668 Soraphen A 0.325 LY294002 0.240 
Vioprolid A 0.183 PMA 0.294 Vioprolid A 0.358 Saframycin  0.354 Nocodazole 0.664 Wortmannin 0.323 Cycloheximide 0.221 
H89 0.169 Soraphen A 0.292 Soraphen A 0.350 Gephyronsäure A 0.350 Emetine 0.658 Myxothiazol A 0.320 Myriaporon 0.220 
Purvalanol A 0.161 H89 0.290 PMA 0.346 Taxol 0.347 Soraphen A 0.655 Saframycin  0.315 Wortmannin 0.218 
Nocodazole 0.150 LY294002 0.288 Wortmannin 0.337 Rhizopodin A 0.347 PD169316 0.643 Simvastatin 0.304 Soraphen A 0.209 
Wortmannin 0.125 Methotrexate 0.249 Nocodazole 0.337 Brefeldin A 0.305 Podophyllotoxin 0.609 Podophyllotoxin 0.300 Tubulysin B 0.193 
Soraphen A 0.124 Oligomycin 0.241 LY294002 0.335 Alsterpaullone 0.304 Colchicine 0.605 Puromycin 0.287 Nocodazole 0.193 
Argyrin A 0.123 Wortmannin 0.234 Scriptaid 0.323 Staurosporine 0.301 Simvastatin 0.604 Epothilon B 0.259 Podophyllotoxin 0.179 
LY294002 0.122 Tubulysin B 0.230 Trichostatin 0.320 H89 0.299 Dexamethasone 0.597 H89 0.249 H89 0.176 
Methotrexate 0.117 Purvalanol A 0.226 Oligomycin 0.316 Vioprolid A 0.288 Cycloheximide 0.589 Nocodazole 0.248 Puromycin 0.165 
Oligomycin 0.109 Simvastatin 0.217 Methotrexate 0.310 Okadaic acid 0.268 Amanitin 0.577 Myriaporon 0.246 Methotrexate 0.165 
Trichostatin 0.104 Podophyllotoxin 0.213 Simvastatin 0.303 DMSO:MeOH 0.256 LY294002 0.554 PmDUD19 0.240 Okadaic acid 0.161 
PMA 0.104 Nocodazole 0.209 Podophyllotoxin 0.298 Podophyllotoxin 0.255 Chelerythrine 0.553 Oligomycin 0.233 Simvastatin 0.161 
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Table 7. Reference compounds used in the high content analysis and impedance measurement 
Compound Mode of action in eukaryotic cells Concentration 
(µM) 
Compound Mode of action in eukaryotic cells Concentration 
(µM) 
A23187 Calcium regulation 110 Mevastatin inhibits cholesterol-biosynthesis 1200 
Actinomycin Inhibition of transcription 4,4 MG132 Proteasome inhibitor 400 
Alsterpaullone Inhibition of CD Kinase 1100 Myriaporon Inhibits  protein synthesis 70 
Amanitin Blocking of mRNA synthesis 1000 Myxothiazol A Affects  respiratory-chain 12 
Anisomycin Inhibition of protein biosynthesis 45 Neopeltolid Affects  respiratory-chain 100 
Aphidicolin Inhibition of DNA polymerization 1000 Nocodazol Inhibits tubulin polymerization 12 
Apicidin HDAC inhibitor 100 Okadiac acid Inhibits proteinphospatases 10 
Apicularen V-ATPase inhibitor 31 Oligomycin F-ATPase inhibitor 70 
Archazolid B V-ATPase inhibitor 3 Oxamflatin HDAC inhibitor 1200 
Argyrin A Proteasome inhibitor 1000 PD169316 p38-MAP kinase inhibitor 10000 
Brefeldin A Destroys golgi apparatus 100 PMA activates protein-kinase C 3500 
Camptothecin Topoisomerase I inhibitor 450 Podophyllotoxin Inhibits tubulin polymerization 2,5 
Chelerythrin Protein kinase C inhibitor 1000 Puromycin Inhibits protein-biosynthesis 500 
Chivosazol A actin polymerisation inhibitor 1,3 Purvalanol A Inhibits CD kinase 2000 
Chondramid C Stabilizes actin filaments 10 Rapamycin PI3 kinase inhibitor 11 
Colchicin Destroys Microtubuli 10 Ratjadon C blocks nuclear receptor 3,5 
Cruentaren A F-ATPase inhibitor 14 Rhizopodin A Inhibits Actin polymerization 20 
Cycloheximid Inhibits protein biosynthesis 450 Saframycin Mx1 Inhibits DNA synthesis 40 
Cyclosporin A Effects calcium-regulation 5500 SB202190 p38-MAP kinase inhibitor 10.000 
Cytochalasin D Promotes actin depolymerization 1000 SB203580 p38-MAP kinase inhibitor 10.000 
Dexamethason Shows immunosuppressive effect 4500 Scriptaid HDAC inhibitor 4000 
Doxorubicin Topoisomerase II inhibitor 340 Simvastatin Inhibits cholesterol-biosynthesis 800 
Emetin Inhibits protein biosynthese 41 Soraphen A Inhibits lipid synthesis 400 
Epothilon B stabilizes  microtubuli 0,55 Staurosporin Inhibits protein kinases 3 
Etoposid Topoisomerase inhibitor 2300 Taxol Stabilizes microtubules 25 
Gephyronic  acid  A Inhibits  protein synthesis 60 Trichostatin HDAC inhibitor 310 
Griseofulvin Inhibits mitotic-spindle formation 10000 Tubulysin B Inhibits polymerization microtubules 0,4 
H89 Protein kinase A inhibitor 10000 Tunicamycin Accumulates misfolded proteins 700 
Indirubin-3'-monoxim Inhibits  CD kinase 8000 Velcade Proteasome inhibitor 11 
LY294002 PI3 kinase inhibitor 10000 Vinblastin Inhibits polymerization microtubules 0,5 
Methotrexat Inhibits DNA synthesis 50 Wortmannin Inhibits PI3-kinase 10000 
 
